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The cover image represents the storm that arises during the growth of a tree in 
a human individual. The initial planting of Streptococcus pneumoniae, represented
by the tree, is harmless to the host at first. However, danger lurks ahead as 
the roots begin to take hold, allowing the pneumococcus to grow in the unknowing
host. This metaphor depicts the critical step of successful colonization of 
S. pneumoniae in the progression towards disease (the storm).
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The burden of Streptococcus pneumoniae
Respiratory infections caused by bacteria and viruses remain a major burden of 
ϐ
population. Globally, lower respiratory tract infections are ranked 4th in the top 
10 causes of death1. Pneumonia alone is responsible for 15% of child deaths 
ϐ2. The most common cause of pneumonia in children
and the elderly is Streptococcus pneumoniaeǡ   ϐ 
that stands out among respiratory pathogens as a global health problem2-6.
S. pneumoniae, or pneumococcus, is a gram-positive bacterium and a commensal 
colonizer that is part of the nasopharyngeal microbiome4,7. Carriage of the
pneumococcus is primarily asymptomatic. However, infrequently S. pneumoniae
invades otherwise sterile compartments leading to disease (Figure 1). Pneumo-
coccal disease primarily presents as mild infections, such as sinusitis and otitis 
Figure 1  Overview of the range of diseases caused by Streptococcus pneumoniae.
Figure is adjusted from Jambo et al. 201012. Acquisition of S. pneumoniae starts with colonization of 
the nasopharynx. In some occasions, S. pneumoniae transits into other niches, including the sinuses,
the middle ear and the lungs, causing sinusitis, otitis media, and pneumonia respectively. The 
pneumococcus is able to enter otherwise sterile compartments of the human body, such as the blood 
(bacteraemia) and the brain where it could lead to septicemia and meningitis. Notably, the incidence 



















media (OM)4,6. These clinical entities form an important cause for child physician 
visits and annual antibiotic prescriptions4,6. Serious invasive illnesses caused 
by S. pneumoniae include pneumonia, bacteraemia, sepsis, and meningitis3-6.
Pneumococcal disease primarily affects young children, the elderly, and immune 
compromised individuals3-6,8. Globally, pneumococcal disease accounts for over 
800,000 deaths among young children each year with a major impact on 
mortality particularly in developing countries3. Among elderly between the ages
of 65 to 85 years, 15% succumbs to pneumococcal pneumonia. Mortality rates
further increase to 30-45% for individuals 85 years or older, which explains why 
the pneumococcus is called “the old man’s friend” ϐ
Osler in 19094,6,9. Pneumococcal infection is treatable with antibiotics. However,
the continuing emergence and spread of antibiotic resistant strains increasingly 
restrict the options for adequate antimicrobial therapy10. Vaccination against 
colonization and disease is a commonly accepted approach for eradication of 
(resistant) pneumococcal serotypes included in the vaccine4,8,11.
Pneumococcal vaccination strategies
 ͳͻͳͳǡ  ϐ        
trial4,13,14. Decades later in 1945 this was followed by studies with a capsular 
polysaccharide vaccine. The capsular polysaccharide surrounding the pneumococcal 
         ϐ 
S. pneumoniae into distinct serotypes, of which more than 95 have been described4,7.
ͳͻ͹͹ͳͻͺ͵ǡͳͶʹ͵ϐ
(PPSV23), respectively, were approved for vaccination. PPSV23, also known as 
Pneumovax 23, reduced pneumococcal disease incidence in the elderly4,15,16. 
PPSV23 was introduced in the US for adults over 65 years of age, but vaccine 
effectiveness against invasive pneumococcal disease remains controversial4,15-18.
The polysaccharide vaccines were not protective in children below the age of 
2 years nor did they induce a memory response19,20. 
In 1929 it was discovered that the conjugation of the capsular polysaccha-
rides to a carrier protein increased vaccine immunogenicity leading to improved 
memory and enhanced immune responses also in young children4,21,22. Nowadays, 
pneumococcal conjugate vaccines (PCVs) are introduced in many industrialized 
countries for childhood vaccination included in the national vaccination
programs4. Prevnar 7 (US) or Prevenar 7 (Europe) is a 7-valent PCV that includes 
polysaccharides from serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. Selection of these
serotypes was based on their prevalence and strong association with invasive
pneumococcal disease in the Western world. However, the disease burden is 
highest in developing countries where different serotypes are circulating and






vaccines both include the same serotypes as in PCV7 to which 3, 6A, 19A are 
added. PCV13 additionally contains serotypes 1, 5, and 7F. Introduction of PCVs 
in industrialized countries has greatly reduced pneumococcal disease and 
carriage by serotypes included in the vaccine (i.e. vaccine (sero)types; VTs)4,6,23,24.
ϐͳ͵Ǥ
illustrated that the use of PCV13 resulted in a cost-effective reduction in 
 ϐ     ͸ͷ   25. Following PCV 
introduction, non-vaccine (sero)types (NVTs) are increasingly isolated from 
patients with invasive disease26-30. The decrease in VT carriage caused by PCV 
immunization has also led to an increased carriage of NVTs, also referred to as 
serotype replacement, which is thought to be a result of changes in the 
nasopharyngeal microbiome26,27,31. Theoretically, infections resulting from 
serotype replacement can be solved by including more serotypes in the PCVs. 
However, the number of capsular polysaccharides that can be coupled to a 
carrier protein is limited due to the complexity of the manufacturing process. 
The addition of polysaccharides also leads to a sharp increase in the vaccine 
production costs. Furthermore, immunological restrictions such as too much 
carrier antigen may impair antibody responses by polysaccharide antigen 
competition or carrier-mediated epitope suppression22,32.
Despite the availability of vaccines and antibiotics, S. pneumoniae still causes 
approximately 1.3 million deaths yearly5. Alternative vaccine strategies 
addressing the limitations of the currently applied strategies are therefore
required to reduce the global burden of pneumococcal disease. Experimental
vaccine development focuses on the use of, preferably highly conserved, 
pneumococcal proteins that are present in all serotypes4,14,22,33,34. These may 
potentially be incorporated in a universal vaccine, protecting against all 
circulating strains. Important candidates for a protein-based vaccine include 
virulence proteins, such as pneumococcal surface protein A (PspA), C (PspC),
and pneumolysin4,14,22,33,34. Although some protein-based vaccines have been 
tested in clinical trials they are still far away from marked approval.
Streptococcus pneumoniae colonization: a prerequisite for disease
Colonization of the nasopharynx by pneumococci is a highly dynamic process
and an essential step preceding pneumococcal disease (Figure 1)4,35. Although
persons from all ages acquire and become colonized by S. pneumoniae, the 
      Ǥ      ϐ
pneumococcal colonization event for a child is around the age of 6 months in 
Ǥϐ
is highly variable and can range between 1-30 weeks depending on the type





acquisition and duration of colonization include breast-feeding, antibiotic 
use, and co-infection with other respiratory pathogens4,38-40. Prolonged carriage 
is characteristic for young children. Colonization duration decreases with
ǡǤǤϐʹ
10% in infants over 5 years of age4,8,41,42. In industrialized countries, the incidence
of pneumococcal carriage varies between 20 and 50% in children below the age
of 3 years, whereas in developing countries, typically all 3-month-old children 
are carrying S. pneumoniae4,8,43. It is therefore not surprising that young children 
are considered the natural reservoir for S. pneumoniae and thus are primarily 
responsible for pneumococcal transmission.
PCVs were initially designed to protect against invasive disease via induction
of systemic anti-capsular antibodies and complement activity that mediate 
pneumococcal opsonization and killing by phagocytic cells4,44,45. However, there 
is increasing evidence that PCVs also reduce the circulation of VTs, suggesting
that PCVs directly affect VT carriage26,27,31. Indeed, a recent clinical trial 
demonstrated that in participants who received PCV S. pneumoniae colonization
was reduced after intranasal challenge46. It has been postulated that the strong
reduction of VT-induced pneumococcal disease by PCVs may primarily be caused
by the PCV’s reduction of VT carriage.
A reduction in pneumococcal colonization can be caused by distinct mucosal 
immune mechanisms (Figure 2). The mechanisms underlying PCV-mediated 
reduction in S. pneumoniae carriage are not yet completely understood, but these 
  ǡ  Ǧϐ  
bacterial cells and prevent pneumococcal adherence to the nasospharyngeal 
epithelium47ǤǦϐ
in colonization by blocking acquisition in mice, although it was repetitively 
shown that antibodies are not essential for protection against pneumococcal
colonization48-50. Alternatively, a memory Th17 response was responsible for
protection against pneumococcal colonization in mice as shown with a whole 
cell vaccine (WCV), e.g. heat-inactivated S. pneumoniae vaccine adjuvanted with
cholera toxin (CT)49,51. This memory Th17 response is accomplished by memory 
CD4+ T cells that produce IL17A upon recognition of pneumococcal antigen 
   ϐ  ǡ   S. pneumoniae at the
nasopharyngeal niche. Notably, a Th17 response against S. pneumoniae in the
ǡϐ
CD4+Th17+ T cells have been detected in the mucosal tissue of the human 
respiratory tract52. However, for clearance of colonizing pneumococci during a








The presence of a relationship between pneumococcal carriage and disease
has been demonstrated by studies in both mice and men in which increased
pneumococcal densities in the nasopharynx are associated with disease
progression38,54-56. This relation is further supported by the observed parallel
decrease in carriage and invasive pneumococcal disease by VTs following
introduction of PCVs8,33. Importantly, during the carriage stage pneumococcal
DNA derived from lysed cells is taken up by neighbouring pneumococci and 
integrated in their genome57. This horizontal gene transfer is the most important 
determinant for the emergence of new variants and selection of antibiotic 
resistance. Therefore, a vaccine that reduces or restricts pneumococcal carriage 
may be an attractive option to prevent disease progression, but also to reduce
pneumococcal transmission. Such a vaccine may simultaneously decrease the 
risk of horizontal transfer and the occurrence of new variants and antibiotic-
Figure 2 Distinct mucosal immune mechanisms reduce colonization 
of S. pneumoniae.
             ϐ
pneumococcal colonization. S. pneumoniae carriage starts by acquisition of the bacterium, which can
ϐǤS. pneumoniae colonization
is established, mucosal neutrophils, macrophages, and Th17 cells directly affect colonizing 











resistant strains. Although there is not yet a licensed vaccine available that 
targets bacterial carriage, the observed reduction in bacterial colonization in 
clinical trials is widely accepted as an endpoint and used as a correlate of 
ϐ8,58-60.
A mucosal vaccination approach to target pneumococcal carriage
Vaccination has been one of the most successful strategies to reduce morbidity 
and mortality caused by respiratory infections. Mucosal vaccination is
particularly appealing as protection can be offered at the site of pathogen entry 
and provides strong mucosal as well as systemic immunity with long lasting 
memory12,61. There are different routes for mucosal vaccination, but the oral and
intranasal applications are the most accessible and acceptable. Intranasal 
vaccination offers additional advantages compared to the parenterally applied
PCV. It is easy to administer, needle-free and therefore administration does not 
require medical staff. It also mimics the natural route of infection potentially 
inducing the most effective immune response. It has been shown that pneumo- 
coccal infection of the nasopharyngeal mucosa protects against both colonization
and disease in mice62. Additionally, different experimental vaccines strongly 
reduce pneumococcal colonization after intranasal immunization49,63,64. We
therefore hypothesize that an intranasal vaccine targeting pneumococcal 
carriage will further reduce pneumococcal morbidity and mortality worldwide 
in both industrialized and developing countries. Currently, there is only one 
  ǡ 	ǡ      ϐ
ϐ65,66. 
An important challenge in the development of mucosal vaccines is the lack of 
suitable adjuvants that are strong enough to break immunological tolerance12,61.
In experimental research, cholera toxin (CT) and non-toxic derivatives of subunit 
A (CTA) and B (CTB) are strong and widely used mucosal adjuvants, but not yet 
approved for human application. Alternatively, bacterial outer membrane 
vesicles (OMVs) represent an interesting novel strategy to deliver vaccine
antigens and are considered natural adjuvants, because of their intrinsic
stimulatory properties to activate the immune system and their particulate 
nature67,68. Recently, OMVs were engineered for recombinant expression of 
(pneumococcal) antigens, combining antigen delivery and natural adjuvanticity 
in a single particle (Figure 3)63,69-71. Importantly, OMVs are strong mucosal 
adjuvants, as it was recently shown that intranasally delivered Escherichia coli
OMVs had comparable adjuvant activity as CT72. Compared to the currently used
pneumococcal conjugate vaccines, OMVs are much simpler to produce at a lower
cost, which allows for easier implementation in developing countries. Currently, 






Neisseria meningitidis, Bexsero, that is proven to be safe and effective in
humans73,74. 
The aim of this thesis is to study the impact of intranasal vaccination on 
pneumococcal colonization and to explore the mucosal immune responses that 
affect S. pneumoniae densities in the nasopharynx. In Chapter 2 of this thesis we 
investigated the applicability of an OMV-based vaccine containing pneumococcal 
model antigens (PspA and pneumolysin) to protect against pneumococcal 
colonization. Conserved pneumococcal proteins are incorporated in vaccines to 
induce broader protection. Chapter 3 therefore describes the role of highly 
conserved protein SP1298, renamed as PapP. This study set out to explain the 
reduction in virulence of S. pneumoniae ϐ  ͳʹͻͺǡ  
observed in animal models of pneumococcal disease75. So far it is unclear
whether a vaccine inducing Th17-mediated immunity that utilizes variable
proteins can offer broad protection against pneumococcal colonization. In
Chapter 4 we explored the feasibility of using a variable pneumococcal protein, 
namely PspA, at the basis of broadly protective vaccine against S. pneumoniae
Figure 3 Salmonella OMVs surface displaying heterologous antigens.
Salmonella was engineered to express an E. coli autotransporter protein (Hbp) fused to multiple 
antigens or antigen fragments from S. pneumoniae at the membrane surface. OMVs are formed 





colonization. We selected the part that induced the strongest protection, i.e. the
Ǧ ȽͳȽʹ Ǥ  ȽͳȽʹ     
were aligned and Th17 memory cross-reactivity of the vaccine with sequenced 
clinical isolates were assessed in ex vivo and in vivo studies. Certain adjuvants 
        ǮǦϐǯ 
against respiratory infections independently of the co-administered antigens.
In Chapter 5, we assessed the effect of mucosal adjuvant CTB on pneumococcal 
densities in the murine nasopharynx. We studied the role of CTB in pneumococcal 
ϐͳȀͳͳǡ
T cells, and macrophages. Also we explored the associated mucosal immune 
mechanisms and focused on T helper cytokines and immune cells with a known 
   Ǥ ϐ  Ǧ  
ϐǡǤǤǡ
  ϐ Ǥ  Chapter 6 we studied the effect of mouse 
genetic backgrounds on vaccine-induced reduction in pneumococcal colonization. 
We studied pneumococcal clearance in C57BL/6, BALB/c, and CB6F1 mice
following vaccination. Furthermore we explored the mucosal immune responses, 
e.g. by measuring T helper cytokines in nasal tissue, for an association with
reduction in pneumococcal colonization. Chapter 7 discusses the age-related 
susceptibility to pneumococcal infection in infants and elderly and offers insight 
into why infections occur at the age extremes of life. Susceptibility to infection is
illustrated as prolonged colonization of S. pneumoniae in the nasopharynx. This
ϐ
in both age groups. Lastly, Chapter 8   ϐ
           ϐ 
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Bacterial outer membrane vesicles (OMVs) are attractive vaccine formulations 
because they have intrinsic immunostimulatory properties. In principle, 
       ϐ 
responses, especially if presented at the vesicle surface and thus optimally 
exposed to the immune system. In this study, we explored the feasibility of our
ǡ ϐ
simultaneously display multiple antigens at the surface of bacterial OMVs, for 
vaccine development. Using two Streptococcus pneumoniae proteins as model
antigens, we showed that intranasally administered Salmonella OMVs displaying 
high levels of antigens at the surface induced strong protection in a murine 
model of pneumococcal colonization, without the need for a mucosal adjuvant. 
Importantly, reduction in bacterial recovery from the nasal cavity was correlated 
    Ǧϐ Ǧͳ͹Ǥ 	ǡ  
ϐ Ǧϐ Ǧͳ͹ǡ 
IgGs, were all improved at increased concentrations of the displayed antigen.
This discovery highlights the importance of an adequate antigen expression 
system for development of recombinant OMV vaccines. In conclusion, our 
ϐ
new generation of OMV vaccines, and illustrate the potential of using this 







Outer membrane vesicles (OMVs), ubiquitously released from the outer 
membrane (OM) of Gram-negative bacteria, are promising as vaccines because 
they combine antigen and adjuvant in a single formulation. The intrinsic adjuvant 
activity provided by the presence of various pathogen recognition receptor 
ligands, such as lipopolysaccharide and immunogenic surface proteins, forms an 
attractive combination with the non-living, particulate nature of the OMVs1-3.
OMVs have protected animals against various pathogens4,5, and a licensed OMV
vaccine against Neisseria meningitidis has been proven safe and protective in
humans6. The interest in OMVs expanded as heterologous proteins were 
successfully incorporated into vesicles7-11, and engineered OMVs were shown to
Ǧϐ9-11 and protection in mice9.
Accumulating evidence indicates that both the magnitude and the breadth 
of the immune response can be improved by secreting or displaying antigens at 
the surface of bacterial and viral vaccine vectors12-17. Instigated by these 
observations, we recently engineered the Escherichia coli autotransporter (AT)
ȋȌϐ
polypeptides at the surface of live bacteria18,19, bacterial ghosts20 and OMVs21. 
The AT pathway is the most widespread system for transport of proteins across 
the Gram-negative cell envelope, employing a relatively simple two-step
Ǥϐ
machinery, after which its C-terminal domain inserts into the OM and forms a 
ȾǦ    
functional N-terminal passenger domain to the cell surface or medium22. Based
on the available crystal structure of the Hbp passenger23, a side-domain 
replacement strategy was developed that allows fusion of multiple heterologous 
sequences to a single, stable Hbp scaffold18. Using various mycobacterial, 
ϐǡ
versatile tool for the simultaneous display of multiple sizeable antigens at the 
surface of live bacteria19 and OMVs21.
Here, we set out to test the applicability of the Hbp platform for development 
of recombinant OMV vaccines, using as model antigens the well-known protective 
proteins pneumococcal surface protein A (PspA) and pneumolysin (Ply) of the
nasopharyngeal colonizer Streptococcus pneumoniae24-26. Current pneumococcal 
conjugate vaccines (PCVs), consisting of capsular polysaccharides, have strongly 
   ǦϐS. pneumoniae
serotypes27Ǥǡϐ28-30
and capsular switching events31, and their accessibility in developing countries 





needle-based administration. These limitations can potentially be overcome by 
development of a novel vaccine based on conserved, non-capsular, proteinaceous 
antigens that is suitable for intranasal administration. We describe here the ϐ
in vivo challenge study designed to test a vaccine formulation consisting of OMVs 
that display heterologous proteins at the surface. We investigated whether 
intranasal immunization with Salmonella enterica serovar Typhimurium OMVs
ϐ     
protect mice against pneumococcal colonization. By assessing immune responses
and bacterial load following intranasal S. pneumoniae challenge in mice 
immunized with various vaccine formulations and regimes, we demonstrate the 
potential of the Hbp platform for recombinant OMV vaccine development and
ϐϐǤ
MATERIALS AND METHODS
Bacterial strains and growth conditions
S.  ͵ʹ͸ͳ ȟtolRA21, and E. coli TOP10F’ and BL21(DE3) were 
grown at 37°C in LB medium containing 0.2% glucose. When appropriate, 
ʹͷɊȀ͵Ͳ
ɊȀǤ S. pneumoniae TIGR432 was grown and vaccination stocks containing 106
   ȋ	ȌȀͳͲ Ɋ     ȋȌ 
prepared as described33.
Plasmid construction
Construction of pEH3-based34 plasmids for expression of Hbp fused to pneumo-
coccal antigen fragments and pET16b(+) vectors (Novagen) for expression of 
PspA and the PdT derivative of Ply35 is described in the Supplementary Materials
and Methods.
Hbp expression, OMV isolation and protein analysis
S.  ͵ʹ͸ͳ ȟtolRA harboring pEH3 vectors was grown until an 
OD660 of ~0.6, at which expression of Hbp derivatives was induced from the
lacUV5 ͳͳͲͲɊ
ͳǤ
To isolate OMVs, culture supernatants obtained by low-speed centrifugation 
  ͲǤͶͷǦɊǦǦ ϐ ȋȌ   
208’000×g for 60 min, separating OMVs from soluble proteins. Pelleted OMVs 
were washed by resuspension in PBS containing 500 mM NaCl (1 OD unit of 
ɊȌ  ͶͶͲǯͲͲͲέg for 2 h, after which they were
ͳͷΨȋͳɊȌǤ






Proteinase K accessibility of OMV proteins was analysed as described21, and
proteins were analysed by SDS-PAGE and Coomassie G-250 (BioRad) staining or 
     ȾǦ   ȋͶ͹͹Ȍ36,
  ǡ  ϐ    ȋ  ȌǤ
Densitometric analysis on Coomassie-stained gels was carried out using a 
Molecular Imager GS-800 Calibrated Densitometer (Biorad) and Quantity One 
software (Biorad). 
Mouse immunizations and challenge
Seven week-old female C57BL/6 mice (Charles River Laboratories) were 
intranasally (i.n.) immunized three, two or one time(s) with 8 OD units of OMVs 
ȋ̱ ͶɊȌͳͲɊǡǦǡ
ȋʹǤͷΨȀϐǡȌǤ
  ϐ     ǤǤ  ͳͲ6 CFU of S.
pneumoniae TIGR4 33. Three days after infection, mice were euthanized, and 
blood and mucosal nasal tissue were harvested. Nasal tissue was homogenized
using an IKA T10 basic blender, and serially diluted samples were plated on 
Gentamicin Blood Agar (Mediaproducts BV) to determine bacterial recovery 
(log CFU/organ). All animal work was performed with approval of the Radboud 
University Medical Center Committee for Animal Ethics. Consequently, three
mice were euthanized and excluded from further experimental analysis after
reaching a humane endpoint, i.e. over 20% weight loss, potentially caused by a
reaction to lipopolysaccharide present in the OMVs.
Detection of antibody responses by enzyme-linked immunosorbent 
assay analysis 
  Ǧϐ 
        
described in the Supplementary Materials and Methods.
	ɀǦͳ͹
Cytokine production in mouse nasal samples were determined with Cytometric 
Bead Array (Becton Dickinson) according to manufacturer’s instructions, using
the Mouse Enhanced Sensitivity buffer kit in combination with the Enhanced 
		ɀǦͳ͹ȋȌǤ
calculated using Soft Flow FCAP Array v1.0 (Becton Dickinson).
Statistical analyses
All statistical analyses were performed using GraphPad Prism version 5.0
(Graphpad Software). For bacterial recovery data, the Grubbs outlier test was 





Bonferroni post-test for multiple groups or Mann-Whitney t test for two groups 
were used for comparisons of protection and immune responses. To determine
the relation between IL-17A and protection, a Spearman Correlation test was
applied.
RESULTS
Selection and fusion of PspA and pneumolysin fragments to Hbp 
ϐ
display system, these two complex, multi-domain proteins were split into 
shorter fragments (Figure 1A). To avoid potential destruction of immune
epitopes, fragments were designed to partially overlap with adjacent sequences. 
PspA was divided into four fragments that cover the N-terminal, surface-
exposed part of the protein (Figure 1A). Of these, two fragments derived from
ǦȽǦȋǮȽͳǯǮȽʹǯȌ
    ǡ  ǦȏȽͳǦȽʹȐ ȋ	 ͳȌǤ  
ǡǦȏ	ǦȐȋ	ͳȌǡ
with two fragments corresponding to the lactoferrin-binding domain (‘LFBD’) 
and the conserved Pro-rich region (‘PRR’) of PspA, respectively. Similarly, 
pneumolysin was divided into three fragments (Figure 1A), of which an 
N-terminal (‘F1’) and a C-terminal fragment (‘F3’) were fused to a single Hbp
   Ǧȏ	ͳǦ	͵Ȑ ȋ	 ͳȌǤ ǡ  
pneumolysin fragment (‘F2’; Figure 1A), that includes the membrane-penetrating 
D3 domain19, caused lysis upon expression in the context of Hbp and was 
therefore excluded from further studies.
Efficient display of PspA and pneumolysin fragments at the surface
of Salmonella OMVs
The three Hbp chimeras were expressed under control of a lacUV5 promoter in a
ȟtolRA derivative of the attenuated Salmonella Typhimurium
strain SL3261 that produces large amounts of OMVs21. A display derivative of 
Hbp lacking domain d1, HbpD (Figure 1B)18, was produced in the same strain 
and the resulting vesicles served as a negative control in subsequent studies. 
OMVs were isolated from cell-free culture supernatants by ultracentrifugation,
after which they were washed with PBS containing a high concentration of NaCl 
to remove peripherally attached soluble contaminants. The absence of live
  ϐ  ǡ    ϐ   
Hbp-antigen chimera by SDS-PAGE (Figure 2A) and immunoblotting (Figure 2B). 
Importantly, and similar to the HbpD control, all three chimeras were exposed at 






(Figures 2B and C). In contrast, degradation of the protease-sensitive C-terminal 
periplasmic domain of OmpA occurred only after permeabilization of the OMVs
ǦͳͲͲǡ ϐ      
Figure 1 Vaccine design.
(A) Schematic representations of PspA and pneumolysin. The slightly overlapping fragments that 
  ȽǦȋȽͳȽʹȌǡ  -
rin-binding domain (LFBD) and the Pro-rich region (PRR) but not the cell wall-anchoring cho-
line-binding domain (CBD) of PspA, and the entire Ply sequence. Numbers above the diagrams and 
boundaries next to the fragments correspond to aa positions calculated from the N termini of 
full-length PspA and Ply. (B) Wild-type Hbp (included for reference) comprises an N-terminal 
cleavable signal sequence (ss), a secreted passenger domain, and a linker (grey) and a C-terminal 
        ȾǦǡ      
passenger. Side domains d1-d5, which are dispensable for secretion and can be replaced by 
heterologous polypeptides, are indicated, while the remainder of the passenger domain is black.
Point mutations D1100G and D1101G (denoted X) prevent autocatalytic cleavage after translocation 
across the OM, creating a surface-exposed (display; D) version of Hbp48. Numbers above the diagrams
correspond to the aa positions of the wt Hbp precursor, calculated from the N terminus. Insertion of 


















































































































Figure 2 Vaccine production.
(A) SDS-PAGE/Coomassie analysis of the vaccine stocks used in the two studies. Equivalent volumes
of vaccine stock containing equivalent amounts of OMVs, based on OD units of the original cultures,
were isolated from S. ͵ʹ͸ͳȟtolRA expressing HbpD or the indicated HbpD-antigen 
ǤͳͲͲɊ
ȋǢ
Ȍǡ  ǦȏȽͳǦȽʹȐ ȋȌǡ  ͳɊ 
Ǥ
Below the panel, relative amounts of Hbp chimera’s and OmpA in OMV samples are displayed as 
determined by densitometric analysis. Highest measured densities were put at 100%. B-C, Equal 
amounts of intact (- tx) and Triton X-100-permeabilized (+ tx) OMVs described in A were incubated
with Proteinase K (+ pk) or mock treated (- pk), separated by SDS-PAGE and detected with (B)
immunoblotting using indicated antibodies, and (C) Coomassie staining. An amount of 0.5 OD units 
of OMV material was loaded in each lane. The Hbp (chimeras) are marked by asterisks, and the OMV
marker proteins OmpF/C and OmpA, and Proteinase K are indicated with arrowheads.
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vesicles (Figure 2C). Differences in expression levels of the various HbpD-antigen
fusion proteins are likely determined by the difference in complexity of the 
inserted fragments. Nevertheless, all Hbp-antigen fusions were visible after 
Coomassie staining indicating that the expression levels are substantial.
Salmonella OMVs displaying PspA fragments protect against 
pneumococcal colonization
To investigate whether Salmonella OMVs displaying PspA and Ply fragments at 
the surface can confer protection against pneumococcal colonization, we made
use of a previously established mouse model37. Mice were intranasally immunized
Ǧǡϐǡ
they were intranasally inoculated with the S. pneumoniae serotype 4 TIGR4
strain. Recovery of live pneumococci from nasal tissue three days post-infection 
ǦȏȽͳǦȽʹȐ
ϐ





          ϐ
Ǧȏ	ǦȐǦȏ	ͳǦ	͵Ȑȋ	ʹȌǡ
immunization was repeated with OMVs displaying one of the antigen fragments, 
ǤǤȏȐȋ	ʹǡͳͲȌǡ̱͵ǦȏȽͳǦȽʹȐ
(Figure 2A, lane 8). However, no reduction in bacterial load was observed 
(Figure S1), suggesting that protection depends on intrinsic features of the
ǤȽǦǡǦ
the surface-exposed S. pneumoniae polyhistidine triad protein D was previously 
shown to be highly immunogenic and more protective than the full-length
protein in a murine sepsis model38, these properties might be related to the
ȽǦȏȽͳǦȽʹȐ25,39. Together these 
data show that the OMV/Hbp platform is suitable for intranasal antigen delivery. 
	ǡǦȽǦ
able to induce protection against pneumococcal colonization.
Immunogenicity of Salmonella OMVs displaying pneumococcal 
antigens
Immunity to S. pneumoniae	ɀȀ
or IL-17A-mediated recruitment of various effector cells including neutrophils 








mice were subjected to subsequent pneumococcal infection, the cytokine levels 
    Ǧ ϐ    Ǧ
induced memory towards the pneumococcal antigen fragments. Interestingly, 
	ɀȋ	ͶȌǡ
 ȀǦȏȽͳǦȽʹȐ  ϐ    Ǧͳ͹
levels compared to control mice (Figure 4B). This strongly suggests that local
Ǧͳ͹ǡ	ɀǡǦ
coccal colonization.
Because IgGs are important for bacterial opsonization and initiation of 
 ǡ ǦǦϐ
IgGs and IgAs in nasal tissue homogenates and sera of immunized mice (Figures 
ͷǡ ʹ  ͵ȌǤ ǡ ϐ     
Ǧϐ
Ȁ
ǦȏȽͳǦȽʹȐǤ  ǡ       
Figure 3 ȀǦϐ
antigen fragment, antigen amount, and immunization number.
Bacterial recovery of S. pneumoniae from nasal tissue three days post intranasal challenge of 
C57BL/6 mice that received (A) three intranasal immunizations with OMVs displaying HbpD, HbpD-
ȏȽͳǦȽʹȐǡ Ǧȏ	ǦȐ  Ǧȏ	ͳǦ	͵Ȑǡ  ȋB) three, two or one intranasal 
immunization(s) (3x; 2x; 1x) with OMVs expressing HbpD or high (H) or 7-fold lower (L) levels of 
ǦȏȽͳǦȽʹȐǤ    ȋαͷǦͳͷ Ȍǡ   






































































































in the other groups. Moreover, there were no differences observed for local IgA 
production between the treatment groups. Together these results show that the 
ȀǦϐǦͳ͹Ǥǡ
the platform can induce local and systemic humoral responses.
Figure 4 Protective immunity correlates with intranasal IL-17A levels.
Nasopharyngeal (AȌ	ɀȋB) IL-17A three days post-infection in mice immunized three times 
     ǦȏȽͳǦȽʹȐǤ ȋC) Nasopharyngeal IL-17A three days 
post-infection in mice immunized three, two or one times (3x; 2x; 1x) with OMVs expressing HbpD
ȋȌ͹ǦȋȌǦȏȽͳǦȽʹȐǤ A-C, *, p < 0.05; **, p < 0.01; *** p < 0.001. 
D, Pooled data from study 1 and 2 for nasopharyngeal IL-17A and number of CFU three days 





















































































































Level of protection is influenced by the vaccine-associated antigen 
load and the number of immunizations
    ȽͳȀȽʹ     
 ǡ  ǦȏȽͳǦ
ȽʹȐȋ	ʹȌ
important determinant for immune responses and protection. To this end, mice
ǦȏȽͳǦȽʹȐ
ϐ̱͹Ǧ
(Figure 2A). Similar to the previous experiment, mice immunized with OMVs 
    ǦȏȽͳǦȽʹȐ  ϐ 
  Ǧϐ Ǧͳ͹    ȋ	 ͶȌǡ   
Ǧϐ
ǡǦϐȋ	ͷǡʹ
and S3B). In contrast, IL-17A and IgG levels were low or undetectable in samples 
   ǦȏȽͳǦȽʹȐǡ
ϐ 
doses of OMVs without pneumococcal protein fragments (Figures 4C, 5B and 
ʹȌǤ	ǡȏȽͳǦȽʹȐ






in mice immunized (A) three times with OMVs displaying the indicated HbpD (chimera), or (B) three, 
    ȋ͵Ǣ ʹǢ ͳȌ    ǡ  ǦȏȽͳǦȽʹȐ  
antigen amount (H; high or L; 7-fold lower). Symbols represent individual mice, and bars represent 












































































































To investigate whether similar levels of protection could be reached with 
fewer immunizations, two additional groups of mice were included that received 
ǦȏȽͳǦ
ȽʹȐǤ  ϐ     
ǡ
but not local IgA levels independently of the number of immunizations (Figures
5B, S2B and S3B). However, although slightly more IL-17A was detected after
 ǡ      ϐ
higher IL-17A production compared to control mice (Figure 4C). Moreover, three
ϐǡ
  ϐ   
with the control (Figure 3B).
In conclusion, the antigen abundance and the number of immunizations 
ϐǦͳ͹S. pneumoniae
Ǥ ǡ    Ǧͳ͹ ϐ
ȋαͲǤͲͲ͵ʹȌ
(Figure 4D), suggesting that local IL-17A responses are crucial for protective 
memory responses induced by our OMV/Hbp antigen display platform.
DISCUSSION
The potential of bacterial OMVs, initially restricted to development of vaccines 
targeting infection with the parent bacterial species, was further expanded
by the possibility of engineering OMVs to contain heterologous antigens7-11.
      ϐǡ   
multiple heterologous polypeptides to the OMV surface19,21. Here we demonstrate 
ϐǡ
S. pneumoniae colonization model, that intranasally administered OMVs 
decorated with heterologous antigens at the surface induce strong protection
that correlates with local IL-17A production. The advantage of displaying
antigens was highlighted in previous vaccine studies showing that secreted or
surface-exposed antigens elicit strong cellular immune responses, because of 
superior antigen processing, and that physical association of PAMPs might play 
a role in enhanced responses12,14-16. Importantly, modulation of antigen levels
revealed that both immune responses and protection are improved as antigen 
concentrations in the vaccine formulation are increased (Figures 3B, 4C and 5B). 
This highlights the importance of an adequate antigen expression system, such 
as the Hbp platform, which mediates expression at strikingly high levels that are 
easily detectable by Coomassie staining. 
Intranasally administered Salmonella OMVs loaded with PspA in the lumen 





peritoneal challenge model9, showcasing that OMV vaccines can be used to 
prevent invasive pneumococcal disease. Although this strategy is used to induce 
broad protection against invasive disease, we decided here to focus on prevention
of S. pneumoniae colonization. Undeniably, targeting the nasopharyngeal 
carriage state with an intranasal vaccine would likely not only protect against 
disease, but also prevent transmission, thereby providing herd immunity and 
simultaneously reducing emergence of DNA exchange-mediated antigenic 
variants43. The potential of our approach is underlined by the observed
     Ǧͳ͹ ǡ  ϐ
 ϐ  Ǧͳ͹ 
immunity to S. pneumoniae42. While others showed systemic ex vivo Th17 
responses associated with protection measured at six days or longer after 
pneumococcal challenge40,42,44,45, we observed that nasopharyngeal IL-17A levels,
as early as three days post-challenge, correlated with protection. Although it is 
currently not clear how the OMVs precisely induce IL-17A production, our 
ϐ        E. coli OMVs46. Possibly,
lipoproteins in the OMVs are involved, as lipoproteins have been shown to have
a strong Th17 inducing capacity and are directly linked to clearance of colonizing
pneumococci47. Encouraged by the promising results obtained with the PspA
model antigen, we are currently incorporating additional highly conserved
antigens with the aim of developing a pneumococcal vaccine that can induce 
serotype-independent protection. 
In conclusion, our results demonstrate the potential of the Salmonella OMV 
surface display platform in vaccine development. The ability to induce strong
protection and local IL-17A production without the requirement of an external
adjuvant is particularly interesting for development of intranasal vaccines 
against mucosal pathogens, a strategy that is currently hampered by the lack of 
suitable mucosal adjuvants. Furthermore, the autotransporter Hbp mediates 
remarkably high antigen densities at the OMV surface, which we showed is
important for induction of protective responses. Considering its compatibility 
with antigens of diverse origins19 and the availability of easy manufacturing
methods using a hypervesiculating attenuated S. Typhimurium strain, the OMV/
Hbp platform holds promise for developing safe yet immunogenic, needle-free 
and affordable recombinant OMV vaccines, applicable to a broad range of 
diseases. Moreover, by allowing simultaneous fusion of multiple antigens to the 
same carrier, the platform opens up the possibility of creating multivalent 
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SUPPLEMENTARY MATERIALS AND METHODS
Plasmid construction 
All reagents were purchased from Roche, except for Phusion DNA polymerase 
(Finnzymes) and SacI (New England Biolabs).All plasmids used for expression of 
Hbp (derivatives) have a pEH3 backbone1ǤȋȟͳȌǡȋȟʹȌ
and pHbpD(d4in), in which sequences coding for side domains d1, d2 and d4 of 
the Hbp passenger were substituted for Gly/Ser-encoding linkers containing
SacI and BamHI restriction sites have been described2. 
Fragments of pspA coding for the N-terminal and the C-terminal portions of 
ȽǦǡ	Ǧǡply encoding 
an N-terminal (F1; aa 1-156), a central (F2; aa 145-421) and a C-terminal 
ȋ	͵Ǣ͵ͷ͹ǦͶ͹ͳȌϐϐ SacI/BamHI sites using
chromosomal DNA of S. pneumoniae TIGR4 as template and primers listed in
Table S1. The resulting PCR amplicons were digested with SacI and BamHI and
inserted into the hbp orfs ȋȟͳȌǡȋȟʹȌȋͶȌǡ
which had been digested with the same restriction enzymes. This approach 




fragments of PspA, the NdeI/NsiI   ȋȟͳȌǦȋȽͳȌ 
ȋȟʹȌǦȋȽʹȌǡǦȋȽͳȽʹȌǤ
Similarly, the NdeI/NsiI   ȋȟͳȌǦȋ	ͳȌ   
ȋȟʹȌǦȋ	͵ȌǡǦȋ	ͳ	͵Ȍ
of a chimera containing both fragments F1 and F3 of pneumolysin. Finally, a 
plasmid was created for expression of Hbp fused to the LFBD and PRR fragments 
     Ȁ   ȋȟͳȌǦȋ	Ȍ 
ȋȟͶȌǦȋȌǤ
ϐǦǦ
and PdT3 were created using the pET16b(+) vector (Novagen). For cloning of pspA,
͵ͳ͹ͶͶϐS. pneumoniae
TIGR4 chromosomal DNA as template. The forward primer nHis-pspA(dN31)-fw 
was designed to contain a His8-epitope encoding sequence and an NcoI restriction 
site, while the reverse primer pspA-rv contained an NdeI site. A synthetic E. coli-
Ǧ     ϐ  NcoI and NdeI
restriction sites was ordered from Life Technologies. The fragments were 
digested with NcoI and NdeI and ligated into pET16b(+), digested with the same 







Overnight cultures of E. coli BL21(DE3) harboring pET16b(+) plasmids for 
expression of PspA and PdT3 were grown at 37°C  in LB medium supplemented
  ȋͳͲͲɊȀȌ    ȋͲǤͶΨȌǤǡ 
were diluted to an OD660 of 0.05 in fresh medium and growth was continued 
under the same conditions. When the cultures had reached an OD660 of 0.6,
ͳͲͲɊ

2 h. Cells were harvested by low-speed centrifugation, resuspended in ice cold 
PBS (pH 7.4) containing 5 mM imidazole and 300 mM NaCl, and lysed in a One 
Shot cell disrupter (Constant Systems Ltd) at 1.72 kbar. Unbroken cells were
removed by low-speed centrifugation. Thereafter, soluble proteins were 
obtained by high-speed centrifugation at 208.000×g at 4°C for 90 min. For PdT, 
Ǧ     Ǧ   ϐ 
ϐȋ
ȌǤ
Bound PdT was eluted over a gradient of 5-500 mM imidazole in PBS (pH 7.4)
containing 300 mM NaCl. Fractions containing His-tagged PdT were pooled and
dialyzed against PBS containing 15% glycerol. The same procedure was followed 
Table S1 Primers used in this study





















to isolate His-tagged PspA, except that the high-speed supernatant and the 
ϐͺ Ǥ
Detection of antibody responses by enzyme-linked immunosorbent 
assay analysis
ϐȋȌʹɊȀϐ
PspA or PdT in carbonate coating buffer (0.1 M carbonate/bicarbonate pH 9.6)
at 4°C overnight. The next day, wells were blocked with 1% BSA (Sigma) and
subsequently incubated for 1 h at 37°C with serum or nasal samples from 
individual mice. Thereafter, the wells were incubated with primary anti-mouse 
IgG-alkaline phosphatase (Sigma) or primary anti-mouse IgA-alkaline phosphatase 
(Southern Biotech) for 1 h at 37°C. Between and after the incubations steps, 
all wells were washed with PBS containing 0.05% Tween-20 (Merck). Samples 
were developed using 1 mg/mL p-nitrophenylposphate in substrate buffer (1 M
diethanolamine, 0.5 mM MgCl2 pH 9.8) (Calbiochem, VWR) and the optical density 
was measured at 405 nm 10 and 30 minutes after substrate addition.
Figure S1 Bacterial recovery upon high expression of PRR.
Bacterial recovery of S. pneumoniae from nasal tissue three days post intranasal challenge of 
C57BL/6 mice that received three (3x) intranasal immunizations of OMVs displaying HbpD or high 
(H) levels of antigen fragment PRR. Each symbol represents an individual mouse, and bars represent 































mice immunized with OMVs displaying A, indicated Hbp (derivatives) or (BȌǦȏȽͳǦ
ȽʹȐȋȌͷǦȋȌǡȋ͵ǢʹǢ
1x). Bars represent mean per group, and symbols represent samples from individual mice. *, p < 0.05;
**, p < 0.01; *** p < 0.001.
Figure S3 ǦϐǤ
Ǧϐ ǡǡ 
immunized with OMVs displaying, (A) indicated Hbp (derivatives) or (BȌǦȏȽͳȽʹȐ
at high (H) or 5-fold lower (L) expression levels, and with varying immunization number (3x; 2x; 1x).
Bars represent mean per group, and symbols represent samples from individual mice. *, p < 0.05; ** 
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Proteins belonging to the DHH family, a member of the phosphoesterase 
superfamily, are produced by most bacterial species. While some of these
proteins are well studied in Bacillus subtilis and Escherichia coli, their functions
in Streptococcus pneumoniae remain unclear. Recently, the highly conserved 
DHH subfamily 1 protein PapP (SP1298) has been reported to play an important 
role in virulence. Here, we provide a plausible explanation for the attenuated 
virulence of the papPǤϐ
͵ǱǦǦͷǱǦȋȌͷǱǦǦȋ͵ǱΫεͷǱȌǦ
(pApA). Deletion of papP, potentially leading to pAp/pApA accumulation, 
resulted in morphological defects and mis-localization of several cell division 
proteins. Incubation with both polar solvent and detergent led to robust killing 
of the papP mutant, indicating that membrane integrity is strongly affected. 
This is in line with previous studies showing that pAp inhibits the ACP synthase,
an essential enzyme involved in lipid precursor production. Remarkably, partial 
inactivation of the lipid biosynthesis pathway, by inhibition of FabF or depletion of 
FabH, phenocopied the papP mutant. We conclude that pAp and pApA phosphatase 
activity of PapP is required for maintenance of membrane lipid homeostasis










the leading causes of infection-related mortality worldwide1ǤǦϐ
pathogen mainly resides on the mucosal surface of the upper respiratory tract 
generally resulting in asymptomatic carriage2,3. However, S. pneumoniae may transit 
to other tissues causing a broad range of diseases varying from non-invasive
infections such as otitis media and sinusitis, to more severe invasive disease, 
including pneumonia, meningitis and sepsis2,4.
Recently, the protein SP1298 of S. pneumoniae TIGR4 (here renamed to PapP
for phosphoaǦͷǱǦpͷǱǦǦȋ͵ǱΫεͷǱȌǦ
phosphatase, see results) was discovered using GAF and Tn-Seq and appears to 
be a highly conserved protein across the different pneumococcal serotypes5,6.
Inactivation of this gene strongly reduced virulence at different stages of 
pneumococcal disease, as studied in murine models of colonization, otitis media, 
pneumonia, and bacteremia7,8, suggesting a critical role for PapP in pneumococcal 
virulence.
PapP is annotated as DHH subfamily 1 protein as it contains the two domains 
DHH and DHH1. The DHH subfamily 1 is part of the superfamily of phospho-
esterases9. Within the phosphoesterases two subfamilies exist: the subfamily 2
found in eukaryotes, and the subfamily 1 found in archaea and bacteria. Although 
these proteins appear to be expressed by most bacteria, little is known about the
function of DHH subfamily 1 proteins in S. pneumoniae.
PapP shares sequence homology with YtqI of B. subtilis, which has both 
oligonuclease and pAp-phosphatase activity10. Of note, most sequence homology 
is shared with SMU.1297, a Streptococcus mutants protein that was reported as
pAp phosphatase in vitro, but which lacks an oligonuclease activity and is 
required for superoxide stress tolerance11. Recently, the PapP ortholog in strain
D39 (SPD_1153) sharing 98% amino acid identity was annotated as Pde2 (PDE:
phosphodiesterase)8. They showed that PapP synergizes with SP2205 (or Pde1) in
a two-step in vitro process, converting c-di-AMP and pApA into AMP. Based on 
enzymatic assays, they hypothesized a role for PapP in cell wall maintenance and 
signaling8, while the conversion of pAp, as previously found for other homologous 
proteins, was not described. Therefore, the function of this nucleotide phosphatase 
remains largely enigmatic, although most studies suggest that PapP homologs 
convert pAp, a byproduct of the panthotenate and CoA synthesis, into AMP10-12.
 ϐǡ      
(ACP), an essential precursor for the initiation of de novo fatty acid synthesis.
Furthermore, it has been shown that ACP synthase activity can be inhibited by 





In this study we demonstrate that PapP is a nucleotide phosphatase converting 
pAp and pApA into AMP in vitro. Deletion of papP ϐ 
morphology and the localization dynamics of several key cell division proteins
in a temperature dependent manner. Furthermore, we discovered that the
membrane integrity of the papP mutant was disrupted and that partial
          ȟpapP
phenotype, thus providing a molecular explanation for reduced S. pneumoniae
virulence.
MATERIALS AND METHODS
Pneumococcal strains, growth conditions and transformation
Pneumococcal strains were routinely grown at 37°C on Blood Agar (BA) or in 
liquid cultures of Todd Hewitt broth with 5 g L-1 yeast extract (THY). For 
microscopy analyses, strains were grown in C+Y medium at 37 °C, 30 °C or 25°C.
For transformation, S. pneumoniae Ϊα͸Ǥͺ
until O.D600nm αͲǤͳǢͲǤʹρȀǦʹȋǦ
Peptide 2) was added and the cells were incubated at 37 °C for 12 min. After DNA
addition, cells were incubated at 30 °C for 20 min, then diluted 10 times in THY 
or C+Y medium, followed by incubation for 1.5 h at 37 °C. Transformants were
selected on Blood agar or Columbia agar supplemented with 3% (v/v) sheep 
blood and the appropriate antibiotic. For induction of the PZnǡͳͲͲρ
ZnCl2 was added to liquid medium or agar plates. When required, the growth
    ͳͷͲ ρȀ  ȋȌǡ ͷͲͲ ρȀ
 ȋȌǡ ͲǤͷ ρȀ  ȋȌ  ͲǤʹͷ ρȀ 
(Ery). Strains and plasmids construction are detailed in SI Methods. Strains are
listed in table 1, plasmids and primers are listed in tables S2-S3 respectively.
Bioinformatic protein conservation analyses and homology 
modeling
To study the conservation of SP1298 (PapP), the amino acid sequence was
aligned with BLAST against the Concise Microbial Protein database with one 
orthologous sequence per species to avoid overrepresentation. 514 proteins 
(e-value <0.001) were selected and aligned using ClustalOmega15. PapP was
ϐͳʹ͹Ǥ
subsequently coupled to species and function using the batch retrieval option in 
the Protein Information Resource (PIR)16 (Table S1).
A homology model for SP1298 was built using the experimentally solved
3D-structure of SH1221 protein from Staphylococcus haemolyticus as a template 
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algorithm with standard parameter settings in the YASARA & WHAT IF Twinset 
was used for model building and analysis17,18.
Protein expression and purification
ϐǤʹͳǦͳʹͻͺ7
͵͹ǏͲǤʹΨͳͲͲɊȀ
ampicillin. When the culture reached an OD660 of 1.0, the incubation temperature
  ͳͺ Ǐ   ʹǤ  
  ͲǤʹΨͳͲͲɊȀ 
OD660 ͲǤͷǤ  ͳͲͲɊ ǦȾǦǦ
(IPTG) was added to induce the overexpression of PapP and the culture was 
ͳͺǏǤ
The cells were harvested by centrifugation, re-suspended in ice-cold PBS
containing 300 mM NaCl, 5 mM Imidazole and Complete protease inhibitor 
cocktail (Roche), and lysed by two passages through a One Shot cell disrupter 
(Constant systems). Cell debris and membrane material was removed by 
low-speed centrifugation at 8,000 x gʹͲͶǏ-
ϐǦʹͲͺǡͷͲͲ g ͻͲͶǏǤ
supernatant was loaded onto a 1 ml HiTrap TALON crude column (GE Healthcare) 
and PapP was eluted with a linear gradient of 5 - 500 nM Imidazole in PBS 
containing 300 nM NaCl at 125 mM Imidazole concentration. The elution peak 
Table 1 Streptococcus pneumoniae strains used in this study
Strain Relevant characteristics Reference
TIGR4 Serotype 4 strain, TIGR4 wild type 13
papP-gfp TIGR4, bgaA::PZn-papP-gfp (Tc
r) This study
CG14 TIGR4, ftsZ::ftsZ-mKate2 (Eryr) This study
CG16 TIGR4, bgaA::PZn-gfp-ftsA (Tc
r) This study
ȟpapP TIGR4, papP::spc (Spr) 7
ȟcps TIGR4, Deletion of the capsule operon 14
ȟsp1479 TIGR4, sp1479::spc (Spr) This study
CG22 TIGR4, papP::spc, ftsZ::ftsZ-mKate2 (Spr, Eryr) This study
CG18 TIGR4, papP::spc, bgaA::PZn-gfp-ftsA (Sp
r, Tcr) This study
ȟpapP* TIGR4, papP::spc, IS1167::pCEP-papP (Spr Kanr) This study
ȟfabH* TIGR4, fabH::ery, bgaA::PZn-fabH (Ery
r, Tcr) This study







using 12,000 – 14,000 MWCO SpectraPor4 dialysis membranes (Spectrumlabs).
The protein was analyzed for purity with SDS-PAGE and Coomassie G250
ǦͺͲǏǦ
the enzymatic activity.
Protein reconstitution with manganese
ϐʹ ͺͲ
ϐ͵ͷͺ͹Ͳ-1.cm-1Ǥϐ
predicted by ProtParam tool19. The Mn2+ concentration in PapP sample was
determined using AA-spectrometer AAS3 (Carl Zeiss, Germany).
To ensure full saturation of the enzyme with Mn2+, PapP was incubated with 
1:2 molar excess of MnCl2 for 20 min at room temperature. Unbound manganese 
ϐ
ǦͷͲȋʹǤͷǡͷȌ
in 50 mM phosphate buffer pH 7.4 in presence of 5% glycerol.
Enzymatic activity assays




respectively. The reaction was stopped after 3, 6, and 9 min incubation at 25 °C
by immediate injection to the HPLC system. The reaction rate was determined
as an increase of AMP product; different reaction stoichiometries for pApA and 
pAp hydrolysis were considered. The kinetic data were analyzed using non-linear 
ǯ ϐ ȋ ǯ ϐ α ͳȌ    
version 7.5 (OriginLab).
The AMP concentrations in incubation mixture were determined by ion-pair 
reversed-phase chromatography using method inspired by Nakajima et al. 20.
	Ɋ    
C18 column (Chromolith RP-18e, 10 x 4.6 mm; Merck) and analyzed using Agilent 
1200 HPLC System with detection at 260 nm. Mobile phase A contained 70 mM 
potassium phosphate buffer pH 6.0, with 4 mM Tetrabutylammonium hydrogen-
sulphate (TBAS, Sigma-Aldrich, USA), as an ion-pair reagent; mobile phase B was 
ǤϐʹȀ
following program: 100% buffer A for 0.06 min; 0–50% linear gradient of B for 
1.0 min; 50% B for 0.25 min; and 100% buffer A for 0.4 min. AMP (Sigma-Aldrich, 
USA), pAp and pApA standards were used for external calibration. Also ADP, ATP 
(Sigma-Aldrich, USA) and c-diAMP and c-diGMP (Biolog, USA) were analyzed as
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Scanning electron microscopy
Bacteria were grown to early exponential growth phase (OD600nm αͲǤͳȌ Ϊ
  ϐ  ʹΨ Ǥ   
analyses were performed as described previously 21Ǥ ϐǡ  
electron microscopy (SEM) samples were dehydrated with a graded series of 
acetone on ice for 15 min for each step. Samples were subjected to critical-point 
drying with liquid CO2 (CPD030; Balzers, Liechtenstein). The dried samples were
    ͳͲǦǦ  ϐ   
ȋͲͶͲǢǡȌϐ
scanning electron microscope (Zeiss DSM 982 Gemini) using an Everhart 
Thornley SE detector and an in-lens detector at a 50:50 ratio at an acceleration 
voltage of 5 kV.
Phase contrast and epifluorescence microscopy
S. pneumoniae was grown in C+Y medium to early exponential growth phase
(OD600nm α ͲǤͳȌǡ         Ǧ Ǥ
Microscopy pictures were acquired using a DV Elite microscope (Applied
Precision) with either a sCMOS (PCO) or a CoolSNAP HQ2 (Photometrics) camera,
using Solid State Illumination (Applied Precision), with a 100x oil-immersion 








acquired and deconvolved using Softworx (Applied Precision) and analyzed 
	ȋǣȀȀϐǤȌǤ
Membrane staining fluorescence microscopy
In order to visualize the membrane of S. pneumoniae with Nile Red, the cells were 
grown in C+Y medium to early exponential growth phase (OD600nm α ͲǤͳȌ 
ͷρȀͷǤ
and spotted onto a PBS-agarose slide. Fluorescence acquisition of Nile red was 
       ϐ ȋ ͷʹͺȀͷͷ͸ Ǣ
emission 571/616 nm) with an exposure time of 300 ms. Pictures were acquired
with Softworx and analyzed using Fiji.
Time-lapse fluorescence microscopy
S. pneumoniae was grown in C+Y medium to late log phase (OD600nm αͲǤ͵Ȍ
diluted 100 times in fresh C+Y medium supplemented (when appropriate) with





medium and spotted onto a polyacrylamide (10%) slide incubated with C+Y 
medium, if required complemented with ZnCl2. Acrylamide pieces were placed

	ȋ	ϐȌ
essentially as described 22Ǥϐ
       ͵͹ι  ͵ͲιǤ  ϐ  
  
	  ʹ ϐ      Ǥ
Exposure time used was 500 ms with 32% excitation light. Movies were acquired
and deconvolved using Softworx and analyzed using Fiji.
Immunofluorescence microscopy
	 ϐ      S. pneumoniae, the
strains were grown in C+Y medium at 37 °C to exponential growth phase (OD600nm 
αͲǤͳȌǡͳǣͳͲͲͲǦͶȋǡ
Statens Serum Institut) was added for 5 min at 4 °C. Afterward, the cells were 
͵ǦΪͳρȀ
anti-rabbit coupled to Alexa Fluor 555 (Invitrogen) was added for 5 min at 4 °C.
The cells were then washed once again in pre-warmed C+Y medium and once 
with PBS before being spotted onto a PBS-agarose slide. Acquisition of the
ϐǦȋȌ
with a CoolSNAP HQ2 camera, an Intensilight light source, with a 100x
ǦǤ	ͷͷͷϐǡ
ϐȋͷʹͺȀͷͷ͸Ǣͷ͹ͳȀ͸ͳ͸Ȍ
time of 800 ms. Pictures were analyzed afterwards with Fiji. 
Capsule quantification
Equal mid-log phase bacterial amounts were re-suspended in deionized water
and chloroform and shaken for 5 min using TissueLyser LT (Qiagen). Subsequent 
centrifugation at 13,000 x g for 10 min resulted in layer separation of which the 
aqueous layer contained polysaccharides. These samples were subjected to
plates coated with anti-serotype 4 (Statens Serum institute, Neufeld Antisera), 
followed by incubation with mouse anti-prevnar sera and subsequent alka-
line-phosphatase-conjugated anti-mouse IgG (Sigma Aldrich). After each step 
the plates were washed with Phosphate Buffered Saline supplemented with 
0.1% Tween-20 (PBST). Substrate solution (p-nitrophenyl phosphate in 10 mM
diethanolamine and 0.5 mM magnesium chloride buffer pH 9.5) was added and
absorbance was measured at 405 nm.
Quantitative analyses of cell wall phosphorylcholine
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     ȋȌǤ   ϐ 
(Nunc) were coated with bacterial lysates in carbonate coating buffer (0.1 M
carbonate/bicarbonate pH 9.6) at 4 °C overnight. For choline detection, plates
were incubated with mouse monoclonal TEPC-15 (Sigma) and secondary 
HRP-conjugated Rabbit anti-mouse antibody (DAKO). Signal was developed 
 ͵ǡ͵ǱǡͷǡͷǱǦ ȋȌ Ǧ   
reaction was stopped using 1.8 M sulfuric acid. Absorbance was measured at 
450 nm. Detection of the choline migration pattern using Western Blot is
described in the Supplementary Materials and Methods.
Lysozyme, ethanol, and Triton X-100 killing assays
Mid-log phase bacterial pellets were re-suspended in 1 mg/mL lysozyme 
(Merck), 25% ethanol (Merck), or 0.025% Triton X-100 (Sigma). Incubation with
  ͵͹ Ǐ  ͵Ͳ    
Triton X-100 was done at room temperature for 10 min. At indicated time points 
(0, 10 or 30 min), samples were 10-fold serially diluted in PBS and spotted onto
      ͵͹ Ǐ Ǥ   ǡ 
colonies were counted and percentage survival was calculated.
Growth curve assay
In order to follow the growth of S. pneumoniae, the strains were grown in C+Y 
medium at 37 °C to early exponential growth phase (OD600nmαͲǤͳȌǡ
to an O.D600nm αͲǤͲͲͳǤ
ȋϐ	ʹͲͲȌ600nm every 10 min either at 37 °C
or 30 °C. Each growth curve assay was performed in triplicate.
Statistical tests
All statistical analyses were performed using GraphPad Prism version 5.0
ȋ
ȌǤϐǡ
and the killing assays were repeated in at least three independent experiments
all performed in duplicate. Data were normalized to wild type assayed in the 
control condition (PBS), and illustrated as mean ± standard error of the mean 
(SEM). Groups were compared with one-way analysis of variance (ANOVA) and 







Protein conservation and structure prediction
Protein sequence homology analyses revealed that PapP of S. pneumoniae TIGR4 
(serotype 4) is a highly conserved phosphatase in Gram-positive bacteria,
mycoplasmas and phytoplasmas. Of the 127 most conserved homologous 
ǡ͵ǱǦ-
ǦͷǱǦȋȌǣǡȋBacillus spp.),
and SMU.1297 (Streptococcus mutans) (Table S1). The latter is 68% identical to
PapP10,11.
Homology-based structural modeling predicts PapP to be a homodimer 
(Figure 1A-C). The catalytic site is formed by Asp26, Asp28, Asp82, His105 and
Asp155, containing a manganese (Mn2+) ion as co-factor (Figure 1C). No trans- 
  ϐǡ
ȋ	ͳǦȌǤϐǡ
      ϐ  ȋ
	Ȍ  
C-terminal extremity of PapP. This genetic fusion was integrated at the non- 
essential bgaA locus, under the control of a zinc-inducible promoter (papP-gfp). 
ǡϐȋ	ͳȌǡ
ϐǤ
PapP converts both nucleotide substrates pAp and pApA into AMP
 ϐ      ǡ    ϐǡ
reconstituted with Mn2+, incubated with its substrate and subjected to HPLC
Ǥϐ
and phosphate with a Km   ͷͺͲά͹Ͳρ  Km/Kcat of 19 ± 3 s
-1.M-1
(Figure 1D). The enzymatic activity increased by adding manganese, but only 
    ȋ	 ʹȌǡ ϐ  2+ is indeed the
co-factor as predicted by protein homology modeling (Figure 1A-C). Highly 
ϐ   ͷǱǦǦȋ͵ǱΫεͷǱȌǦ ȋȌ  
was also detected Km   ͸͹ά ʹͲρ Km/Kcat of 2100 ± 500 s
-1.M-1
(Figure 1D). A similar Km  ȋʹ͵Ǥͻ͸ά ͹Ǥ͹ͺρȌ   
ortholog from S. pneumoniae D39 named SPD_1153 or Pde28. No hydrolysis of 




 Ǥ  ǡ   ϐ  ͵ǱǦ  
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Figure 1  PapP structure and enzymatic activity.
The predicted structure of PapP is based on the crystal structure of SH1221 from S. haemolyticus
(43% shared identity). (A) PapP is predicted to form a homodimer. The PapP model was structurally 
aligned with the SH1221 template (gray). PapP monomers are indicated in blue and pink. (B) 
Monomeric structure of PapP. (C) The catalytic site is predicted to contain a Mn2+ ion (green sphere) 
bound by Asp26, Asp28, Asp82, His105 and Asp155. (D) Steady-state kinetic analysis of PapP 
catalyzed hydrolysis of pAp (left) and pApA (right) with the corresponding Km and Vmax values. 











S. pneumoniae deficient for papP shows aberrant morphologies
It was established that deletion of papP leads to reduction of pneumococcal 
virulence at many stages of disease7. In order to understand the underlying 
mechanisms of virulence attenuation when the pAp phosphatase is absent, we 
investigated the cell morphology of a S. pneumoniae 
Ͷϐ
papP ȋȟpapP). Morphology analysis by phase contrast microscopy and membrane 
staining with Nile red revealed that the papP mutant only forms diplococci at 
early exponential growth phase, while the wild type forms long chains (Figure
2A). This is in line with the study of the PapP ortholog in S. pneumoniae D39
(serotype 2) where deletion pde2 ϐ8. Another
striking observation was that the cell-poles of the papP mutant were pointier 
compared to the wild type cells when measuring the pole-angles of the cells
(Figure S4). Furthermore, cells of the papPϐ
had a wider cell diameter (Figure 2B). To characterize the cell morphology in 
higher resolution we performed scanning electron microscopy (SEM). The 
 ϐ   papP ϐ  
shorter chain length consisting of only few cocci with sharp cell-poles (Figure
2C). Protrusions on the cell surface appeared in all S. pneumoniae strains and 
could likely be capsule artifacts induced by the method23. Complementation of 
papP deletion by an ectopic version of papP ȋȟpapP*) reversed the diplococcus
phenotype, as this strain only forms long chains and possesses a wild type cell 
ȋ	ʹ͵ȌǤϐ
that reversion of papP mutation restored the wild-type phenotype (Figure 2C). 
These observations suggest that papP ϐ
S. pneumoniae. In addition to morphology defects, analysis of the growth rate in 
liquid culture at 37 °C revealed that the papP mutant demonstrates a reduced
 Ͷ͸ȋͻͷΨϐ ͶͶǤͳ 
ͶͻǤͳȌ͵ͶȋͻͷΨϐ͵ͷǤͷ͵͹ǤͶȌ
(Figure 2D). Taken together, these results indicate that absence of PapP directly 
ϐS. pneumoniae.
The polysaccharide capsule is unaffected in the absence of PapP
It is known that the polysaccharide capsule plays a crucial role in virulence of 
S. pneumoniae. Indeed, the non-encapsulated S. pneumoniae R6 strain (derivate
from D39 strain) is non-virulent. Interestingly, strain R6 only forms diplococci 
instead of chains24. Taking this into account, the phenotype observed in absence
of PapP may be caused by perturbations in capsule production. To test this, we
ϐͶϐ
antibody. Interestingly, the signal illustrative for capsule presence appeared
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suggests that despite the morphological differences, the papP mutant displayed 
Ǥϐ
capsule production, bacterial lysates were assayed for the amount of capsule. 
 Ǧ   
Ͷǡ 
Ͷȟcps, was included as negative
control (Figure 3B). Strikingly, all three TIGR4 strains, wild-type, mutant and 
complemented strain, showed similar capsule polysaccharide levels (Figure 3B). 
These data clearly indicate that the polysaccharide capsule remained intact in 
S. pneumoniaeϐǤǡ
atypical morphology of the mutant.
Figure 2  Morphological and growth defects of the papP mutant.
(A) Phase contrast microscopy (left panel) and Nile red staining (right panel) of TIGR4 wild type, 
ȟpapP  ȟpapPȗǤ  ǡ ͵ ρǤ ȋB) Cell width (p-value < 0.0001) and cell length (p-value 
δ ͲǤͲͲͲͳȌ   
Ͷ  ȋ Ȍ ȟpapP (green). (C) Scanning electron 
ȋȌ
ͶǡȟpapPȟpapP*.ǡͳǡͷρǤȋD) Growth curve of 

ͶȋȌȟpapP (green) at 37 °C in liquid C+Y medium. SEM for TIGR4 wild 








Effects of papP inactivation on the cell wall
ϐ
papP, qualitative and quantitative analyses were performed to probe the
phosphorylcholine moieties of the pneumococcal teichoic acids. No differences 
were found in phosphorylcholine production between wild type, mutant, and
complemented strain, as measured in a quantitative ELISA (Figure 4A). The 
phosphorylcholine migration pattern as determined by Western blotting appeared
identical between the three variants (Figure 4B). These data indirectly indicate
that lipoteichoic acid (LTA) and wall techoic acid (WTA) are unaffected in the 
Figure 3  Intact polysaccharide capsule in papP ϐS. pneumoniae.
(AȌ ϐ  ȋȽǦȌ      
Ͷ ǡ
ȟpapPȟpapP* ǦͶǤǡ͵ρǤȋB) All strains were screened 
     Ǧ ǡ    ȋȟcps) as negative 
control. Data are normalized from three independent experiments performed in duplicate. Results
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papP Ǥǡϐ
ȟpapPǡȟpapP*, and wild type (Figure S5).
Furthermore, the effect of absence of papP on peptidoglycan was studied in a 




(mean survival of 1.8%), which lacks peptidoglycan N-acetylglucosamine 
deacetylase A (PgdA), an enzyme directly involved in peptidoglycan cross-linking 
(Figure 4C)25Ǥȟsp1479
mutant implies that this may not be caused by a direct effect on peptidoglycan.
Figure 4  The effect of PapP absence on cell wall components.
(AȌǦǡȋȟpapP) and complemented mutant strains 
ȋȟpapP*) as measured by an ELISA-based assay. A higher OD450 indicates a higher choline content. (B)
Analysis of phosphorylcholine in the cell wall by Western blotting. The phosphorylcholine migration 
pattern analyzed by SDS-PAGE and Western blotting in wild type (wt) , papP ȋȟpapP) and 
ȋȟpapP*) strains. The results represent phosphorylcholine migration patterns from
three independent experiments (#1, #2, #3). (C) Survival of pneumococcal strains in a lysozyme killing 
ǡ    ȟsp1479. Choline expression levels show normalized data from three 
independent experiments performed in duplicate. Lysozyme data are combined from four independent 
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Loss of papP perturbs cell division protein dynamics 
The cell division machinery of S. pneumoniae involves many important proteins
ϐǦ26,27. Deregulation of these proteins could therefore
result in cell morphology defects. In order to determine whether the
ȟpapP mutant could be attributed to a deregulation
of the division process, we inserted an ectopic copy of a N-terminal GFP fusion of 
the early cell division protein FtsA under control of a zinc-inducible promoter in 
    ȟpapP strains, resulting in strains CG16 and CG18,
respectively. As expected, in the wild type cells, FtsA is recruited early at the 
new septum and thus localizes exclusively at mid-cell at early exponential 
growth phase (Figure 5A). However, the signal in the papP mutant appears to be
at mid-cell but also at the old division site (Figure 5A). To exclude that addition 
of Zn2+ induced synthetic effects, we constructed a strain expressing a functional 
    	   ϐ
mKate2 (strains CG14 and CG22). This construct was inserted at the TIGR4 ftsZ
locus, under the native promoter in order to keep the original FtsZ expression 
Ǥ	ϐ	Ǧ
  ȟpapP (Figure 5B). To better understand the localization
 	ǡ Ǧ ϐ͵͹ιǤ
Interestingly, while FtsZ was instantly disassembled from the old septum and
re-assembled at the new septum in the wild type strain (Figure 5C, Movies S1
ʹȌǡȟpapP
mutant (Figure 5C, Movies S1 and S2). Similar results were obtained for GFP-FtsA 
(Movie S3). To further characterize the dynamics of these two cell division 
proteins, the distance between FtsA or FtsZ and the closest pole of the cell was 
measured. When plotted with the cell length, two different clusters are clearly 
visible for the wild type, indicating that FtsA and FtsZ are either at the old or the
new division site, or at both positions (Figure 5D and E). However, the two 
distinct clusters disappeared for the mutant strain, giving way to a heterogeneous 
distribution (Fig. 5D and E). This indicates that FtsA and FtsZ are not only 
present at both the old and new septum, but also in between these two positions 
at one moment of the cell cycle (Figure 5F). Taken together, these results show 
that inactivation of papP results in mis-localization of FtsA and FtsZ.
Localization of cell division proteins is temperature dependent in 
ȟ
To characterize the FtsZ dynamics of the papP mutant in more detail, we used
ǦϐǦ
30 °C, a temperature known to slow down the cell cycle compared to the previous 










	 ϐ  ȋ
ȌȋȌǤǡ͵ρǤȋB) Localization of 
	Ǧʹ
ͶȟpapP. The mKate2 signal (left panel) is overlaid with the 






ͶȟpapP depending on cell 
size. (EȌ	Ǧʹ
ͶȟpapP depending
on cell size. (FȌ   
Ͷ    ȟpapP cell division. Compared to the wild type
situation where FtsZ (red) seems to be directly reassembled at the new division site, it seems to
slowly slide from the old to the new septum in the papP mutant (green arrows) over the cell cycle.










mutant after a few division cycles, followed by a quick death of the cells (Figure
6A and Movie S4). Identical results were obtained with GFP-FtsA (S5 Movie). 
Fluorescence microscopy of cells grown at 30 °C until early exponential growth 
ϐ
displayed abnormal morphologies and FtsZ was frequently mis-localized (Figure
͸ȌǤϐǦ
technique for FtsZ mis-localization. Growth in liquid C+Y medium at 30 °C also
      ȟ     
stationary phase at lower cell density (Figure 6C). These data suggest that the 
papP mutant is cold sensitive, especially when also harboring a FtsZ-RFP fusion. 
To further characterize the temperature sensitivity, the mutant strain was
grown at even lower temperatures (25 °C) and FtsZ localization was monitored. 
Despite a very slow growth at this temperature, FtsZ is still well localized in the
wild type strain (Figure 6D). Surprisingly, the mutant strain shows many 
elongated cells displaying a helical pattern of FtsZ (Figure 6D). Thus, our data 
indicate that absence of the pAp phosphatase (PapP) leads to mis-localization of 
cell division proteins in a temperature-dependent manner.
Lack of PapP diminishes cell membrane integrity
Many cell division proteins are directly or indirectly anchored to the cell
membrane. For instance, FtsA is a membrane-associated protein that anchors
FtsZ28. A change in membrane properties can thus impact their localization. 
To assess whether membrane integrity may be reduced upon papP deletion, 
pneumococcal strains were screened for survival in both organic solvent and
detergent killing assays. As hypothesized, the papP mutant appeared highly 
susceptible for ethanol (Figure 7A) and Triton X-100 in comparison with the wild
type strain and the complemented mutant (Figure 7B). Survival in absence of 
papP was reduced approximately 5- and 4-fold in ethanol (13%) and Triton X-100 
(20%) killing assays, respectively. These data clearly indicate an increased
sensitivity of S. pneumoniae ϐ  papP to both organic and solvent 
compounds that is likely caused by an unstable and more accessible membrane. 
This is supported by the increased sensitivity of the papP mutant against 
selected antibiotics (Table S4).
FabF or FabH inactivation phenocopy papP deletion 
In order to investigate whether the phenotype of the papP mutant is the result of 
fatty acid biosynthesis perturbation, we sought to partially inactivate this
process. Bacterial type II fatty-acid synthasis (FASII) inhibition seems a good 
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biosynthesis29. For instance, the proteins FabH and FabF are respectively 
responsible for the initiation and elongation of the fatty acid chains. However, 
due to their essentiality, their inactivation by deleting the corresponding genes is 
not possible. On the other hand, it has been reported that FabF can by inactivated 
by a bacteriostatic drug, platensimycin30. To examine the effect of fatty acid
synthesis inhibition by platensimycin on pneumococcal morphology, the wild
  ͲǤ͹ͷρǤ-1 platensimycin to early 
Figure 6 	ȟpapP.
(AȌϐ	Ǧʹ
ͶȟpapP at 30 °C. The 
ϐ       Ǥ  ǡ ͵ ρǤ ȋB) Localization of 
	Ǧʹ
ͶȟpapP grown at 30 °C. Overlay between the phase contrast 
images (left panel) and the mKate2 signal (middle panel) is shown (right panel). The white arrows 
	Ǥǡ͵ρǤȋC) Growth curve of TIGR4 wild type (dark 
ȌȟpapPȋȌ͵ͲιǤ
ͶȟpapP are shown in clear grey and 
clear green, respectively. (DȌ	Ǧʹ
ͶȟpapP grown










exponential growth phase and cell morphology was assessed by phase contrast 
microscopy. A concentration was used at which the maximum optical density 
of S. pneumoniae was reduced by two-fold (MC50) (Figure S6)31. Strikingly, 
platensimycin treatment resulted in the formation of only diplococci (Figure 8A)
and chains of cells were no longer observed. This shows that partial inactivation 
of the fatty acid biosynthesis by inactivation of FabF is able to phenocopy the
papP mutant in this regard. 
Next, we assessed the effect of FabH depletion on S. pneumoniae morphology 
by constructing a strain expressing an ectopic version of fabH under a zinc- 
inducible promoter and made a deletion of the native fabH gene in presence of 
Zn2+ ȋȟfabH*). Phase contrast microscopy revealed a wild type phenotype when 
grown in the presence of 0.1 mM Zn2+ ȋ	ͺȌǤϐ
minor expression of FabH, which is likely due to the leakage of the zinc-inducible
promoter32, Strikingly, when grown without zinc, chain formation was absent 
and cells display a diplococcus phenotype (Figure 8B). Apparently, reducing
available FabH also phenocopies inactivation of papP. Taken together, these
ϐ
resulting in the observed morphological defects.
Figure 7  Loss of PapP increases susceptibility to organic solvent and detergent.
   ǡ  ǡ  ȋȟpapP), and complemented mutant strain 
ȋȟpapP*), in an (A) organic solvent ethanol and (B) detergent Triton X-100 killing assay. Ethanol and 
Triton X-100 killing show normalized data from three independent experiments performed in 
duplicate. Results are provided as average ± SEM and compared by one-way ANOVA and Tukey’s
ǤϐȗȗȗǡδͲǤͲͲͳǢȗȗǡδͲǤͲͳǢȗǡδͲǤͲͷǤ
BA
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DISCUSSION
The papP deletion mutant showed in a previous study decreased virulence in all 
stages of pneumococcal disease, which strongly indicates a critical role for papP
in S. pneumoniae pathogenesis 7. Remarkably, S. pneumoniaeϐ  papP
showed an abnormal morphology and was substantially weaker in various
killing assays compared to wild type strains and the complemented mutant. 
Altogether, our data indicate that loss of papP results in a cell integrity defect,
ϐ7,8.
In this study we show that PapP is a phosphatase able to convert two 
Ǧ ǡ ͵ǱǦǦͷǱǦ ȋȌ 
Figure 8 ȟpapP morphology.
(A) Phase contrast microscopy (left panel) and Nile red staining (right panel) of TIGR4 wild type 
ͲǤ͹ͷρȀǤǡ͵ρǤȋB) Phase contrast microscopy (left 









D39 PapP ortholog (Pde2) was recently described and hypothesized to be
implicated in c-di-AMP signaling and cell wall homeostasis, as pApA is a product of 
in vitro degradation of c-di-AMP8,33. However, it is unknown in which quantities and
during which other metabolic processes pApA is produced in S. pneumoniae.
More importantly, its biological role remains largely unknown. A possibility is 
that pApA is a metabolite generated during other S. pneumoniae metabolic 
processes, including lipid metabolism, which may be undetectable due to a fast 
degradation into end products like AMP. This theory is supported by our 
observation that PapP breakdown of pApA is remarkably rapid (Figure 1D). 
In addition to pAp as substrate, Uemera and colleagues reported that Nrn
degrades short RNAs, e.g. nanoRNAs. This dual preference for nanoRNA and pAp 
conversion has also been described for other DHH subfamily 1 proteins, including
RecJ, Orn, and YtqI10,34,35, suggesting a similar activity for PapP. Whether
nanoRNA degradation contributes to the phenotype of S. pneumoniae ϐ
for PapP remains speculative. Namely, Mechold and colleagues reported that 
RNase activity is redundant10, indicating that absence of a single RNase would
not affect RNA metabolism. In addition, RNase activity has not been described 
for S. mutans protein SMU.1297, which shares 68% homology with PapP11.
It is remarkable that PapP is highly conserved in Gram-positive bacteria,
mycoplasmas and phytoplasmas, all containing a single membrane. In this
regard, it is tempting to speculate that these single membrane-containing 
bacteria are more vulnerable for distortion of the lipid membrane homeostasis. 
 ϐ          
membrane integrity of S. pneumoniae (Figures 7A and B), which makes PapP an 
attractive target for therapeutic interventions for Gram-positive infections.
Perturbing the membrane altered the localization dynamics of key cell
division proteins FtsA and FtsZ (Figures 5 and 6). A recent body of work has
shown that cell division in S. pneumoniae is orchestrated by a complicated 
phosphorylation cascade via the eukaryotic-type serine-threonine kinase 
StkP36. It would be interesting to see what the effects of membrane perturbations,
such as those caused by papA deletion, are on the signaling at the level of StkP
and downstream proteins.
In conclusion, we hypothesize that in S. pneumoniae lacking the pAp
phosphatase PapP, pAp and pApA levels will increase thereby inhibiting AcpS12. 
Subsequently, decreased enzyme activity may lead to reduced precursor
formation, which is required to start fatty acid synthesis, thereby hampering de 
novo lipid production12. The resulting reduction in membrane integrity provides 
a plausible explanation for altered cell morphology and susceptibility and 
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discovered conserved pneumococcal proteins will improve our understanding 
of pneumococcal physiology and pathogenesis. Gaining insight into S. pneumoniae
membrane homeostasis and virulence may reveal potential targets that will aid 
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SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
Western blotting to determine phosphorylcholine in the cell wall 
Bacterial lysates were obtained as described (see Materials & Methods: 
‘Quantitative analyses of cell wall phosphorylcholine’). Lysates were diluted in
Tricine sample buffer (1M Tris-Cl pH 6.8), loaded on Tris acrylamide gels (29:1 
acrylamide/bis, 0.3% SDS in 3M Tris-Cl pH 8.45, 80% glycerol), and ran at 100 V.
Samples were transferred to a PVDF membrane using a semi-wet system
(Bio-Rad) applied to 230 mA. Subsequently, the membrane was incubated with
primary mAb TECP-15 (Sigma) followed by incubation with secondary 
HRP-conjugated rabbit anti-mouse antibody (DAKO). Signal was developed
using ECL prime western blotting detection reagent (Amersham, GE Healthcare) 
and detected using enhanced chemiluminescence with a FluorChem E apparatus 
(Westburg).
Strain construction 
Plasmids used in this study are listed in table S2, primers are listed in table S3.

Ͷ ȟpapP  ȟpapP* were constructed as previously described1. Strain
papP-gfp was constructed by transformation of S. pneumoniae TIGR4 wild type
with plasmid pMK17-papP. This plasmid was constructed by amplifying papP on
TIGR4 genomic DNA using oligos papP-FW-NotI and papP-RV-XbaI. The resulting
PCR product was digested using NotI and XbaI and ligated in the corresponding
sites of plasmid pMK17 (M. Kjos and J.-W. Veening, unpublished data) allowing 
insertion of a C-terminal fusion of papP with the monomeric super-folder GFP 
into the bgaA locus under control of the zinc-inducible promoter PczcD (PZn).
Transformants were selected on Columbia agar supplemented with tetracycline. 
Both strains CG16 (TIGR4, bgaA::PZn-gfp-FtsA) and CG18 (TIGR4, papP::spc, 
bgaA::PZn-gfp-FtsA) were constructed by transformation of S. pneumoniae TIGR4 
ȟpapP, respectively, with plasmid pJWV25-gfp-ftsA2 in order to 
introduce a genetic fusion gfp-ftsA into the bgaA locus under control of the zinc
inducible promoter PZn. In order to create the strains CG14 ( ftsZ::ftsZ-mKate2) 
and CG22 (papP::spc, ftsZ::ftsZ-mKate2), S. pneumoniae TIGR4 wild type and 
ȟpapP, were transformed with a DNA fragment ftsZ-mKate2-ery constructed as
described by Beilharz et al.3  ϐ   ǦǦ	 
ftsZ-down-RV. This allows introduction of a genetic fusion ftsZ-mKate2 in place 
of the native ftsZ gene under control of the native promoter. Transformants were
ǦǤȟfabH* was constructed
in two steps. First, TIGR4 wild type was transformed with plasmid pMK11-fabH.
This plasmid was obtained by amplifying the gene fabH on TIGR4 genomic DNA 
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the plasmid pMK11 allowing insertion of an ectopic version of fabH under control
of the zinc inducible promoter PZn into the bgaA locus. Afterwards, the resulting 
        ϐ
region of fabH and an erythromycin marker. This latter construct was obtained 
by assembling the fragments corresponding to the upstream and the downstream 
region of fabH with the erythromycin marker using Gibson assembly. The 
ϐǦǦ	
and fabH-up-RV-ery and the downstream part using primers fabH-down-RV and
fabH-down-FW-ery. The fragment corresponding to the erythromycin marker 




Susceptibility to selected antibiotics was tested using the disc diffusion assay. 
Overnight cultures were suspended in PBS and used for inoculation of BA plates. 
Discs (SensiDisc, Becton Dickenson) were dispensed onto the plates after which
ͷɊǣȋͲǤʹͷρȀρȌǡ
ȋ͵ ρȀρȌǡ  ȋʹǤͷ ρȀρȌǡ  ϐ ȋͳ ρȀρȌ  
EUCAST standards. BA plates were placed at 37°C overnight and the diameter of 
bacteria-free zones were measured the next day.
Western blotting for detection of lipoproteins
Bacterial lysates were obtained as described (see Materials & Methods:
‘Quantitative analyses of cell wall phosphorylcholine’). Lysates were diluted in 
ͷͲȾǦǡǦ
4-15% gradient gels (Bio-Rad), and ran at 100 V. Samples were transferred to a 
	ȋϐȌǦȋǦȌ
at 230 mA. Subsequently, the membrane was incubated with primary mAb
against lipoproteins MetQ, PpmA, PsaA, and SlrA (mouse IgGs), and control protein
enolase (Rabbit IgG) followed by incubation with secondary HRP-conjugated
antibodies (DAKO). Signal was developed using ECL prime western blotting 
detection reagent (Amersham, GE Healthcare) and detected using enhanced
chemiluminescence with a FluorChem E apparatus (Westburg). Densitometric 










Figure S2 The effect of manganese (Mn2+) and magnesium (Mg2+) supplementation
on PapP enzymatic activity towards substrate pAp.
ͲǤͳ ρ     ͸ ρ   ͵Ͳ      ͹Ǥ 
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Figure S3 Comparison of papP mediated hydrolysis of c-di-AMP and pAp. 100 
ɊǦǦʹͷιͲǤͳɊpapP.
(A) After 10 min an aliquot of incubation mixture was analyzed for parental compound and AMP
   ȋ ȌǤ ǡ       ȋͳͲͲ ρ ϐ
concentration) and after 10 min incubation another aliquot was analyzed (red line). (B) A detailed 
view of the above shown chromatographic records with zoomed y-axis. No detectable presence of 
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Figure S4 Cell-poles pointiness of the papP mutant.
ǦεʹͲͲȋȌǡȟpapP (white),
ȟpapP* (grey) or the wild type subjected to 1 min chain disruption by bead beater (wild type BB). 
Results are illustrated at average ± SD and compared by one-way ANOVA and Tukey’s multiple
ǤϐȗȗȗȗǡδͲǤͲͲͲͳǤ
wt οpapP οpapP* wt οpapP οpapP* wt οpapP οpapP*
#1 #2 #3
Figure S5ϐpapP deletion on lipoprotein expression.
The presence of A. cytoplasmic protein enolase (control) and lipoproteins B. MetQ, C. PpmA, D. PsaA,
 Ǥ     ȋȌǡ   ȋȟȌ   ȋȗȌ    
Western blotting. Results are illustrated from three independent experiments (#1, #2, #3). Graphs 
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Remaining supporting information
Movies S1-5 can be found in the online version of this article at the publisher’s 
website. 
Figure S6 Determination of optimal platensimycin concentration.
Growth curve of TIGR4 wild type at 37 °C in liquid C+Y medium complemented with different 
platensimycin concentrations. An optimal concentration was used where the maximum optical 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S2 Plasmids used in this study
Plasmids Relevant characteristics Reference
pMK17-gfp-papP Amp, tet, bgaA, PZn-papP-gfp This study
pJWV25-gfp-ftsA Amp, tet, bgaA, PZn-gfp-ftsA
2
pMK11-fabH Amp, tet, bgaA, PZn-fabH This study
















Table S4  Antibiotic susceptibility using Disk Diffusion measured as 
inhibition zone (mm)
Wild type ȟ ȟȗ
penicillin 37 mm 48 mm 36 mm
erythromycin 26 mm 34 mm 24 mm
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The current pneumococcal conjugate-based vaccines protect against severe 
ǡǤ	ǡϐ
of these vaccines is subject to serotype replacement, while polysaccharide 
         ǦϐǤ
Hence, vaccines based on antigens other than polysaccharides are needed to
protect against pneumococcal infection and to further improve current vaccination 
strategies. Pneumococcal protein antigens, such as pneumococcal surface 
protein A (PspA), have been shown to evoke strong protection. However, PspA is 
a variable protein and therefore less suitable as vaccine antigen. We have 
previously shown that outer membrane vesicles (OMV) displaying the N-terminal
ȽͳȽʹStreptococcus 
pneumoniae colonization, upon intranasal vaccination. Here, we sought to examine 
the cross-reactive potential of a variable antigen inducing Th17-mediated 
Ǥ    Ǧ   
Ͷ ȽͳȽʹ 
strongly protect against colonization in a Th17 dependent manner. Furthermore
Ǧ
ͶȽͳȽʹ
with other pneumococcal strains. By using sequences of 345 pneumococcal 
ǡϐ͵ͷȽͳȽʹǤ
Representative strains from each group were used to conduct an ex vivo
screening to determine Th17 cross reactivity. These ex vivo recall responses
were strongly predictive for in vivo IL17A levels in the nasal tissue of mice 
following heterologous challenge. This is turn was associated with a reduction 
in pneumococcal colonization. Although PspA is highly variable, the 35 groups 
accounted for 90% prevalence in a large carriage cohort and a single (TIGR4) 
ȽͳȽʹͳͻǤͳΨǤǡ
work describes an easy tool to assess vaccine cross-reactivity and illustrates the 







Respiratory bacterial infections remain a major cause of severe morbidity and
mortality worldwide, both in infants as well as in adults1,2. Vaccination is
considered one of the most cost-effective strategies to reduce the global burden 
of disease, the associated healthcare costs and the risk of emerging antibiotic-
resistant strains3. Vaccination against Streptococcus pneumoniae is implemented 
in different parts of the world. However, it is estimated that still about one
million children die of pneumococcal disease every year (WHO)1,2. Pneumococcal
polysaccharide conjugate vaccines (PCVs) are designed based on epidemiological 
data from the Western world. These protect against serotypes that are most 
prevalent and are most frequently associated with severe invasive disease. PCVs 
  ϐ   ͳ͵   ͻ͹ ϐ 
that are circulating world-wide4. This is an important limitation and during the 
last decade, non-vaccine variants of S. pneumoniae have emerged, causing severe
invasive disease5-7. The phenomenon of strain or serotype replacement and the 
remaining high disease burden in developing countries highlight the need for 
broader protective vaccines against S. pneumoniae.
Currently, there is much attention for the development of novel, broadly 
protective, protein-based vaccines8-13. Vaccination with variable proteins, which
are generally highly immunogenic, are known to offer strong protection11,14-16.
Nevertheless, similar to capsule-based vaccines, immunization with protein
Ǧϐ
a selection of strains4. Therefore, variable proteins have been considered less
suitable antigens for a universal vaccine given their strong epitope heterogeneity. 
Whether variable proteins are suitable antigens when aiming at the induction of 
cellular immunity, e.g. Th17 memory, is still unclear.
In this study, we investigated the feasibility of inducing cross-protection 
against pneumococcal carriage using a variable protein antigen known to induce 
Th17 immunity. The best studied protein vaccine target in S. pneumoniae is 
Pneumococcal Surface Protein A (PspA), which is a virulence factor that binds
lactoferrin and interferes with complement-mediated opsonization17,18. PspA is 
expressed by most pneumococcal strains and it consists of an N-terminal alpha-
helical coiled coil domain, the most variable and most immunogenic part, a 
Ǥϐ
  ϐ
(CDR)19. It has been proposed that a vaccine combining family 1 and family 2 
would provide universal protection against pneumococcal disease, but protection 
was not observed for all pneumococcal strains20-26. Previously, we generated 





   ǡ  ȽͳȽʹ ǡ   Ǥ   
vaccination with this formulation confers strong protection against pneumococcal
colonization14.
Using bioinformatics analysis on the sequences of 345 invasive pneumococcal 
      ϐ     ȽͳȽʹ
domain of PspA. Vaccine cross-reactivity with these clinical strains was assessed
in a Th17-based ex vivo screen, in which murine derived splenocytes were
restimulated with whole pneumococcal cells. The IL17A levels, measured ex vivo,
strongly correlated with the in vivo IL17A levels detected in the nasal cavity 
following infection with the clinical strains, which in turn highly correlated
with protection against colonization. Moreover, based on the prevalence in a 
ǡ͵ͷȽͳȽʹ
ͻͲΨǤǡȽͳȽʹ
would cover approximately 19.1% of all circulating pneumococcal strains, which 
suggests that a universal vaccine, (partly) based on variable proteins is feasible.
MATERIALS AND METHODS
Bacterial strains and growth conditions
S.͵ʹ͸ͳȟtolRA, E. coli TOP10F’ and BL21(DE3) were grown at 
37 °C in LB medium containing 0.2% glucose. When appropriate, kanamycin was 
ʹͷɊȀǡ͸ǤʹͷȀǡ
 ͵Ͳ ɊȀǤ ͵ʹ͸ͳȟtolRAȟmsbB was grown at 30 °C in LB medium lacking 
NaCl (LB-0), supplemented with 2 mM CaCl2, 2 mM MgCl2 and 0.2% glucose. 
Pneumococcal laboratory strains and human clinical isolates, belonging to the 
Pneumococcal Bacteremia Collection Nijmegen (PBCN), were grown in Todd
Hewitt Broth supplemented with yeast extract until mid-log phase and stored at 
-80°C until further usage27,28. Pneumococcal stocks, used for mouse challenge 
infections containing 106 ȋ	ȌͳͲρ
saline (PBS), were prepared as described previously14.
ȟmsbB OMV production strain
 ȟmsbB derivative of SǤ  ͵ʹ͸ͳȟtolRA was created by allelic
exchange through double cross-over homologous recombination essentially as 
described by Kaniga et al. with some amendments29Ǥ ϐǡ 
extension PCR was used to amplify a fragment representing an almost completely 
truncated form of msbB plus the ~1000 bp up- and downstream regions of msbB
on the S. Typhimurium SL3261 genome. S. Typhimurium SL3261 genomic DNA 






fw + msbB_b rv and msbB_c fw + msbB_d_XbaI rv (Table S1).  The PCR product 
was digested with XbaI and cloned into XbaI-cut suicide vector pSB890
(TetracyclinR, SucroseS)30ǤͺͻͲǦȟmsbB suicide vector was transformed
into the E. coli Ⱦʹͳ͸ͺο͵ͷasd gene and can only 
grow in the presence of diaminopimelic acid (DAP). The resulting transformant 
͵ʹ͸ͳȟtolRA for 8 h on plate in the
ȋͷͲɊȀȌǤ
were selected on plate in the absence DAP. Resolution of merodiploids and
ǦȟmsbB were achieved by selecting for
resistance of the Salmonella mutants to sucrose (10%) on LB-0 plates. Positive
ϐmsbB locus using primers msbB_seq fw
and msbB_seq rv (Table S1). In accordance with reports describing an altered 
sensitivity of Salmonella ȟmsbB strains towards salts31ǡ ͵ʹ͸ͳȟtolRAȟmsbB
was maintained on LB-0 (agar) medium supplemented with 2 mM Mg2+ and 2
mM Ca2+ at 30 °C.
Mass spectrometry on lipopolysaccharides
The lipopolysaccharides (LPS) from S. Typhimurium SL3261 and mutant 
͵ʹ͸ͳȟtolRAȟmsbB ϐǦ
extraction followed by reversed phase solid phase LPS extraction (RP-SPE) 
using C4 ZipTips® micropipette tips (Millipore)32. Negative-ion electrospray 
ionization Fourier transform mass spectrometry (ESI-FT-MS) was performed on 
ȋϐȌǤǡͷρͷͲΨ
(v/v) 2-propanol, 0.07 mM TEAA pH 8.5 were infused into the FT-MS by static 
nano-ESI33,34. The spray voltage was set to -1 kV and the capillary temperature to 
ʹͲͲǏǤǡ
was produced. The MS instrument was calibrated with a Pierce Negative Ion 
  ȋ ϐȌ     
following standard procedures provided by the manufacturer (Thermo
ϐȌǤ	  Ǧ
collision-induced fragmentation (SID). Y- and B-type fragment ions, 
corresponding to the lipid A and oligosaccharide moieties of LPS, respectively,
were generated by SID at a potential difference of 100 V. Fragment ions are
annotated according to the nomenclature of Domon and Costello35. Mass spectra 
were charge-deconvoluted using the Xtract tool of Thermo Xcalibur 3.0 software
ȋ ϐȌǤ        
masses. Proposed LPS compositions are based on the chemical structure of the 







 ȋοͳȌ  ȋοʹȌ      
domains d1 and d2 of the Hbp passenger were substituted for Gly/Ser-encoding




and overhangs suitable for In-Fusion cloning. Chromosomal DNA of PBCN79 and 
PBCN87 was used as a template in combination with the primer pairs a1_PBCN79 
fw + a1_PBCN79 rv and a1_PBCN87 fw + a1_PBCN87 rv, respectively (Table S1).
      Ȁ  ȋοͳȌ 
In-Fusion technology according to manufacturer’s protocols (Clontech
ǡǤǡǡǡȌǡȋοͳȌǦȽͳȋ͹ͻȌ
 ȋοͳȌǦȽͳȋͺ͹Ȍ41Ǥ ǡ ȋοʹȌǦȽʹȋ͹ͻȌ  -
ȋοʹȌǦȽʹȋͺ͹Ȍǡ Ƚʹ    ʹǡ
were generated making use of the same methodology. The respective primer
pairs used for PCR were a2_PBCN79 fw + a2_PBCN79 rv and a2_PBCN87 fw +
ʹ̴ͺ͹ǡȀǦȋοʹȌ
ǤǡȽͳȽʹ
fragments were created by substituting the NdeI/NsiI   ȋοͳȌǦ
Ƚͳȋ͹ͻȌ ȋοͳȌǦȽͳȋͺ͹Ȍ   ȋοʹȌǦȽʹȋ͹ͻȌ




Isolation procedure and design of S. ȽͳȽʹ
the S. pneumoniae TIGR4 background was previously described14. To isolate
͵ʹ͸ͳȟtolRAȟmsbBȽͳȽʹͺ͹
͹ͻϐǤ͵ʹ͸ͳȟtolRAȟmsbB





       ϐ  
previously14,42.
ȽͳȽʹ
Genome sequences and serotypes were obtained from Cremers et al.27,28. PspA






conserved signal sequences, the CDRs and the conserved C-terminal domains 
against all protein coding sequences of the genomes using blastp43. Conserved
ȽͳȽʹ
the protein sequence between the signal sequence and the proline rich region 
(PRR) with MEME using default settings44. Variable domains were numbered 
according to their sequence conservation. Overrepresented peptides were 
ͳ͵ȽͳȽʹ
region with the level of IL17A production after splenocyte stimulation. 
Mouse immunization and challenge 
Seven week old female C57Bl/6 (Charles River Laboratories), C3H/HeJ (Jackson 
Laboratories), and IL17R-/- mice received three intranasal (i.n.) immunizations 
  ȋʹǤͷΨ Ȁ ϐǡ   Ȍ  ͳͲ ρ
ͺȟmsbBȋ̱ͶɊ
ȌȽͳȽʹͳͷΨ14. C3H/HeJ 
mice were immunized with OMVs derived from S. Typhimurium containing
wild-type msbBǤ Ǧͳ͹ΫȀΫ   
bred in Louisiana State University Health Sciences Center Animal Care 
Facilities45ǤϐǡǤǤ
with S. pneumoniae and three days post-infection euthanized. Mice were 
terminally bled from which serum was obtained and stored for later analyses. 
Nasal tissue was harvested, homogenized using IKA T10 basic blender and used
for inoculation of Gentamicin Blood Agar (Mediaproducts BV) plates to 
determine bacterial recovery (Log10 CFU). Remaining nasal tissue was stored
and spleens were harvested for further analysis. All animal work was performed 
with approval of the Radboud University Medical Center Committee for Animal
Ethics (RU-DEC2014-206).
Whole cell ELISA
Bacterial cultures were heat-killed at 56 °C for 1 h and taken up in an equal
        ϐ  ȋȌ  Ͷ ι
overnight. Next day, the plates were blocked with 1% bovine serum albumin 






at 37 °C for 1 h. Between incubation steps, wells were washed with PBS containing
ͲǤͲͷΨ ǦʹͲ ȋȌǤ     ͳͲͲ ρȀ
3,3',5,5'-Tetramethylbenzidine (Sigma-Aldrich) in 0.05 M phosphate-citrate 
substrate buffer (Sigma-Aldrich) and was stopped using 1.8 M H2SO4. Optical 





Human PBMC isolation & stimulation
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from whole blood
with density gradient centrifugation using Lymphoprep (Axis-Shield). The blood 
was diluted 1:1 with PBS and added on top of the Lymphoprep. Centrifugation 
was performed at 750 x g to separate PBMCs from the other blood components.
PBCMs and CBMCs were harvested and washed two times with PBS and
centrifuged at 500 x g. Subsequently, the cells were washed in RPMI-glutaMax©
(Life Technologies) with 10% Fetal Calf Serum (FCS, Greiner Bio-One) and
centrifuged at 250 x g. PBMCs were resuspended in RPMI+ 10% FCS and counted
the cells using Türk’s solution (Merck) and a haemocytometer (Bürker Bright-
Line Labor Optik).
PBMCs (5x105 cells/well) were added to round-bottom 96 wells plates (Nunc)
ǦȟmsbB OMVs expressing
Hbp. PBMCs were incubated at 37 °C and 5% CO2 for 24 h. Supernatant was
harvested using centrifugation at 450  x g and stored at -20 °C until further
analysis.
Mouse splenocyte isolation and stimulation
Harvested spleens were temporarily stored in RPMI-glutaMax© (Life Technologies)
with 10% Fetal Calf Serum (FCS, Greiner Bio-One) and 1% penicillin streptomycin
͹Ͳρȋ	Ȍ
suspensions. Erythrocytes were lysed using RBC lysis buffer (eBioscience), after 
which cells were thoroughly washed. Splenocytes (5x10E5 cells/well) were
added to round-bottom 96 wells plates (Nunc) and mixed with 5x105 CFU of 
ͳ ʹͲͲρǤ
incubated at 37 °C and 5% CO2 for 72 h. Supernatant was harvested by 
centrifugation at 450 x g and stored at -20 °C until further analysis.
Cytokine analyses
	ȽͳȾ
using ELISA kits (Pelpair reagent set, Sanquin, Amsterdam, The Netherlands).
These kits were used according to the manufacturer’s instructions. The detection 
	ȽͳȾͳͻǤͷȀǤ
Mouse IL17A concentrations were measured in the supernatants collected
after restimulation of the splenocytes using the commercial Mouse IL-17A ELISA
MAX™ Standard (Biolegend, ITK diagnostics) according to the manufacturer’s
instructions. The detection limit was 31.25 pg/ml.
IL17A production in mouse nasal samples was determined with Cytometric 
Bead Array (Becton Dickinson) according to manufacturer’s instructions, using 






Sensitivity Flex set for IL-17A (Becton Dickinson). Concentrations were 
calculated using Soft Flow FCAP Array v1.0 (Becton Dickinson).
Vaccine coverage prediction
ȽͳȽʹǡ
vaccine coverage, available sequences from pneumococcal isolates collected in 
large carriage cohort were used. We assessed 614 previously reported pneumococcal
carriage isolates from Massachusetts collected from 2001-2007. The details of 
this study population have previously been reported46. In addition, we extended 
this sample to include 738 carriage isolates collected from 2009-2014 from the 
same study population. In total, 1352 isolates including 33 serotypes were 
ȽͳȽʹǤ͵ͷpspA ȽͳȽʹ
used to generate a custom database that was provided to SRST2 v0.2.047. For 
each isolate, Illumnia MiSeq 2x150 bp sequencing reads were mapped to variants 
using default settings (90% minimum nucleotide identity and 10% maximum
nucleotide divergence) to determine the variant genotype (Table S3).
Statistical analyses
All statistical analyses were performed using GraphPad Prism version 5.0
(Graphpad Software). Human cytokine data were analyzed using Wilcox-
on-signed rank test. For bacterial recovery data, the Grubbs outlier test was
  ϐǤǦ
Bonferroni post-test for multiple groups or Mann-Whitney t test for two groups
were used for comparisons of vaccine-induced reduction in pneumococcal
colonization and nasal IL17A immune responses. Ex vivo Th17 screening data
were compared to RPMI using Univariate analysis of variance with Dunnet’s 
post test in SPSS. 
RESULTS
Protection upon immunization with LPS-detoxified OMVs
 ǡ     ȽͳȽʹ 
Hbp-based antigen display platform, and produced by attenuated and hyper-
vesiculating SǤ͵ʹ͸ͳȟtolRA, were previously used for intranasal 
vaccination14. This formulation conferred strong protection against pneumococcal 
colonization, illustrating the potential of an OMV/PspA-based vaccine14. Since a
ǡǦϐ
OMV production strain. To this end, we inactivated the msbB gene of strain





moiety, which is less immune reactive in humans compared to wild-type
hexa-acylated lipid A due to reduced responses via Toll-like receptor (TLR)4
activation48Ǥ   ϐ  Ǧ	     ȟmsbB
mutant has reduced hexacylated lipid A and increased pentacylated A (Figure
ͳǦȌǤ͵ʹ͸ͳȟtol-
RAȟmsbB  ϐ  	Ƚ  ͳȾ   
  ͵ʹ͸ͳȟtolRA harboring an intact msbB (Figure S1C-D), which 
ϐ  ϐ Ǥ ǡ Ǧ
  
ϐǦȽͳȽʹ
οmsbB OMVs, to a similar level as in the Salmonella OMVs used in our previous
Ǧϐȋ	ͳȌ14. Furthermore, a reduction in
οmsbB OMVs
ȽͳȽʹǡ
οmsbB Salmonella strain are still suitable for vaccination (Figure 1A). In agreement 
with this observation, reduction in pneumococcal load was independent of 
Ǧ ǡ   ϐ     ͵Ȁ ǡ
containing a point mutation in the Tlr4 gene, resulting in reduced responses to
LPS (Figure 1B)49. 

ͶȽͳȽʹ
ͳ͹ȋ	ͳȌǡȟmsbB had no effect on the induction 
of IL-17A. Based on these and previous data we hypothesize that the Th17
response induced by our OMV-based vaccine contributes to a reduction in 
S. pneumoniae14Ǥ  ϐ    ͳ͹     ǡ
ͳ͹ϐ
ͶȽͳȽʹ
an infection with S. pneumoniae. Three days post-infection bacterial recovery 
resulted in absence of protection (i.e. no reduction of colonization) (Figure 1D)45.
ǡ          ȽͳȽʹ
induce Th17-mediated protection against colonization.
ȽͳȽʹ
To determine Th17-mediated cross-protection of our OMV-based vaccine against 
other pneumococcal strains, we made use of a sequenced collection of 349
invasive clinical isolates obtained from patients with pneumococcal bacteremia,
hospitalized in two hospitals in The Netherlands between 2001-201127,28. PspA
ϐȽͳȽʹȋ	ʹȌǤ
This fragment was (partly) undetectable in 4 pneumococcal strains due to
sequencing errors, and these strains were therefore excluded from further 
study. 
      ȽͳȽʹ   






Figure 1  OMV-induced reduction in pneumococcal colonization is IL17-dependent.
ȋǢȌȽͳȽʹȋǦȽͳȽʹǢ
black circles) derived from (A, C, D) SalmonellaȟmsbB or (B) wildtype (msbB+) Salmonella. Intranasal 
infection was performed using TIGR4 (homologous challenge). Bacterial recovery (Log CFU) was
calculated 3 days post-infection from the nasopharyanx of (A) C57BL/6, (B) C3H/HeJ, and (D)
IL17R-/- mice. (C) IL17A measured in the nasal tissue of vaccinated C57BL/6 mice. Data represent 
individual mice and bars indicate group mean ± SEM. *, p < 0.05;  **, p < 0.01.
Figure 2ȽͳȽͳǤ
(AȌ
ͶȽͳȽʹ et al.14. The slightly overlapping 
ȽǦȋȽͳȽʹǤǦ-
ing domain (LFBD), the Proline-rich region (PRR) and the choline-binding domain (CBD) of PspA
were not included in the vaccine. (BȌȽͳȽʹ͵Ͷͷ
ǤǡȽͳȽʹ
vaccine region into six Variable Regions (VR1-6). Some VRs appeared more conserved and were 
alternately expressed by the clinical isolates. Percentage of VR expression among pneumococcal 
isolates was calculated. Presence of the VR is shown in percentages.
A B C D



























ȽͳȽʹ      ȋȌǡ  ͳǦ͸ǡ 
(Figure 2B; Table S2). Sequences in VR1 were the most conserved among
pneumococcal strains, whereas sequences in VR6 were most variable. This 
means that sequence variation increased with increasing VR number. Also, these 
VRs were not present in all pneumococcal strains. The majority of clinical 
isolates expressed VR2 (98.6%), VR3 (99.7%) and VR4 (98.4%). A selection of 
strains had VR5 (27.3%) in between VR4 and VR2. Either VR1 (33.9%) or VR6 
ȋͷͳǤͳΨȌʹǤȽͳȽʹǡ͵Ͷͷ
strains were divided into 35 different groups (Table S1). Interestingly, this novel 
ȽͳȽʹ ϐ     Ǥ  ȽͳȽʹ
    ϐ ǡ   
ȽͳȽʹȋʹȌǤ
Vaccine-induced IgG and Th17 cross-reactivity with pneumococcal 
invasive isolates






To test IgG cross-reactivity, ELISA plates were coated with whole pneumococcal 
cells and incubated with pooled sera from mice immunized with OMVs expressing

ͶȽͳȽʹǤǦ 
    Ǥ

Ͷ ȽͳȽʹǦϐ 
 Ǧ  ʹ͸ͺ  ͵ʹͳǡ 
ʹ͸ͺ
ͶȽͳȽʹȋ	ʹȌǤ
We developed an ex vivo Th17 screening assay using mouse splenocytes to
ǦǦͳ͹ϐ
 
Ͷ ȽͳȽʹǤ     

ͶȽͳȽʹ
challenge. The cells were incubated with the 35 representative pneumococcal 
strains for three consecutive days, after which IL17A levels were measured in 
cell supernatants by ELISA. Splenocyte restimulation of control mice (immunized
with OMV/HbpD but infected with TIGR4) showed extremely low to undetectable
IL17A concentrations (Figure S3). In contrast, splenocyte restimulation of TIGR4 
ȽͳȽʹǦ   Ǧ   
Ǥ
Ͷʹ͸ͺȋȽͳȽʹȌ
resulted in high IL17A concentrations (Figure 3). Interestingly, restimulation
with pneumococcal strains PBCN64, 461, 266, 321, and 16 also showed a
ϐ   ͳ͹ ǡ     

ͶǤ       ȽͳȽʹ 







  Ƚʹ Ǥ  ǡ   Ǧ Ǧ
ͳ͹ϐ
 ǡϐ
on ex vivo IL17A levels (Figure S5).
Ex vivo Th17 responses predict in vivo nasal IL17A levels
Next, we assessed whether the IL17A levels measured in the ex vivo splenocyte
assay predicted in vivo vaccine-induced IL17A responses in the nasal cavity.
We determined whether infection with heterologous strains would activate the
vaccine-induced Th17 memory response in the nasopharynx of animals vaccinated 

ͶȽͳȽʹǤex vivo Th17 screening (see Figure 3), we selected
two groups of strains inducing high and low concentrations of IL17A after 
restimulation (‘high IL17A’: PBCN266 and 321 and ‘low IL17A’: PBCN200 and 
EF3030). Mice were immunized with either control OMVs (HbpD; control) or 

ͶȽͳȽʹȋǦȽͳȽʹȌ
homologous (TIGR4) or heterologous selected strains. Vaccination with OMVs 
ȽͳȽʹ     ͳ͹   ȋ	
S6A), indicating that empty OMVs induce IL17A to a low extend. Homologous 
 
Ͷ ϐ   ͳ͹  ȽͳȽʹǦ
animals (Figure S6A). Likewise, heterologous challenge with  ‘high IL-17A’ strains 
ȋʹ͸͸͵ ʹͳȌϐͳ͹
ȽͳȽʹǦ         ȋ	
S6B-C). In contrast, heterologous challenge with ‘low IL17A’ strains (PBCN200 
Figure 3 Ex vivo vaccine-induced Th17 memory cross-reactivity with
clinical isolates.
  Ǧ         ȟmsbB
  ȽͳȽʹ ȋǦȽͳȽʹȌǤ      
selected pneumococcal isolates for three days. IL17A was measured in cell supernatant. IL17A levels
  α ͳͲ    ά Ǥ     






control vaccinated animals (Figure S6D-E). Combining the data of the individual
 Ǯͳ͹ǯ ϐ 
nasal IL17A following vaccination, unlike ‘low IL17A’ strains (Figure 4A). 
Vaccine-induced nasal IL17A contributes to heterologous protection
ϐ
colonize the murine nasopharynx without vaccination (Figure S7A, C, E, G, I). 

ͶȽͳȽʹȋǦȽͳȽʹȌ
OMVs (HbpD) and received a homologous (TIGR4) or a heterologous infection
with ‘IL-17A high’ strains (PBCN266 and 321) and ‘IL-17A low’ strains (PBCN200
Figure 4 Ex vivo Th17 responses are predictive for in vivo nasal IL17A
and a reduction in CFU.
ǡȟmsbBȋȌȽͳȽʹȋǦȽͳȽʹȌǤ
Intranasal infection was performed using TIGR4 (homologous challenge), selected clinical strains
(heterologous challenge), or laboratory strain EF3030 (heterologous challenge). (A) IL17A levels in 
nasal tissue and (B) bacterial recovery were assessed following infection with TIGR4, PBCN266, 
PBCN321, PBCN200, and EF3030. Results were pooled for heterologous high and low IL17A low
strains respectively. Data represent individual mice and bars indicate group mean ± SEM. *, p < 0.05;













cinated and control animals following challenge with ‘IL-17A low’ strain 
ʹͲͲȋ	͹Ȍǡϐ	
was observed  for ‘IL-17A low’ strain EF3030 (Figure S7J). Colonization of 
	͵Ͳ͵Ͳ  ϐ   ȽͳȽʹǦ ǡ  
difference in CFU was less than one order of magnitude (Figure S7J). Interestingly,
ͳ͹ȽͳȽʹǦ
following EF3030 infection (Figure 4E), suggesting that mucosal responses
other than IL17A contributed to the vaccine-induced reduction in colonization50.
 	    ϐ   
colonization of the ‘IL17A high’ strains selected in the ex vivo screen (Figure 4B), 
which was not observed for the ‘low IL17A’ strains. Together, these results
illustrate that IL17A contributes to protection against heterologous strains, 





Of the 1352 isolates derived from a large carriage study, genotypes were able to
be determined for 89.3% (Table 1). Among those genotyped, the average
mapping coverage was 99.6% with a mean nucleotide divergence of 0.4% 
ȋͲǤͲȌǤȽͳȽʹ͵ͳȋͳͲͲ͹ͳ̴Ͷ͓ͷ͸̴ͲͳͶ͵ʹȌ
ȋͳͲΨȌ ͹ȋͳͲͲͷͲ̴ʹ͓ʹͳ̴ͲͲ͵ʹ͸ȌȋͻǤͲΨȌǤȽͳȽʹ
to be determined among 144 isolates (Table 2). Nineteen (25%) of the
  ȽͳȽʹ    ǡ 
play a limited role in invasive disease51.  However, almost half (46.2%) of serotype




vaccine, we calculated the prevalence of pneumococcal strains that could be 

ͶȽͳȽʹǡex 
vivo high IL17A concentrations in our study predict in vivo protection. For this, a 
Ǧϐͳ͹ex vivo Th17 screening was 
ȋ	͵ȌǤϐͳ͹







Table 1  ȽͳȽʹ
Row Labels PBCN ID Protein Total (n=1352) Percent
ND N/A N/A 144 10.7%
Variant1 6 10050_2#2_00383 16 1.2%
Variant2 9 10050_2#4_00581 35 2.6%
Variant3 16 10050_2#8_00268 48 3.6%
Variant4 22 10050_2#11_00768 0 0.0%
Variant5 23 10050_2#12_01906 25 1.8%
Variant6 34 10050_2#20_01349 5 0.4%
Variant7 36 10050_2#21_00326 122 9.0%
Variant8 39 10050_2#22_01317 11 0.8%
Variant9 42 10050_2#24_00225 8 0.6%
Variant10 57 10050_2#30_00292 36 2.7%
Variant11 64 10050_2#35_00095 31 2.3%
Variant12 68 10050_2#37_01815 22 1.6%
Variant13 78 10050_2#41_00777 1 0.1%
Variant14 79 10050_2#42_00670 115 8.5%
Variant15 83 10050_2#45_00391 1 0.1%
Variant16 87 10050_2#48_00214 103 7.6%
Variant17 89 10050_2#50_00198 47 3.5%
Variant18 118 10050_2#71_00865 2 0.1%
Variant19 200 9953_7#38_01834 2 0.1%
Variant20 215 9953_7#47_00982 82 6.1%
Variant21 218 9953_7#49_01131 31 2.3%
Variant22 235 9953_7#58_00025 15 1.1%
Variant23 264 9953_7#79_01103 0 0.0%
Variant24 266 9953_7#81_00909 110 8.1%
Variant25 268 9953_7#82_01423 35 2.6%
Variant26 306 10071_4#18_00006 3 0.2%
Variant27 321 10071_4#30_00648 29 2.1%
Variant28 325 10071_4#32_00112 23 1.7%
Variant29 333 10071_4#40_00911 2 0.1%
Variant30 342 10071_4#46_00491 30 2.2%
Variant31 356 10071_4#56_01432 135 10.0%
Variant32 372 10071_4#71_00979 18 1.3%
Variant33 382 10071_4#80_00989 59 4.4%
Variant34 461 10208_2#57_01836 6 0.4%







more than 1350 carriage strains. 
DISCUSSION
In most cases, immunizations with variable, often highly immunogenic proteins,
offer strong protection upon homologous challenge11,14-16. Variable proteins show 
considerable surface epitope heterogeneity between subtypes and are therefore 
usually seen as unsuitable antigens to induce broad protection. However, 
whether variable proteins might induce a more broad Th17-mediated protection 
against bacterial carriage has, to our knowledge, not been investigated. In this 
study, we used PspA of S. pneumoniae as model antigen for the design of a 
universal vaccine to protect against carriage, an important prerequisite for




























  Ǥ Ǧϐ     ϐ Ǧ

ͶȽͳȽʹǤ	ǡ
an assay to determine Th17-based cross-reactivity that strongly predicted in 
vivo recall IL17A responses following vaccination. Vaccination with OMVs 
 
Ͷ ȽͳȽʹ      
showed strong induction of IL17A upon ex vivo restimulation, illustrating the
potency of such a vaccine to offer broader protection. Strikingly, the use of a
ȽͳȽʹȋ
ͶȌ ͳ͹ǦǦ
could theoretically cover 19.1% of a large carriage cohort.
There is evidence that PspA could potentially offer universal protection 
against pneumococcal disease. It has been proposed that broad protection can
be accomplished by a vaccine that combines family 1 and 2 PspA proteins19.
Animal studies indeed showed that a vaccine combining the N-terminal part of 
family 1 and 2 PspA protected against infection with different pneumococcal
ǡϐ
conserved CDR and PRR region of PspA20-25,52-54. These broadly protective 
antibodies recognizing the PRR region of PspA pose a problem for human 
application as they were shown to cross-react with proteins from the human 
heart and skeletal muscles55ǤȽͳȽʹ
fragment, part of the N-terminal region, for a broad vaccine that induces
Th17-mediated protection. The use of sequenced clinical isolates allowed us to




with pneumococcal strains in relation to actual in vivo protection. Even though
cross-reactivity of colonization-induced IgG with heterologous pneumococcal 
strains in a whole cell ELISA was detected, no protection against disease was
found56. Vaccine-induced IgG binding to the heterologous strains in the animal
experiments may be hampered by differences in pneumococcal serotypes57,
which was also observed in our experiment. Although pneumococcal strains

Ͷʹ͸ͺ    ȽͳȽʹǡ 
 ʹ͸ͺ
reduced (Figure S2), which suggests that bacterial factors including capsule 
thickness and antigen expression levels might interfere with vaccine-induced 

  Ǥ      Ǧϐ 
  
discriminate between surface and subcapsular PspA, indicating ELISA is less
predictive for in vivoǦϐ

capsule expression56.
Our study further points out that cross-reactivity of vaccine-induced 
 ϐ  ȽͳȽʹ      






3 and S2). This could be explained by the fact that the Th17 memory response is
mediated by CD4+ T cells and MHCII antigen presentation of linear peptides58,59,
whereas IgG binding often depends on conformational epitopes that can be 
masked by other components such as capsule and surface proteins and are 
therefore not always available. Similar to IgG binding capacity, reactivation of 
ͳ͹ ǡǡ  ϐ 
expression. In the ex vivo Th17 cross-reactivity screening, IL17A concentrations 
were reduced when splenocytes were exposed to lower PspA concentrations or 
to a highly encapsulated pneumococcal strain (Figure S5B-C). Similarly, others
have shown that ex vivo splenocyte-derived IL17A by WCV-immunized animals
slightly differed between different isogenic capsule-switch strains57. In the same 
study, vaccination with a whole cell vaccine followed by a homologous challenge 
induced Th17 memory responses in the spleens of mice57. Consistent with these
ǡȽͳȽʹͳ͹
memory responses in mouse splenocytes, which we used to screen for 
heterologous cross-reactivity across 345 sequenced invasive isolates. This
represented a simple method to screen for vaccine cross-reactivity among 35 
ȽͳȽʹ͵ͷǤ
We showed that IL17A measured in the ex vivo assay was highly predictive for in 
vivo nasal IL17A levels induced by the OMV-based vaccine.

ͶȽͳȽʹ 
pneumococcal colonization in homologous challenge infection, but was less 
pronounced after a heterologous challenge infection (Figure S7D and F). This 
demonstrates that although equal levels of ex vivo IL17A were measured for
restimulation with TIGR4 (strain background vaccine) and the clinical ‘high
IL17A strains’ (Figure 4 and S6), this does not result in a similar degree of 
protection. One explanation is that vaccine-induced IgG binding to conformational
epitopes may play a role, which has a stronger effect on homologous challenge,
contributing to a better reduction in pneumococcal colonization as compared to 
the reduction of the heterologous strains. Secondly, the concentration of nasal 
IL17A was slightly lower in mice infected with heterologous strains. Also, the 
kinetics of a nasal IL17A in response to pneumococcal infection may differ 
between homologous and heterologous strains, which could not be determined
ͳ͹ϐǦ
infection. Interestingly, compared to laboratory strain TIGR4, PBCN266 and 
PBCN321 colonized the murine nasopharynx at higher densities (Figure S7D, F). 
The increased densities suggest that these clinical strains have an increased 
capacity to colonize the murine nasopharynx, compared to TIGR4. This may 







with empty OMVs was observed for TIGR4 and other clinical strains (Figures
S7B and S8). This reduction in CFU was associated with increased nasal IL17A
ȋ	͸Ȍǡͳ͹ϐ
in pneumococcal load. Mucosal adjuvants such as CTB and CT were also described
      ϐ ǡ  
underlying mechanisms might differ50,60. IL17A might be derived from macrophages, 
ǡ͵ɀɁǡ
respond to S. pneumoniae infection upon recognition61. The current study did not 
   ϐǤǡ
further study is needed to determine their role in a reduction in bacterial
colonization. 
ȽͳȽʹ   
the majority of the N-terminal region of PspA and is an interesting vaccine target 
based on existing literature in both mouse and human14. Importantly, the PRR 
ǦȽͳȽʹ
fragment of PspA55. Multiple studies show that the coiled-coil N-terminal domain 
is implicated in cross-reactivity and cross-protection with pneumococcal 
strains20-22,25,52,53,62. In mouse and human, T-cell and antibody epitopes are 
localized to this particular fragment of PspA62-67. Since mucosal CD4+IL17+ T cells
were detected in the human upper respiratory tract, it is possible that these cells 
play a role in protection against bacterial colonization in humans, like we have 
observed in our mouse studies68. Whether an OMV-based vaccine inducing Th17 
immunity that reduces pneumococcal colonization will also prevent and/or
reduce pneumococcal disease and transmission remains to be studied. 
 ϐ    ȽͳȽʹ   ͵Ͷͷ  
isolates from the Netherlands appears to be consistent in other regions of the
world, as determined by using a large carriage cohort. Except for serotype 23B, 
which was not present in the invasive cohort of 345 clinical isolates. Importantly,
ȽͳȽʹǡ 
ȽͳȽʹͳ͹
pneumococcal colonization (Figure S9). The method for Th17 cross-reactivity 
screening, as described in the current study, can be applied to pneumococci
collected in any region of the world, as well as for screening of cross-reactive
Th17 responses by other variable proteins. This is particularly interesting as
currently global efforts are undertaken to sequence thousands of pneumococcal 
strains before and after vaccine introduction in developing countries69. This
allows for the measurement of vaccine-escape mutants and devise next-generation 
vaccines that are able to limit escape, such as an OMV-based protein vaccine. 






for cross-protection against pneumococcal carriage via a Th17-dependent 
clearance mechanism. Vaccine cross-reactivity and the capacity to evoke in vivo
protection can easily be measured in an ex vivo Th17 screening, which allows for 
selection of a combination of variable protein antigens to increase vaccine
coverage. The current study indicates that the use of variable proteins, inducing
Th17 immunity, should be considered in future vaccine development programs 
when aiming at broad protection against bacterial carriage. 
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Table S1 Primers used in this study
Name Sequence (5’ 3’) Features
msbB_a_XbaI fw cgcatctagaagcgtctgacatgggaagtc XbaI site underlined
msbB_d_XbaI rv cgcatctagaattgtggctaaggtcgaacg XbaI site underlined
msbB_b  rv catgcttttccagggtctgc

































a2_PBCN87 rv taccgctgccggatccctctttttctagtccctgaac overhang for In-Fusion
cloning into pEH3-HbpD
in bold








Row Labels PBCN ID Protein Total (n=1352) Percent
ND N/A N/A 144 10,7%
Variant1 6 10050_2#2_00383 16 1,2%
Variant2 9 10050_2#4_00581 35 2,6%
Variant3 16 10050_2#8_00268 48 3,6%
Variant4 22 10050_2#11_00768 0 0,0%
Variant5 23 10050_2#12_01906 25 1,8%
Variant6 34 10050_2#20_01349 5 0,4%
Variant7 36 10050_2#21_00326 122 9,0%
Variant8 39 10050_2#22_01317 11 0,8%
Variant9 42 10050_2#24_00225 8 0,6%
Variant10 57 10050_2#30_00292 36 2,7%
Variant11 64 10050_2#35_00095 31 2,3%
Variant12 68 10050_2#37_01815 22 1,6%
Variant13 78 10050_2#41_00777 1 0,1%
Variant14 79 10050_2#42_00670 115 8,5%
Variant15 83 10050_2#45_00391 1 0,1%
Variant16 87 10050_2#48_00214 103 7,6%
Variant17 89 10050_2#50_00198 47 3,5%
Variant18 118 10050_2#71_00865 2 0,1%
Variant19 200 9953_7#38_01834 2 0,1%
Variant20 215 9953_7#47_00982 82 6,1%
Variant21 218 9953_7#49_01131 31 2,3%
Variant22 235 9953_7#58_00025 15 1,1%
Variant23 264 9953_7#79_01103 0 0,0%
Variant24 266 9953_7#81_00909 110 8,1%
Variant25 268 9953_7#82_01423 35 2,6%
Variant26 306 10071_4#18_00006 3 0,2%
Variant27 321 10071_4#30_00648 29 2,1%
Variant28 325 10071_4#32_00112 23 1,7%
Variant29 333 10071_4#40_00911 2 0,1%
Variant30 342 10071_4#46_00491 30 2,2%
Variant31 356 10071_4#56_01432 135 10,0%
Variant32 372 10071_4#71_00979 18 1,3%
Variant33 382 10071_4#80_00989 59 4,4%
Variant34 461 10208_2#57_01836 6 0,4%
Variant35 477 10396_8#26_00179 0 0,0%






Figure S1 ȟmsbB OMVs reduced hexacylated LPS and cytokine 
production by human PBMCs.
(A-B) Sections of the charge-deconvoluted negative-ion (ESI-FT) SID mass spectra of LPS from S.















































(1 PEA + 2 P + 2 GlcN + 4 C14:0(3-OH) + 1 C14:0 + 1 C12:0)


















fragment ions corresponding to lipid A moieties are depicted. Annotations refer to monoisotopic 
mass values. The ion peaks of masses 1797.220 and 1920.228 u obtained from the LPS of the parent 
strain correspond to hexa-acylated lipid A species carrying two phosphates (P) and two P plus a 
 ȋȌ ǡ Ǥ   ȟmsbB mutant the main ion peaks of 
masses 1710.030 and 1587.022 u from the LPS correspond to penta-acylated lipid A species which 
lost a C14:0 fatty acid as compared to the main lipid A species of the parent strain. PEA:
phosphoethanolamine; P: phosphate; GlcN: glucosamine; C12:0: dodecanoic acid; C14:0: tetradecanoic 
acid; C14:0(3-OH): 3-hydroxy-tetradecanoic acid; C16:0: hexadecanoic acid; Ara4N: 4-amino-4-deoxy-L-
arabinose. (C-D) Human PBCMs were stimulated with equal amounts (1 ng/mL) of wildtype or




Figure S2 Vaccine-induced IgG cross-reactivity with clinical isolates.











Figure S3 Ex vivo vaccine-induced Th17 memory cross-reactivity.
  Ǧ         ȟmsbB
OMVs expressing no pneumococcal antigen (HbpD; control). Single cell suspensions were obtained 
and stimulated with selected pneumococcal isolates for three days. IL17A was measured in cell
Ǥ ͳ͹   α Ͷ    ά Ǥ  
ordered based on serotype. ST: serotype; PBCN#: PBCN number; TIG: TIGR4; EF: EF3030.
Figure S4 Ex vivo vaccine-induced Th17 memory cross-reactivity.
(AȌȽͳȽʹex vivo IL17A levels among clinical isolates. 
Tree indicates that pneumococcal strains with an ex vivo high IL17A share a similar sequence in the 
ȽʹȽͳȽʹǤȋBȌͳ͹Ƚʹȋͳ͸ͷǦʹͲ͸Ȍ
among the 42 amino acids.
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Figure S5 ϐ ex vivo IL17A.
  Ǧ         ȟmsbB
  ȽͳȽʹ ȋǦȽͳȽʹȌǤ      
ǡ
ͶǡϐȋA) serotype,
(B) capsule, and (C) PspA antigen levels. (AȌʹ͸ͺ͵͸ͲȽͳȽʹǡ
but belong to a different serotype. This is similar for PBCN64 and PBCN252. Splenocytes were 
exposed to (BȌ  
Ͷǡ   
Ͷ ȋȟȌǡ  
Ͷ  
(cps+++), and (CȌ Ǧ    ȋͲǤͳǢ ͲǤ͵Ǣ ͳǢ ͵Ǣ ͳͲ ρȀȌǤ ͳ͹ 
Ǥͳ͹αͷǦͻάǤ








Figure S6 Ex vivo Th17 responses are predictive for in vivo nasal IL17A.
ǡȟmsbBȋȌȽͳȽʹȋǦȽͳȽʹȌǤ
Intranasal infection was performed using TIGR4 (homologous challenge), selected clinical strains 
(heterologous challenge), or laboratory strain EF3030 (heterologous challenge). IL17A levels in
nasal tissue were assessed following infection with (A) TIGR4, (B) PBCN266, (C), PBCN321, (D)
PBCN200, and (E) EF3030. Data represent individual mice and bars indicate group mean ± SEM. *, 








Figure S7 Vaccine-induced nasal IL17A reduces pneumococcal colonization.
ǡȟmsbB ȋȌȽͳȽʹȋǦȽͳȽʹȌǤ
Intranasal infection was performed using TIGR4 (homologous challenge), selected clinical strains 
(heterologous challenge), or laboratory strain EF3030 (heterologous challenge). (A, C, E, G, I) 
Clinical isolates were tested for colonization of the murine naspharynx. In vaccinated animals three
days post-infection, bacterial recovery was assessed of (B) TIGR4, (D) PBCN266, (F) PBCN321, (H) 
PBCN200, and (I) EF3030. Data represent individual mice and bars indicate group mean ± SEM. *,
p < 0.05; **, p < 0.01; ***, p < 0.001.
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ȋȌȟmsbB empty OMVs (HbpD). Intranasal 
infection was performed using TIGR4 (homologous challenge). Three days following challenge












Ͷǡͺ͹͹ͻǤȋB-E) Mice were vaccinated with empty 
ȋǢȌȽͳȽʹȋǦȽͳȽʹǢȌȋB) 
PBCN87 or (C) PBCN79. Bacterial recovery was assessed three days following homologous intranasal 
Ǥαͷ   ex vivo Th17 memory 
cross-reactivity assays. Vaccine-induced IL17A levels of the (D) PBCN87 and (EȌ͹ͻȽͳȽʹ
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For many bacterial respiratory infections, development of (severe) disease is 
preceded by asymptomatic colonization of the upper airways. For Streptococcus 
pneumoniae, the transition to severe lower respiratory tract infection is 
associated with an increase in nasopharyngeal colonization density. Insight into 
how the mucosal immune system restricts colonization may provide new 
strategies to prevent clinical symptoms. Several studies have provided indirect 
evidence that the mucosal adjuvant Cholera Toxin subunit B (CTB) may confer
ǦϐǤǡ
reduces pneumococcal load in the nasopharynx, which required activation of 
ǦͳȀͳͳϐǡǤϐ
suggest that CTB-dependent activation of the local innate response synergizes
with non-cognate T cells to restrict bacterial load. Our study not only provides 
insight into the immunological components required for containment and 
clearance of pneumococcal carriage, but also highlight an important yet often 




REDUCTION IN PNEUMOCOCCAL DENSITY BY CTB
5
INTRODUCTION
Bacterial respiratory tract infections are a major cause of severe morbidity and 
mortality worldwide, both in infants as well as in adults1,2. The gram-positive 
pathogen Streptococcus pneumoniae (the pneumococcus) in particular remains 
an important bacterial pathogen, despite the availability of effective vaccines. 
The pneumococcus colonizes the mucosal surfaces of the upper respiratory tract 
for weeks to months, typically in the absence of clinical symptoms. However,
under certain conditions, pneumococcal colonization may progress to disease, 
ranging from mucosal infections such as sinusitis and otitis media to potentially 
life-threatening invasive infections such as pneumococcal pneumonia, meningitis 
and sepsis. Progression to disease has been associated with a concomitant 
increase in bacterial density in the nasopharynx3-6. Increased insight into, not 
only the acquired immune response, but also in the early (innate) mechanisms 
that may limit the density and duration of nasopharyngeal colonization with 
S. pneumoniae ϐ
preventive or therapeutic strategies to reduce the burden of pneumococcal
disease. In this study, we make use of the observation that certain adjuvants can
confer protection against respiratory infections, independent of co-adminstered
ϐ ǡ   ϐ  ǮǦϐǯ Ǥ   
adjuvants is Cholera Toxin (CT), which is produced by Vibrio cholerae, the 
causative agent for severe cholera in humans7. CT is comprised of an enzymatically 
active subunit A (CTA) and a non-toxic subunit B (CTB), the latter of which has 
previously been shown to bind to the GM-1 ganglioside. GM-1 is present on all
nucleated cells, resulting in uptake of the toxin. For decades, both cholera toxin 
(CT) and its A or pentameric B subunits (CTA and CTB, respectively) have been
used as a highly effective mucosal adjuvant, mostly in experimental preclinical 
models8. The versatility and potency of CTB in particular is illustrated in many 
studies, including against pneumococcal colonization9-12. An interesting yet 
  ϐ        
with CTB alone, thus without additional antigens, can also reduce pathogen load,
e.g. against S. pneumoniae  ϐ9,13Ǥ  ϐ  
CTB may be able to confer mucosal protection in a non-cognate manner. Here, we
examine the effects of CTB on pneumococcal density, using a mouse model of 
nasopharyngeal colonization. We studied the role of CTB in pneumococcal 
clearance, with a particular focus on caspase-1/11, mucosal T cells and macro- 








This study was conducted according to the national guidelines. The protocol
was reviewed and approved by Institutional Animal Care and Use Committee
Radboud University Medical Center (‘Dierexperimentencommissie van de Radboud 
Universiteit’) (DEC number 2011-107, 2011-259, 2013-055, and 2014-188).
Mice experiments 
Outbred CD-1, C57BL/6 (Charles River Laboratories, France), C57BL/6 Ccr2-/-,
Scid-/- (Jackson Laboratories, ME, USA) and Casp-1/11-/- mice14 were housed under 
SPF conditions. Mice were immunized intranasally (i.n.) with one or three doses 
ͶɊȋǡǡȌͳͲρǡǡ
 ϐ  ȋ ǡ  Ȍ13. Where
ǡͳͲͲρǤǤ15, or
an equivalent dose of empty liposomes. For challenge, mice were infected i.n.
with 106 CFU of strain BHN100 (serotype 19F) or with PBS seven days after CTB 
Ǥǡϐ
was harvested and homogenized (IKA T10 blender). For bacterial enumeration, 
samples were serially diluted on blood agar plates containing gentamicin 
(Mediaproducts BV, The Netherlands) and incubated at 37°C overnight.
Immunohistochemistry 
For immunohistochemistry experiments, mouse heads were obtained seven and
ten days post CTB treatment. The skin, ears and whiskers were removed and
  ϐ  	 ϐ  ͶͲΨ ǡ ͷΨ  ǡ
3.7% formaldehyde and 45% of 0.9% sodium chloride solution for three days16.
ϐ͸ǤͷΨͶͲι
which the mouse heads were cut in three transversal slices of 2 mm thick. After
ʹͶ   Ǧϐ  ͷΨ  ǡ  
with increasing concentrations of ethanol (70%, 90%, 96%, 100%) followed by 
ǤϐͶρ
were prepared. Prior to immunohistochemical staining, slides were dewaxed 
and rehydrated followed by blocking with 2% bovine serum albumin, 2% normal 
goat serum, and 2% normal mouse serum in 0.05% PBS-Tween 20. Slides were 
then stained overnight at 4 °C with antibodies against CD3 (A0452, DAKO,
Belgium) and F4/80 (MCA497G, AbD serotec, United Kingdom). Biotinylated
antibodies (Vector Laboratories, CA, USA) were used as secondary antibody,
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then counterstained with haemotoxylin (1:3), dehydrated and coverslipped 
using Entellan (Merck, The Netherlands). Digital images were obtained using a
̹   ȋ 	ǡ ǡ ȌǤ ϐ 
positively stained cells in selected regions in the murine nasopharynx, as
indicated in Supplementary Figure 1A (F4/80) and 1B (Ly6G and CD3), was 
performed with FIJI software17.
Nasal samples and qPCR 
For gene expression analysis, Trizol (Invitrogen, Life Technologies, The Netherlands)
was added to homogenized nasal tissue samples and 1:5 diluted with chloroform.
After centrifugation, the upper phase was harvested and mixed with an equal
amount of 70% ethanol. RNA isolation was performed using the Qiagen RNeasy 
mini kit according to the manufacturer’s instructions. To remove contaminating 
DNA, the Turbo DNAfree kit was used (Ambion, Life technologies, The Netherlands), 
after which cDNA was generated using iScript (Bio-Rad, The Netherlands)
according to the manufacturer’s protocol. Realtime gene expression was 
performed using Taqman with the following primer-probe combinations: Il1b
(Mm00434228_m1), Cd19 (Mm00515420_m1), Cd3 (Mm00599684_g1), Foxp3
(Mm00475162_m1), Il17a (Mm00439618_m1), Infg (Mm01168134_m1), Il10
(Mm01288386_m1), and Gapdh (Mm99999915_g1) (all from Life Technologies, 
The Netherlands). Reaction mixes contained cDNA, Taqman probes Sso Advanced
Universal probe Mastermix (Bio-Rad). In total, 45 cycles were ran using a CFX96 
TouchTM Real-Time PCR detection system (Bio-Rad) with the following program: 
95°C for 3 minutes, 95°C for 15 seconds, 60°C for 30 seconds. 
Statistical analyses
RNA expression and bacterial counts were analyzed using GraphPad Prism 
version 5.0 (Graphpad Software, CA, USA). Comparisons of CFU counts between 
groups were performed using the one-way analysis of variance (ANOVA),
followed by a Bonferroni post test. 
       ϐ   Gapdh and
illustrated as fold-change according to the Livak method 18. The non-parametric 
unpaired T test and One-Way ANOVA with Bonferroni post test was applied for 
analysis of differences in gene expression and immunohistochemistry analysis 
ǦǤϐ







CTB transiently reduces the nasopharyngeal pneumococcal load
 ϐ    ǤǤ    
pneumococcal density in a murine model of nasopharyngeal colonization. To
this end, outbred CD-1 mice were treated i.n. with CTB or PBS (mock) for three
ʹǦ Ǥ    ϐ ǡ
challenged i.n. with S. pneumoniae. At two and four days after challenge, mucosal
nasal tissue, consisting of nasal associated lymphoid tissue (NALT) and epithelial
cells, was obtained and the pneumococcal load in the nasopharynx was 
Ǥ Ǧ    ϐ  
pneumococcal load in comparison with mock-treated mice, both at day 2 and 4
post-challenge (Figure 1A and B). These results demonstrate that CTB reduces
pneumococcal colonization in the absence of prior exposure to pneumococcal
Ǥϐ
CTB, mice were treated with Immune Stimulating complexes (ISCOMs). ISCOMs 
represent an alternative mucosal adjuvant, which for instance is used in a
ǤǤϐ19,20. In contrast to CTB, we found
no reduction in pneumococcal load in ISCOMs-treated mice following challenge
as compared to mock-treated mice (Figures 1A and B). This implies that the 
observed effect on pneumococcal load is not a universal trait of all mucosal
adjuvants. 
To examine the duration of the CTB-mediated effects on pneumococcal load, 
we repeated the experiment described above, but challenged the mice two
ϐǤǡ
found a reduction in pneumococcal load (Figure 1C), similar to our previous 
ϐǤǡ   ͶǦ 
(Figure 1D).
Thereafter, we investigated whether a single vaccination with CTB would
result in the same level of reduction of pneumococcal density. Groups of naïve 
͸Ǧͺͷ͹Ȁ͸ȋαͳͲȀȌǤǤ
(mock) and subsequently were infected seven days later with S. pneumoniae.
Enumeration of bacterial load, three days post-infection, indicated that 
treatment with a single dose of CTB induced a similar reduction as compared to 
mice that had received three doses (Figure 2A). Collectively, the protection 
observed in both inbred and outbred mice supports the ability of CTB to 
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Role of inflammasome in CTB-induced reduction
in pneumococcal load
  ϐ Ǧ
bone marrow derived macrophages14Ǥϐ
is also activated by CTB in vivo, in the nasopharynx, we performed qPCR analysis 
on Il1b expression in nasal tissue of mice treated with a single i.n. dose of CTB or
PBS. Groups of mice were either challenged i.n. with S. pneumoniae or with mock.
Figure 1 CTB induces a transient reduction in pneumococcal colonization.
CD-1 mice received three i.n. treatments with CTB, PBS (mock), or ISCOMs with a two-week interval.
Bacterial recovery in mice challenged with S. pneumoniaeϐ
 ϐ ȋA) 2 and (B) 4 days post-infection to assess bacterial load in the nasal tissue.
Bacterial recovery in mice that received S. pneumoniae infection two weeks post-immunization and 
ϐȋC) 2 and (D) 4 days after challenge. Bacterial recovery was assessed in nasal tissue
and presented as Log10	ǡȋαͻǦͳͲȌ
bars indicate group mean ± SEM. The dotted line represents the lower limit of detection. One-way 










  ͳͲ    ȋǤǤ    Ȍǡ ϐ
elevated Il1b expression was measured in the nasal tissue (3.9 ± 2.4 fold, Figure
3A). Subsequent challenge with S. pneumoniae further increased Il1b expression 
(Figure 3A). 
      ͳȾǤ     
macrophages in the nasopharynx, immunohistochemistry (IHC) was performed 
on the nasal tissue seven days after CTB- or mock-treatment. Although 
macrophages (F4/80+ cells) were already relatively abundant in mock-treated 
ǡϐ
(Figure 3B and C). Next, we determined the presence of neutrophils (Ly6G) in
the nasal tissue derived from the same mice, using IHC. More neutrophils were
ǡϐ
mock treated mice at seven days post-infection (Figure 3D).
As the CTB-induced increase in Il1b expression suggests a role for the 
ϐǡCasp1/11-/- mice. Casp1/11-/- mice
ϐ ǦͳǦͳͳǦǦͳȾ
pro-IL18 into their biologically active forms14. Casp-1/11-/- mice were treated and 
infected as described above and the bacterial load in the nasopharynx was
Figure 2 CTB required caspase-1/11, T cells and macrophages for reduction in 
pneumococcal load.
Mice received a single i.n. treatment with CTB or PBS (mock) and were challenged with S. pneumoniae
seven days post-treatment. Mice were euthanized 3 days post-infection, e.g. 10 days post-treatment 
and nasal tissue was harvested to assess bacterial load. Bacterial recovery in (A) C57BL/6 mice, (B)
C57BL/6 Casp-1/11-/- (Casp-/-) mice, (C) C57BL/6 Ccr2-/- mice, and (D) C57BL/6 Scid-/- mice. Bacterial 
recovery is illustrated as Log10 	ǡȋαͷǦͳͲȌ
and bars indicate group mean ± SEM. The dotted line represents the lower limit of detection Mann 
Whitney T test was performed for comparison between CTB- and PBS-immunized mice. *, p < 0.05; 
ǡϐǤ
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Figure 3  CTB upregulates Il1b and recruits macrophages to the nasal mucosa.
(A) C57BL/6 mice received a single i.n. dose of CTB or PBS (mock), which were either challenged with 
S. pneumoniaeȋΪȌǦȋǦȌϐͳͲǦǡǤǤ͵Ǧ
infection. Nasal tissue was harvested 10 days post-treatment and analyzed for local expression of 
Il1bǤ     α ͷǦͺ     Ǥ  
  ȟȟ       ά Ǥ    ʹǦ 
considered biologically relevant (dotted line). (B-C) C57BL/6 mice received a single i.n. CTB or PBS
(mock) treatment. At seven days post-immunization the heads of the mice were collected and 
      ϐ  	ͶȀͺͲǦ
ǤͷͲρρǤȋB) Pictures are 
  Ǧ ȋ α ͶȌ Ǧ ȋ α ͶȌǤ ȋCȌϐ 
 ȋ	ͶȀͺͲȌ Ǧ ȋ α ͶȌ Ǧ ȋ α ͶȌ  	 Ǥ ȋD)
ϐ ȋ͸
Ȍ Ǧ ȋαͶȌ Ǧ ȋαͶȌ	
software. Data are illustrated as the positive stained area divided by the total area measured with 
ǤǦϐ








determined at three days post-infection. In contrast to wildtype C57BL/6 mice,
no reduction in pathogen load was observed in the Casp-1/11 ϐ 
ȋ	ʹȌǡϐǤ
CTB polarizes mucosal T cells 
T cells, in particular CD4+ IL17-producing T cells, are thought to be an important 
component of the mucosal immune response to S. pneumoniae21. We therefore
used IHC to evaluate the presence of T cells (CD3+) in mice treated with CTB or 
PBS, similar to the macrophages described above. Whilst mock-treated mice
showed only low numbers of CD3+ T cells in the lamina propria, treatment with 
CTB resulted in a strong increase in T cells in the sub-epithelial layer (Figure 4A 
ȌǤϐǡCd3, using the pan-B cell 
marker Cd19 as a control. Whilst no changes were observed in Cd19 expression 
in CTB-treated mice, expression patterns of Cd3 were in line with IHC
observations, demonstrating a 4.8-fold increase (± 2.3) in nasal Cd3 gene
expression in CTB-treated mice compared to mock-treated controls mice (Figure 
4C and D). This effect was even more pronounced following S. pneumoniae
infection (6.7 ± 3.6 fold, Figure 4D).
To further understand whether CTB affected the polarization of T cells into 
Th17, Th1 or Treg cells, we determined the nasal gene expression of Il17a, Ifng
and Il10, respectively. Although IL17 has previously been implicated in mucosal 
protection against S. pneumonia21,22, we could not detect Il17a in the nasopharynx 
of either CTB immunized or control mice (Figure 5A). Although low expression
of Il17a was observed in some mice following i.n. infection with S. pneumoniae,
the majority of mice still did not produce detectable Il17a (Figure 5A). This 
suggests that the reduction in pneumococcal load is independent of IL17. In 
contrast, nasal expression of Ifng and Il10  ϐ  
CTB-treated mice compared to controls (15.8 ± 7 fold and 6.1 ± 3 fold respectively,
Figures 5B and C). This increase was augmented in the presence of S. pneumoniae
infection (38.9 ± 29 fold and 9.9 ± 4 fold respectively, Figures 5B and C). Taken
ǡϐͳȀǡͳ͹ǡ
responses in the nasal mucosa.
Reduction of pneumococcal load is dependent on both T cells 
and macrophages
To further investigate the contribution of T cells and macrophages to 
CTB-mediated reduction in pneumococcal density, Scid-/- and Ccr2-/- mice were 
used. Scid-/-ϐǡ
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Figure 4 CTB increases Cd3 expression and recruits T cells to the nasal mucosa.
C57BL/6 mice received a single i.n. CTB or PBS (mock) treatment. At seven days post-immunization 




software. Data are illustrated as the positive stained area divided by the total area measured with 
SEM. (C-D) C57BL/6 mice received a single i.n. dose of CTB or PBS (mock), which were either 
challenged with S. pneumoniae ȋΪȌǦȋǦȌϐͳͲǦǡ
e.g. 3 days post-infection. Nasal tissue was harvested 10 days post-treatment and analyzed for local
expression of B-cell and T- cell markers (C) Cd19, (D) Cd3ǤαͷǦͺ
Ǥȟȟ
mean ± SD. An increase above 2-fold was considered biologically relevant (dotted line). Unpaired T 
    Ǧ    ϐ  







ϐϐ23. Scid-/- and Ccr2-/- mice were
treated with a single dose of CTB or PBS and infected seven days later. Bacterial 
load was determined three days after challenge. In contrast to the B6 controls, 
CTB-mediated protection was absent in both Scid-/- and Ccr2-/- mice (Figure 2A, 
  ȌǤ  ϐ       ϐ
monocytes is an important component of the CTB-mediated clearance of 
S. pneumoniae, but also that the reduction in pneumococcal load is likely dependent 
on T cells.
Macrophages are essential for the CTB-mediated effects
Macrophages can play a role early after CTB treatment by priming the local
immune response to pneumococcal infection. Alternatively, they can also play a
role as (recruited) effector cells in pneumococcal clearance, i.e. at a later stage. 
To distinguish between these two possibilities, we used clodronate-loaded 
liposomes to deplete nasal macrophages at two different time points15. Depletion 
ϐϐϐȋ	ʹA-B). Macro- 
phages were either depleted in mice one day before (-1d) or six days (+6d) after 
CTB treatment in other mice, followed by infectious challenge seven days after 
CTB treatment. Three days after CTB treatment, pneumococcal load was
Figure 5 ϐǦǤ
C57BL/6 mice received a single i.n. dose of CTB or PBS (mock), which were either challenged with S. 
pneumoniae ȋΪȌǦ ȋǦȌϐͳͲǦǡ ǤǤ͵Ǧ
infection. Nasal tissue was harvested 10 days post-treatment and analyzed for local expression of T 
cell cytokines (A) Il17a, (B) Ifng, and (C) Il10Ǥαͳ͵ǡ
Ǥȟȟά
SD. An increase above 2-fold was considered biologically relevant (dotted line). Unpaired T test was
applied to fold-change data for comparison between CTB and PBS-treated mice. **, p < 0.01; *** 
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determined. Protection was still observed at both time points following
treatment with empty liposomes (Figure 6A). Whilst early depletion of macro-
phages (-1d; CL early) did not abrogate protection (Figure 6B), protection was
lost in mice that had received clodronate liposomes at the +6d (CL late) time
point (Figure 6C). These results strongly suggest that the CTB-mediated 
reduction in pneumococcal load is dependent on the recruitment of macrophages. 
Of note, in all clodronate-treated mice, an increased bacterial load was observed
as compared to mice treated with empty liposomes, which highlights the critical 
role for macrophages in the control of primary pneumococcal infection24.
DISCUSSION
Previous studies have shown indirect evidence that the mucosal adjuvant CTB is 
able to reduce pathogen density after challenge with respiratory pathogen, 
ϐǤ
densities have been associated with progression to disease and/or transmission3-6,
insight into the mechanisms that restrict pneumococcal load in the nasopharynx 
is important. Here, we demonstrate that CTB reduces nasopharyngeal density in 
Figure 6  Reduction in pneumococcal colonization is directly mediated by 
macrophages.
C57BL/6 mice received i.n. CTB or PBS (mock), S. pneumoniae infection and bacterial recovery was
assessed in nasal tissue 3 days post-infection. (A) Bacterial recovery in mice additionally treated 
with empty liposomes (EL). Bacterial recovery in mice receiving additional treatment with clodro-
nate-loaded liposomes (CL) to deplete nasal macrophages (B) early (1 day before CTB treatment) or
(C) late (6 days post-treament, 1 day prior to challenge infection). Bacterial recovery is illustrated as
Log10 	ǡ  ȋαͷǦͳͲȌά







a murine model of pneumococcal colonization, a process that critically required
caspase-1/11 activation,  T-cells, and macrophages. 
When we challenged mice 14 days after CTB treatment, the reduction in 
bacterial density was not observed anymore at the 4-day time point, suggesting
that the effect of CTB is transient. This coincides with the observation that the 
Ǧϐ
levels at 10 days after treatment (Figure S3). Others have also observed complete
clearance of pneumococcal carriage in mice up to four weeks after CTB-
treatment13, showing CTB-mediated reduction in pneumococcal density can 
sustain for a prolonged period. The fact that a reduction in bacterial load was
observed in both outbred (CD-1) and inbred mice (CD57BL/6) increases the 
likelihood that the phenotype is independent of genetic background. The effects 
of CTB on pathogen load appear not to be limited to S. pneumoniae (this paper), 
     ϐ  9. It is unclear whether the 
mechanisms by which CTB restricts bacterial and viral infection are identical. 
ǡϐȋ͵Ȍ
ϐ25,26.
ϐ in vitro. Kayagaki
et alǤ    ϐ  ͵  Ǧ 
ǦǡǦͳȾ14. NLRP3 is 
also highly expressed by respiratory epithelial cells in both mice and men27. Of 
ǡϐǦ
        ǦͳȾ 
IL-1828. This is in line with other studies showing that the CTB-mediated
response is dependent on TLR co-signaling14,29. In our model, it is possible that 
the effects of CTB are dependent on the presence of microbiota-derived 
co-signals30. Alternatively, Phongsisay recently reported that CTB is able to 
activate TLR4 by itself, as shown by the reduction in cytokine expression of ex 
vivo CTB-treated bone marrow-derived macrophages and peritoneal cells from
TLR4-/- mice31.
We found that macrophages play an important role later after CTB treatment, 
i.e. just prior to pneumococcal challenge. This is in line with studies demonstrating 
  ϐ   
primary pneumococcal infection24. At present, it is unclear what the primary 
mechanism is that drives the recruitment of these macrophages, as protection 
was still observed when macrophages were depleted early after CTB 
administration. We also observed increased numbers of neutrophils after CTB 
treatment, although it was not found for all CTB treated mice.
ǤǦϐ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for effective clearance of pneumococcal colonization21,22. However, these memory 




There is increasing attention to tissue resident memory cells (TRM), which have
also been described to respond in an innate manner. CTB has previously been 
shown to polarize T cells into Th1 and Treg33-35. Indeed, we show that 
ͳͲ	ɀǤ
source of these cytokines remains unknown, recent literature has shown that 
TRM 	ɀǦ
to in vivo ϐ36-39Ǥϐ
1. CTB promoted IfngǡʹǤǦϐǡ͵ Ǥ
reduction in pneumococcal density was dependent on caspase-1/11 activation. 
ǡϐ
to restrict bacterial density in the nasopharynx in a model of pneumococcal 
colonization. Our study not only provides further insight into the biological
mechanisms for containment of pneumococcal density in the nasopharynx, but 
also improves our understanding of the underlying mechanisms through which 
 ǡ     ǡ  ϐ
ϐϐǤ
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SUPPLEMENTARY MATERIALS AND METHODS
Flow cytometry 
ϐǡ
and mice were intracardially perfused with PBS. Nasal tissue was collected in
RPMI supplemented with 5% fetal calf serum (FCS), 1 mg/ml collagenase type 2 
(Sigma, MO, USA), and 20 U DNase I (Roche, MO, USA), and incubated at 37°C for
30 min after which single cells were treated with RBC lysis buffer (eBioscience,
ǡȌǤϐ	ɀȀȋȌ
cells were stained with macrophage marker F4/80 APC (AbD Serotec, United 
Kingdom) in PBS + 1% bovine serum albumin (BSA) in the dark on ice for 30 min. 
 ϐ ͳΨ ʹͲ 
ϐǤ	ȋǡ
Inc, OR, USA). For gating, lymphocytes were selected using FSC and SSC and
F4/80 positive cells were selected based on the SSC and F4/80 expression. 
Figure S1 ϐǤ
	   ȋ Ȍ   ϐ ȋA) 
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Figure S2 Intranasal clodronate-loaded liposomes treatment depletes nasal
macrophages.
C57BL/6 mice were i.n. treated with empty liposomes (EL; control) or clodronate-loaded liposomes
ȋȌǤ	ͶȀͺͲϐ
cytometry. Gating was performed on the F4/80 positive cells within the lymphocyte population and 
numbers show the percentage F4/80 positive cells. (A) Baseline macrophage levels in nasal tissue





C57BL/6 mice received a single i.n. CTB or PBS (mock) treatment. At ten days post-immunization the
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Vaccination has been one of the most successful strategies to reduce morbidity 
and mortality caused by respiratory infections. Differences in the host genetic
background and environmental factors can contribute to heterogeneity in the 
   Ǥ     ϐ  
genetics on vaccine-induced protection against pneumococcal colonization,
using two commonly used inbred mouse strains, i.e. C57BL/6 and BALB/c, as
well as the F1 cross of these two strains. Groups of mice were vaccinated intra- 
nasally with a vaccine formulation containing the model antigen, pneumococcal
surface protein A (PspA), with the well-known mucosal adjuvant, cholera toxin
subunit B (CTB). Baseline colonization varied between mouse strains with high
    ȀǤ    ϐ
reduced pneumococcal density in all mouse genetic backgrounds, however, 
strong differences were observed in the magnitude of protection. We examined 
immunological parameters known to be involved in vaccine-induced mucosal
ǡ  Ǧϐ     
cellular immunity to S. pneumoniae. Ǧϐ 
    
ϐǤǡ
ͳ͹ǡ	ɀǡͳͲǡͶǡϐǤ
This suggests that a reduction of bacterial load in different genetic backgrounds
can be achieved in a similar way, likely via a Th17 response. Increased insight 
into the different immune mechanisms that affect pneumococcal carriage will 








The human immune system is capable to respond to highly diverse and 
constantly evolving pathogens1,2. From both experimental animal studies as 
well as human studies it is known that the genetic background is an important 
determinant of pathogen susceptibility3-9. Host genetic components are also 
known to affect vaccine-induced responses10-12. Importantly, a vaccine is made 
to protect all individuals within the vaccinated population and an effect of 
individual genetic makeup on the establishment of vaccine-induced protection 
may thus lead to inadequate protection.
In this study we focus on Streptococcus pneumoniae,  Ǧϐ
pathogen ranking among the top 10 of infection-related mortality and causing 
severe diseases, including pneumonia and sepsis13-15. Since colonization is a 
prerequisite for both transmission and invasive disease, targeting pneumococcal
       ϐ    Ǧ
coccal disease16. Pre-clinical evaluation of experimental human vaccines is 
typically performed in single inbred mouse strains, such as C57BL/6 and BALB/c.
Considering that these vaccines are intended to work in a heterogenic population, 
      ϐ    Ǥ
C57BL/6 and BALB/c mice are known to induce Th1 and Th2-prone responses, 
respectively. Conversely, vaccine-induced reduction of pneumococcal colonization 
was previously shown to be dependent on a Th17 response17,18.
In this study, we investigated the effect of mouse strain genetic background 
ϐS. pneumoniae, using the model 
antigen pneumococcal surface protein A (PspA). Protection outcomes were then 
correlated to differences in cellular and humoral immune markers.
MATERIALS AND METHODS
Mouse vaccination and infection studies
Seven week-old female C57BL/6J (inbred), BALB/c (inbred), and CB6F1 (outbred)
mice, a cross between BALB/c × C57BL/6J (Charles River Laboratories), received
  ȋǤǤȌ   ͳͲ ρ ϐ  
from TIGR4 (kindly provided by Mucosis B.V., Groningen, The Netherlands) with 
ͶρȋȌͶρȋȌͳͲɊǡǦ
ǡ   ȋʹǤͷΨ Ȁ ϐǡ   Ȍ19.
ϐ
i.n. with 106 CFU of S. pneumoniae TIGR420Ǥϐ
challenge, after which both nasal lavage was obtained and mucosal nasal tissue 





Colombia Agar with Gentamicin (Mediaproducts BV) to determine bacterial
recovery (log CFU/organ). Nasal tissue was homogenized in 1 mL PBS using an
IKA T10 basic blender and used for later analyses. All animal experimentation 
was performed in accordance with and approved by the Radboud University 
Medical Center Committee for Animal Ethics (DEC2013-266).  
Detection of nasal antibody responses
   ϐ  ȋȌ    ʹ ɊȀ 
ϐȋͲǤͳȀͻǤ͸Ȍ
at 4°C overnight20. The following day, wells were washed with PBS containing 
0.05% Tween-20 (PBST; Merck), blocked with 1% BSA (Sigma) and incubated 
with individual mouse serum samples for 1 h at 37 °C. Wells were washed with 
PBST and incubated with anti-mouse IgG-alkaline phosphatase (Sigma) for 1 h at 
37 °C. After washing, samples were developed using 1 mg/mL p-nitrophenyl-
posphate in substrate buffer, 1 M diethanolamine, 0.5 mM MgCl2 pH 9.8, 
(Calbiochem, VWR) and optical density was measured at 405 nm 10 and 30
minutes after substrate addition.
	ɀǡͶǡͳ͹ͳͲ
	ɀǡͶǡͳ͹ͳͲ
the Cytometric Bead Array kit. The Mouse Enhanced Sensitivity buffer kit 
ȋȌ	ɀǡͶǡͳ͹ͳͲ
Sensitivity Flex sets (Becton Dickinson) was used according to manufacturer’s
instructions. Concentrations were calculated using Soft Flow FCAP Array v1.0
(Becton Dickinson) with 274 fg/mL as the lower limit of detection.
Statistical analyses
The Mann-Whitney t test was applied to CFU numbers and cytokine levels for 
comparison between vaccinated and control mice. Antibody and cytokine
concentrations, and bacterial load were analyzed using Spearman rank 
correlations. All statistical analyses were performed using GraphPad Prism










Baseline pneumococcal colonization densities differ between 
genetically distinct mouse strains
   ϐ      
colonization, we used three different mouse strains: C57BL/6 (inbred), BALB/c 
(inbred) and CB6F1 (outbred, BALB/c × C57BL/6). The mice received three
intranasal immunizations with CTB only (mock) or PspA plus CTB at two-week 
intervals and were challenged intranasally with S. pneumoniae at three weeks 
post-vaccination. Five days after infection, bacterial colonization was determined 
in the nasal cavity.
Remarkably, infection in mock-immunized mice led to clear differences in 
baseline pneumococcal densities between the different genetic backgrounds 
ȋ	ͳȌǤͷǦǡȀϐ	
recovered from the nasopharynx compared C57BL/6 and CB6F1 mice. The 
intra-group variation is relatively small for BALB/c mice (Log CFU 1.56), but 
larger in both C57BL/6 and CB6F1 mice (Log CFU 2.43 and 4.00, respectively).
This variation in initial colonization between the strains suggests that the
kinetics of pneumococcal clearance differ per mouse strain.
Figure 1 Baseline pneumococcal colonization and vaccine-induced protection 
against pneumococcal colonization in C57BL/6, BALB/c, and CB6F1 
mice.
Mice were 3x i.n. immunized with PspA + CTB, or CTB only (control mice) and challenged i.n. at three
weeks post-immunization with 106 CFU of S. pneumoniae. Bacterial recovery was determined in two 
independent studies at 5 days post-infection in C57BL/6, BALB/c, and CB6F1 mice. Symbols 






Vaccine-induced reduction of S. pneumoniae colonization in
genetically distinct mouse strains
	ǡ   ϐ      
reduction in S. pneumoniae colonization following vaccination with PspA. In all 
Ǧǡϐ
Ǧϐȋ	ͳȌǤǦ-
ed mice, the degree of intra-strain variation in colonization densities, and thus
clearance capacity following vaccination, differed per mouse strain. At day 5
post-infection, BALB/c mice showed overall minor variation (Log CFU 2.19), in 
contrast to C57BL/6 and CB6F1 mice that illustrate higher intra-strain variations 
(Log CFU 4.60 and 2.79, respectively) (Figure 1). The results suggest that the 
initial magnitude of colonization is indicative for intra-group variation in Ps-
pA-vaccinated animals. Notably, the variation within mock-vaccinated (CTB) 
mice might also be caused by antigen-independent effects of CTB on 
pneumococcal density21. Together this illustrates that PspA vaccine-induced 
reduction in pneumococcal colonization can be achieved in distinct genetic 
backgrounds, although the actual reduction in pneumococcal load seems to be
ϐ      ǡ    
dependent.
Levels of PspA-specific IgG in all mouse strains
It has previously been described that antibodies can contribute to prevention or
clearance of pneumococcal colonization22-26. To examine the antibody response 
ǡǦϐ

ϐ  ǦǤ      ϐ
  Ǧϐ 
  ȋ	 ʹǦȌ   




C57BL/6 and CB6F1 mice, i.e. mean levels of 181 ng/mL and 325 ng/mL
respectively, while in BALB/c mice mean levels of 45 ng/mL were measured. In
  ǡ   
 ϐ   
reduction in colonization (Figures 2D-F).
Nasal T helper signature cytokine levels in distinct mouse strains
Cellular responses have also been associated with clearance of pneumococcal 
colonization17,18. To investigate the contribution of cellular immunity, hallmark T 
  	ɀ ȋͳȌǡ ͳ͹ ȋͳ͹Ȍǡ Ͷ ȋʹȌǡ  ͳͲ ȋȌ
ϐǦǤͶ
Ǥ	ɀǡ







IL17A levels after vaccination with PspA, compared to mock-vaccinated animals 
ȋ	͵ǦȌǤǡǦϐͷ͹Ȁ͸
͸	ͳǡϐȀǤͳͲ
was detectable in nasal tissue of all mice. However, no differences were observed 
between mice immunized with PspA as compared to their respective mock- 
treated controls (Figures 3D-F). Taken together, increased concentrations of 




Mice received three i.n. immunizations with PspA + CTB, or CTB only (control mice) and i.n. infection 
with 106 S. pneumoniae   ǦǤ    ϐ 
ǦǦϐ
ȋA) C57BL/6, 













Nasal IL17A correlates with vaccine-induced reduction in 
S. pneumoniae colonization
To identify relations between T helper cytokines and vaccine-induced reduction 
of colonization of S. pneumoniae, we correlated the nasal cytokine concentrations 
of individual mice with their respective pneumococcal load, as determined at 
ϐǦǤ ͳ͹ 
C57BL/6, BALB/c and CB6F1 mice (Figures 4A-C). A strong negative correlation 
was observed between nasal IL17A and bacterial load in the noses of BALB/c
mice (Figure 4B), with a p-value of 0.0006. Nasal IL10 did not correlate with 
bacterial load in the three mouse strains (Figures 4D-F). In conclusion, only 
IL17A, and not IL10, was associated with vaccine-induced protection against 
pneumococcal colonization.
Figure 3 Increase in nasal IL17A, but not IL10, in C57BL/6, BALB/c,
and CB6F1 mice.
       ǡ  ǤǤ  ǡ  ϐ  












It is widely accepted that the genetic makeup of the host is a critical determinant 
for susceptibility to infection1,2,8. Although genetic variation also affects the
quantity, persistence and type of immune responses10, its effect on vaccine 
ϐ Ǥǡ
ϐǦǤ
Immunization with PspA in combination with an adjuvant has previously shown
to confer protection against pneumococcal colonization in a range of different 
mouse strains20,27Ǥǡϐ
load between C57BL/6, BALB/c and CB6F1, following mock-vaccination and 
vaccination with PspA. The lower pneumococcal densities in C57BL/6 and CB6F1 
suggest that these strains are intrinsically more resistant to pneumococcal
Figure 4 IL17A correlates with pneumococcal density in the nasopharynx.
T helper cytokines were correlated with bacterial recovery derived from the nasal tissue of mice 
ǤǤǡϐǤ
cytokines concentrations of (A-C) IL17A and (D-F) IL10 in C57BL/6, BALB/c and CB6F1 mice 









colonization than BALB/c mice. Pneumococcal densities were correlated to
ϐ
nasal IL17A as common mechanism for clearance in C57BL/6, BALB/c and CB6F1
mice.
Murine studies of pneumococcal carriage have demonstrated that protection
against colonization is critically dependent on a Th17 response. This response is 
induced by colonization, but also by intranasal vaccination with e.g. inactivated 
whole pneumococci17,18,20,28. Notably, these studies were performed only in the 
C57BL/6 background. In the current study, an increased IL17A response was 
observed in C57BL/6, BALB/c, CB6F1 mice vaccinated with PspA. Also in all 
three mouse genetic backgrounds, nasal IL17A correlated with a reduction in 
Ǥͳ͹ϐ
the bacterial load present in the nasopharynx. It has previously been
demonstrated by our group that IL17A in nasal tissue correlates with a reduction 
in pneumococcal load20. Surprisingly, BALB/c mice showed the highest increase 
in nasal IL17A (Figure 3B). This might suggest that the kinetics of IL17A are 
different between mouse strains and could mean that in our study the time point 
to measure IL17A in BALB/c and CB6F1 is suboptimal. In our study, BALB/c mice
appear to be more susceptible to pneumococcal colonization than C57BL/6 and
CB6F1, based on the initial magnitude of pneumococcal load in the nasopharynx
of mock-vaccinated mice. This led us to question whether BALB/c mice
potentially have a slower IL17A response, as protection was less pronounced in
these mice. We hypothesize that IL17A is of great importance for reduction of 
pneumococcal colonization, but that the height and kinetics are determined by 
the mouse genetic background. Notably, differences observed between genetic




is mediated by agglutination22. In this process, antibodies agglutinate bacterial cells
and accelerate clearance from the nasopharyngeal mucosa. Recently, our group 
Ǧϐ
agglutination (Unpublished data). In our study, we observed that the mice from 
ϐ
Ǧϐȋ	ʹǦȌǤ
together with the increase in nasal IL17A induced by vaccination may syner-
gistically cause a reduction in pneumococcal load.
In conclusion, the current study demonstrates that vaccine-induced reduction
of S. pneumoniae colonization was independent of the mouse strain used. However, 
the level of reduction strongly varied between the different mouse strains.









reduction of pneumococcal load. Altogether, improved understanding of the 
immune mechanisms underlying vaccine-induced protection against pneumococcal 
colonization will contribute to the development of future mucosal pneumococcal 
vaccines.
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Altered macrophage biology 
drives age-related susceptibility 
to infection – lessons from 
pneumococcal colonization 







Many infectious diseases primarily strike the very young and very old. Although 
members of both age groups are often targeted by the same infectious agent, a 
mechanistic understanding of this age-related susceptibility is generally lacking.
One such example is infection caused by Streptococcus pneumoniae (the
pneumococcus), which was recently investigated in infant and aged mice in two 
independent studies that demonstrated prolonged carriage in both age groups. 
A common theme in these studies involved altered macrophage responses that 
delay pneumococcal clearance from the respiratory mucosa. Herein, we discuss
age-related defects in macrophage biology that contribute to susceptibility to
Ǥǡϐ
to suboptimal macrophage recruitment, although regulated differently in the
young and old. Collectively, these studies provide insight into the underlying









Young children have an elevated risk of infection, which remains a leading source 
of morbidity and mortality in this age group1-3. With increasing age, the
susceptibility to infection gradually decreases4. However, the risk for infection
increases again later in life and is a major contributor to morbidity and mortality 
among the elderly5. The very young and very old are often struck by the same 
infectious disease due to a similar array of infectious agents. An example is 
ǡϐ
life6,7. Our understanding of the underlying mechanisms that drive this 
age-related susceptibility to pneumonia remains incomplete, and, in particular, 
it is unknown whether there might be common themes among the young and old.
The age-related susceptibility to infection as occurs in humans can be 
recapitulated in various animal models8. One such model involves the study of 
pneumococcal carriage. Colonization along the mucosal surfaces of the 
nasopharynx is the source of organisms aspirated into the lower airways and, 
ǡϐ
pneumonia. The susceptibility to pneumococcal infection in both infant and
aged mice correlates with prolonged carriage similar to humans9-11. This murine 
model has been used to dissect the host responses that explain why infants and
the elderly have an increased risk for pneumococcal infection compared to 
normal adults8,12,13.
Factors affecting the clearance of pneumococcal colonization were recently 
investigated in both infant and old mice respectively by two independent 
studies9,10. Indeed, these reports demonstrate that similar mechanisms, 
including altered macrophage responses and increased levels of mucosal 
ϐǡ
old. Herein, we discuss the age-related defects in macrophage responses in both
Ǥ	ǡϐ
in the very young and very old may drive suboptimal macrophage responses. 
Together, these common themes may provide insight into the susceptibility to 
infection at the extreme ages of life.
An age-related defect in monocyte recruitment following infection
Prolonged carriage in both age groups is associated with a reduced capacity to
eliminate the infectious threat9,14,10,15,16. Mucosal clearance requires a sustained
ϐ	ͶȀͺͲ+ macrophages derived from the monocyte pool to the airways at 
sites of pneumococcal colonization of epithelial surfaces, although once within 
the airway lumen these no longer display markers typical of monocytes13,17,18.





requirement for expression of the chemokine receptor CCR2, involved in
monocyte migration13. Since infant and aged mice both show delayed pneumo- 
coccal clearance, the dynamics of monocyte/macrophages effectors have been
the focus of investigation (Figure 1)9,10,13,18-28. During infection, circulating blood 
monocytes are recruited to the site of infection upon recognition of an infectious 
threat, in particular via pattern recognition receptors such as TLR218,29. These 
macrophage responses are critical for restriction and elimination of the 
ǡ    ϐ     
adaptive immunity29. The importance of TLR2 was illustrated by a delayed
 ϐ    S. pneumoniae from the nasopharynx in 
adult tlr2-/- mice9,12. There are differences in TLR2 responses between the young
and adults, however, these do not account for the susceptibility to colonization
observed in infant mice as tlr2 ϐ     
colonization, unless TLR2 expression is very low infant mice9,14. Importantly, the 
delayed clearance of the infection in the infant coincided with reduced 
macrophage numbers in the nasopharynx as compared to adult mice9. When
ϐʹ
numbers equivalent to those in adults, pneumococcal clearance was accelerated9.
ϐ
ϐǤ
In contrast, in aged mice an increased rather than decreased monocyte 
ϐ          
pneumococcal infection10Ǥ  ǡ ǡ   ϐ  
study of Krone et al. which demonstrated reduced macrophage numbers in the
nasopharynx of aged mice following pneumococcal infection15. A possible 
   ϐ ϐ   	ͶȀͺͲ 
detect macrophages. This may give an underestimation of the macrophages 
present in the nasopharynx, as the study by Puchta and colleagues demonstrated 
that F4/80 expression was strongly reduced on the macrophages recruited
following infection10,15. How increased monocyte numbers in the very old hamper
clearance of infection is currently unclear, but these observations suggest that 
monocyte function in the aged is impaired. Similar to the human infant, aged
human monocytes and aged mouse lungs demonstrated reduced PRR responses,
including sensing through TLR2, resulting in reduced cytokine expression4,16.
   ϐ        
monocyte function, multiple studies demonstrated impaired phagocytosis of 
human monocytes derived from aged individuals30-32. In this regard, it has also 
ϐ
   ǡ     ϐ







macrophage recruitment observed in aged mice may further enhance pneumo- 
coccal infection and thereby delay elimination. This is supported by the 
ϐǦ	
in aged mice to normal levels improved pneumococcal clearance10. In summary, 
ǡǡϐ
account for increased susceptibility in both young and aged mice.
Age-related alterations in CCL2 and CCR2 determine susceptibility 
to infection
ϐ
and the elderly? Monocyte recruitment to the site of infection is mediated by 
local upregulation of CCL2, the major chemokine stimulating the recruitment of 
monocytes17,29,34. CCL2 is produced by epithelial and immune cells in response to 
TLR activation by detection of bacterial components at the site of infection9,10,17,29,35.
Recruited myeloid cells then become an additional source of CCL2 creating a 
positive feedback loop. The establishment of a concentration gradient of CCL2 
ϐ
ʹϐǤ
will affect monocyte recruitment to the site of infection. The two recent studies 
Figure 1 Overview of altered macrophage biology in the very young 
and the very old.
Monocyte responses vary at different ages and correlate with susceptibility to pneumococcal 
infection. With increasing age, monocyte recruitment becomes more pronounced and monocyte 
CCR2 expression increases. In contrast, baseline CCL2 levels decrease with increasing age, allowing 





of pneumococcal infection in infant and aged mice demonstrated alterations in 
expression of CCL2 and CCR2 in both age groups (Figure 1)9,10. The net effect of 
these perturbations in CCL2 and CCR2 expression is dysfunction of monocyte
recruitment into infected tissues that results in delayed clearance and
exacerbated infection29,33.
Under normal physiologic conditions, infant mice express higher levels of 
CCL2 in the nasopharynx compared to adults9. CCL2 expression may already be
at maximum levels in infants, as it was not further upregulated following 
infection. While this would be expected to promote a strong signal for monocyte 
recruitment, baseline CCL2 levels were also high in infant sera, thus no
concentration gradient can be established by the local response to infection9.
This gradient could be restored by exogenous expression of CCL2 to generate
Ǧ  ϐ     
thereby promote pneumococcal clearance9,36. As would be expected from the 
high levels of its ligand, murine CCR2 expression on infant monocytes was
reduced as compared to adult cells9. This reduced level of CCR2 on monocytes, 
ǡϐϐ17,29.
In contrast to infant mice, baseline CCL2 levels in aged mice were not 
different from normal adults10. Additionally, during infection, CCL2 expression 
 ϐ        Ǥ
Baseline levels of CCR2 expression were increased on aged murine monocytes
ϐ
in aged mice10. Together, the stronger CCL2 gradient and increased expression of 
CCR2 during aging potentially contribute to a more robust monocyte recruitment 
    ϐǤ      
mice have an initial delayed response to infection due to an incapacity to respond 
ǡϐ
ϐ10,16.
In sum, these data demonstrate that tight regulation of CCL2 and CCR2
expression is required for optimal monocyte recruitment in order to clear an 
infection. The very young and elderly show altered regulation of the CCL2 and 
CCR2 axis, although these manifest differently, that underlies their defective
monocyte recruitment leading to increased susceptibility to infection.
The age-related elevated baseline inflammation drives suboptimal
monocyte influx 
Evidence suggests that in both the young and the old it is high levels of mucosal
ϐʹʹȋ	ͳȌǤ
ǡϐǡ








attributed to environmental factors associated with age.
ǡϐ
    ϐ   
infection. In the infant nasopharyngeal mucosa this was characterized by 
increased expression of CCL2, CCL7 and IL6 compared to adults9. Furthermore, 
the observation of increased levels of CCL2 in infant sera indicated systemic 
ϐǤʹ
CCL7 appeared to be a consequence of nasopharyngeal microbiome acquisition 
during the newborn period since microbiome depletion by maintaining the 
dams on broad-spectrum antibiotics restored baseline CCL2 and CCL7 expression 
to adult levels9Ǥ ϐ
due to leakage of bacterial products at colonized surfaces into otherwise sterile 
sites, an event previously linked to the newborn period37. Pneumococcal 
infection of pups of formerly antibiotic-treated mothers led to adult-like numbers
of mucosal macrophages, which corresponded with reduced bacterial density.
These data provided key support for the conclusion that high baseline 
ϐ      ǡ ǡ ǡ
   ϐ   9. How
this affected CCR2 expression was not studied, but the infant microbiome could
play a role, since it has been shown that stimulation of human monocytes with 
pathogen-associated molecular patterns like LPS reduced CCR2 expression38.
ϐ
as shown by the study of Siegel et al. may come as a surprise, since young children 
are generally considered to be non- or low-immune responders, both in their 
mucosa as well as in their circulation4,39Ǥǡϐ
ϐ
ϐǤ
 ǡ  ϐ       
hallmark of aging and contributing factor underlying their increased mortality 
due to infectious and immune-related diseases4,16,40. In both aged mice and 
ǡ  ϐ   	Ƚ
levels at baseline4,10,16,40Ǥ   ϐ    	Ƚ 
drives suboptimal macrophage responses during aging was proven through two 
Ǥ	ȽǦϐǦ	Ƚ
treatment of aged wild type mice restored monocyte numbers to normal young 
adult levels and promoted pneumococcal clearance10Ǥϐ
ǡǮϐǦǯ
the elderly, was linked to increased CCR2 expression on monocytes10. This would 





ǡ    ϐ    33.
ϐʹ
Ǥϐ	Ƚ͸
levels in the nasopharyngeal mucosa of aged mice was similar to young adult 
animals10Ǥǡϐ
following infection10Ǥϐ
mice is unclear. Observations from Puchta and colleagues hint that these 
cytokines may be produced by macrophages, as the increased mucosal 
ϐ  ϐ  10.
Importantly, anti-TNF treatment did not restore monocyte production in the 
bone marrow of aged mice, suggesting an intrinsic cell defect rather than chronic 
ϐ     ϐ  
bone marrow during aging. It would be interesting to assess whether this 
increased monocyte production is also responsible for the increased chronic 
ϐǤǡ
ϐǡ9.
     ϐ      
altered macrophage biology and affects susceptibility to infection. How this is
regulated and how it negatively impacts immune responses, including those
determined by macrophages, should be a topic of future research. A further 
ϐʹʹ
both age groups, although to our knowledge the mechanisms by which the CCL2/
CCR2 axis is regulated have only been partly deciphered17,29. This is an important 
topic since monocytes and their recruitment have a pivotal role during infection,
as demonstrated in the case of pneumococcal colonization, as well as other 
immune-related diseases17,19.
Conclusions
Individuals early and late in life are at increased risk for infections. However, the 
mechanisms by which this is established are not fully understood. Recent work 
illustrated that susceptibility to infection in the young and very old maybe more 
similar than initially believed. One such shared mechanism involves defects in 
monocyte/macrophage responses, which are critical for infection biology, and
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Novel strategies to improve the protection against 
Streptococcus pneumoniae
Streptococcus pneumoniae is a resident of the human upper respiratory tract.
S. pneumoniae carriage is asymptomatic and occurs multiple times throughout 
life1. Despite its commensal lifestyle the pneumococcus is a major cause of 
infection-related mortality worldwide1-4. Widespread PCV vaccination of infants 
has greatly reduced the incidence of pneumococcal disease in all age groups1,4-6.
However, a major burden of disease remains, especially in developing countries1-3
where PCVs are not universally available for all young children7. Even when a 
high vaccine coverage will be achieved in those countries, PCV may not be as 
effective as in the Western world. This is due to the observation that pneumo-
coccal serotypes other than those most prevalent in Western countries and in 
the current PCVs, are widely circulating and causing disease in endemic settings1.
It is therefore conceivable that PCV coverage will be lower leading to accelerated 
serotype replacement8-10.
In order to increase the broadness of protection, PCVs with an increasing 
number of capsular polysaccharides have been developed, including a 15-valent 
PCV that has been tested in clinical studies11,12. However, inclusion of more
polysaccharide variants may not be the solution, since head-to-head comparison 
of the PCVs showed that inclusion of more capsular polysaccharides reduces
Ǧϐ13,14. Also production costs will increase as a
consequence of the addition of more capsular polysaccharides1. These limitations
in the use of multicapsular containing PCVs have accelerated the development 
of protein-based vaccines aiming at serotype-independent protection1,15,16.
Pneumococcal carriage in the young and elderly
The large reduction in pneumococcal disease by PCV is partly caused by direct 
effects on pneumococcal carriage and transmission1,8,9,17. Reduction of colonization 
will be an important primary endpoint for studies with future vaccines. The 
immunological pressure by PCV vaccination has resulted in serotype replacement, 
Ǧϐ1,8-10.
Infants are highly susceptible to pneumococcal carriage as compared to 
adults. Studies demonstrate prolonged carriage events in infants with increased 
pneumococcal densities1,18Ǥϐ
world generally occurs around the age of 6 months1,19. In contrast, practically all
children in developing countries are carriers within three months of age. Young
children are considered to be the natural reservoir of S. pneumoniae and





show that the percentage of carriage in adults may be underestimated due to the
method used for detection20. Carriage in the elderly has hardly been studied.
Knowledge about the duration of carriage and pneumococcal density in this 
ϐǤǡ
carriage are similar in young and old mice, e.g. both show prolonged colonization 
at higher densities as compared to adult mice21-23.
The mechanisms underlying the increased susceptibility for infections by 
S. pneumoniae in the age extremes of life are only partly understood, but much 
ascribed to immaturity (infants) and senescence (elderly) of the immune
system24. Interestingly, recent evidence indicates that prolonged colonization in 
         ϐ 
drives macrophage dysfunction, although regulated differently in the young and
old (Chapter 7)21-23. A critical hallmark in this respect is the increased chronic 
ϐǡ ϐǦ22,24. Young children 
are generally considered less responsive to infections and vaccines, but there is
ϐ
at baseline (Chapter 7)23.
Prolonged colonization in the young and the old can possibly be attributed
to differences in Th17 and Treg immunity. A skewed Th17 and Treg balance with
relatively lower Th17 and higher Treg responses is observed in the nasopharynx 
of young children with lower IL17A and higher IL10 levels compared to adults25,26.
This is in agreement with the observation that carriage positive children have a
lower Th17/Treg ratio, e.g. reduced IL17A and elevated IL10, compared to 
carriage negative children26. Similar studies following pneumococcal carriage in 
the elderly are lacking. However, increased Treg and reduced Th17 responses
are also characteristic of the very old since during aging Th17 immunity wanes 
and Treg responses increase24. We therefore hypothesize that Treg responses
may limit Th17-mediated immunity. A direct inhibitory effect of IL10 addition on 
IL17A production has been observed in mouse macrophages that were
re-stimulated with WCV27. However, none of these studies coupled altered Th17/
Treg ratio’s to bacterial killing by macrophages or neutrophils, cells that are
both essential for clearance of pneumococcal carriage28-30.
Together, susceptibility to pneumococcal carriage of infants and elderly may 
be caused by similar mechanisms, steered by increased levels of baseline
ϐȋChapter 7)25,26. Therefore, improved knowledge about mucosal
immune responses may help to understand the mechanisms that increase 
susceptibility for infection by S. pneumoniae. 
Although data from animal studies indicate that the very young and very old 
are similarly colonized by S. pneumoniae (prolonged colonization and increased
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between both extremes of age22,23. In industrialized countries, 20-50% of the
children below the age of three years is carrier of S. pneumoniae, whereas the 
elderly are colonized at a steady level of 10-20% similar to adults1,19,31,32.
Importantly, in young children pneumococcal invasive disease rates are 
associated with carriage frequency: more and longer carriage events increase 
the chance of progression to disease33. Pneumococcal carriage density and
duration should therefore be reduced in children in order to prevent progression 
to disease33. In contrast, each single carriage event in elderly has a high likelihood 
to progress into pneumococcal disease34,35. Therefore, pneumococcal acquisition 
should be prevented in the elderly36Ǥǡϐ
a reduction in pneumococcal transmission by reducing pneumococcal 
colonization at the population level.
Selection of antigens and adjuvants for a protein-based vaccine 
against S. pneumoniae carriage
Several protein-based vaccines have been designed to target pneumococcal 
carriage. Selection of the antigens combined with the right type of adjuvant is 
ϐǤ
be accomplished by two distinct vaccine-induced immune mechanisms: 1) an 
antibody response that prevents pneumococcal acquisition via agglutination 
and thus blocks colonization37,38, or 2) a Th17 response that reduces the density 
and duration of pneumococcal colonization which is likely due to the recruitment 
of neutrophils leading to uptake and killing of the pneumococcus (Figure 1)28-30.
These two vaccine-induced responses and their distinct modes of action
determine the selection of the type of antigen. For example, antibody-mediated 
immunity requires surface exposed antigens accessible for antibody binding
despite the presence of a polysaccharide capsule1. Antigen surface exposure is 
not a requirement for a vaccine with Th17-mediated immunity. Following
bacterial engulfment by phagocytic cells, both intracellular and surface exposed
pneumococcal protein peptides are loaded onto MHCII and presented to Th17 
cells28-30,39. This in turn leads to the recruitment of neutrophils and macrophages 
to the site of infection and engulfment of pneumococci without the need of 
ϐǤ
The type of vaccine-induced immunity is critical for the choice of a suitable 
adjuvant. Aluminum salts are licensed for human use. These generate high 
antibody levels following parental administration1Ǥ  ϐ
antibodies that are systemically generated are actively transported over the 
mucosal epithelium resulting in bacterial agglutination37,38,40. Intranasal 
vaccination is preferred in order to establish vaccine-induced Th17 memory in 





vaccines tested in animal studies often use cholera toxin (CT) and derivatives 
(including CTB - Chapter 5), which may not be suitable for human use41. The lack 
of suitable mucosal adjuvants for human application is an important challenge 
for intranasal vaccination41.
Salmonella OMVs are attractive delivery vehicles for mucosal delivery of 
vaccine antigens with intrinsic adjuvant activity (Chapters 2 and 4)42-46.
We demonstrated that Salmonella OMVs are strong mucosal adjuvants which
Figure 1 Overview of vaccine-mediated effects of antibody- and 
Th17-immunity on pneumococcal carriage.
Ǧ    Ǧϐ  ȋȌ   ͳ͹Ǧ
intranasal vaccine have distinct effects on pneumococcal carriage. Vaccine-induced antibodies
prevent pneumococcal colonization, whereas a Th17-mediated vaccine response reduces pneumococcal 
colonization by decreasing density and duration. Therefore, the mucosal immune responses that 
impact on pneumococcal carriage differ between vaccines that mediate antibody- and Th17-immunity. 
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allow for vaccine-induced reduction of pneumococcal colonization in an IL17 
receptor dependent manner (Chapters 2 and 4)46,47. Our studies further 
illustrate the potency of Salmonella OMVs for mucosal application and the
induction of vaccine-induced Th17 memory responses. Although Salmonella
OMVs have not yet been tested for human application, a Neisseria OMV-based
vaccine (Bexsero) has recently been licensed48. Future studies will elucidate 
whether Salmonella OMVs are a suitable adjuvant for human intranasal 
administration. Salmonella OMVs with surface exposed pneumococcal antigens
will be tested for their impact on pneumococcal carriage (acquisition and 
density), preferably in the human challenge model. Mucosal adjuvants may also
have antigen-independent effects on pneumococcal carriage, which is described 
for CTB (Chapter 5) and also observed for Salmonella OMVs (Chapter 4).
ϐ
area, which requires more attention. In conclusion, the selection of the right 
antigens and adjuvant can only be based when the mechanisms of protection in 
humans are understood.
Towards universal protection using protein-based vaccines
Several experimental protein-based vaccines have been developed. These
ϐǤ
whole pneumococcal cell vaccine is WCV, a killed unencapsulated pneumococcal
strain. In animal studies WCV offers strong protection against pneumococcal
colonization. This vaccine is currently studied in a phase II clinical trial, but the 
results remain to be seen15,28,30,49.
ϐȋȌ
been tested in intranasal vaccination studies aiming to reduce S. pneumoniae
carriage. In general, variable proteins offer strong protection against 
pneumococcal colonization following vaccination46,50,51. However, conserved 
proteins are preferred because their low level of variation will likely result in
universal protection against all circulating pneumococcal strains. In multiple
intranasal vaccination studies a reduction in pneumococcal colonization 
following mucosal vaccination with conserved proteins was demonstrated52,53.
An important limitation of subunit vaccines is that vaccination may result in the
   ϐ    ǡ ǤǤ  
mutants54Ǥ  ϐ ǡ   ǡ  
been described5,55. This implies that PspA is not essential for pneumococcal 
colonization or disease. Proteins with a critical role in cell function are less
likely to emerge as vaccine escape mutants. We found that conserved protein
PapP has a critical role in pneumococcal lipid metabolism and can therefore be a 





   ϐ        
pneumococcal colonization.
Novel protein-based vaccines need to offer broad protection and thus ideally 
cover all circulating pneumococcal strains1,15,16. Prediction of broad protection is
based on immunological assays that address cross-reactivity of vaccine-induced
responses with other pneumococcal strains. Our studies indicate that the degree 
of cross-reactivity is dependent on the type of immune response. For example 
ȽͳȽʹǦϐ
Ǧ
to whole pneumococcal strains (Chapter 4). The low level of antibody-mediated 
cross-reactivity could be the result of the use of a variable protein fragment 
from PspA as vaccine antigen. 
Variable proteins often show surface epitope heterogeneity, as is known for
ȽͳȽʹǦ 1. However, surprisingly, sharing identical 
antigens does not always guarantee cross-reactive antibody responses, as
demonstrated in our study in which different clinical isolates with an identical 
ȽͳȽʹȋChapter 4). This 
may be due to different levels of capsule expression or to different type of 
capsules. Nevertheless, we observed, using an ex vivo restimulation assay, strong 
vaccine-induced Th17 cross-reactivity (Chapter 4). Furthermore, this was
highly predictive for in vivo re-reactivation of vaccine-induced Th17 memory 
responses in the murine nasopharynx following infection with other
pneumococcal strains (Chapter 4). We demonstrated that Th17-based cross-re-
  ϐ
expression levels. More importantly, in vivo reactivation of these responses 
protected against some, but not all pneumococcal strains (Chapter 4). This
demonstrates that ex vivo cross-reactivity does not equal in vivo protection. 
Cross-reactivity of WCV has been primarily addressed in ex vivo
immunological assays of both IgG and Th17. Based on these results WCV was 
predicted to induce broad protection15,56,57. This is supported by the fact that 
WCV contains all (conserved) proteins of a pneumococcal cell. It has been shown
that WCV offers in vivo protection against serotype 3, 5 and 6B strains56,58.
However, the evaluation of in vivo cross-reactivity was limited to three strains. 
Establishment of broad protection may also be limited by the fact that WCV 
Ǧϐ
strain-independent responses15,53,57. In animal studies it was demonstrated that 
a single colonization event protected against re-infection by the same strain, e.g.
Ǧϐ 28,30. However, humans become repeatedly colonized
by different pneumococcal strains throughout their life, showing previous 
carriage events do not offer strain-independent protection against colonization
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Prediction of the degree of coverage induced by WCV is also complicated by 
the fact that it is not completely understood which proteins are driving
Ǧ Ǥ       ϐ 
proteins that are part of WCV elicited IL17A in an ex vivo splenocyte restimulation
assay52. This is suggestive of the contribution of these proteins to WCV-induced 
immune responses. This is promising, since conserved proteins are thought to 
increase strain-independent protection. However, vaccination with these 
conserved antigens evoking an IL17A response did not protect against 
pneumococcal colonization52Ǥ    ϐ    
which proteins are driving vaccine-induced protection of WCV thus hampering 
the prediction of vaccine coverage. 
Based on our current knowledge of pneumococcal carriage in humans and 
animal studies, variable proteins may dominate immune responses causing
strain-dependent rather than strain-independent protection. This is supported
by studies in children showing high natural antibody levels which are directed 
against variable proteins including PspA following natural exposure to 
S. pneumoniae59,60. A possible explanation is that variable proteins may outcompete
 ȋȌ ǡ     ϐ  
processing and peptide loading on MHCII thereby dominating MHC presentation39.
We hypothesize that serotype-independent protection may be improved by 
ϐȋȌǤ
vaccine-induced protection towards conserved antigens, shared by all 
circulating pneumococci, and thus promote increased coverage.
Together, our studies suggest that the highest cross-reactivity with pneumo-
coccal strains is achieved by a vaccine that induces Th17-mediated, rather than
antibody-mediated immunity. Our work further points out that prediction of 
vaccine coverage should not be limited to ex vivo immunological assays and 
ϐ in vivo vaccination studies using heterologous challenge 
strains. Also, in case of a whole cell vaccine or a vaccine combining multiple
proteins, knowledge about the proteins that drive vaccine-induced protection
will facilitate prediction of vaccine coverage. Alternatively, insight into why 
some (in particular variable) proteins dominate immune responses over other 
(more conserved) proteins will help to select the best vaccine antigens. 
Novel protein-based vaccines in clinical trials
To date, effects on colonization as primary end point were only studied in two 
vaccine trials with protein-based vaccines. However, both vaccines were 
designed to protect against disease and not against carriage. These vaccines, 
ϐ
ǡȋͳȌǤ





in the GSK vaccine61Ǥϐǡǡ
PcpA in the formulation62. The choice for these proteins was based on: i) 
increased mucosal and serum antibody levels against these proteins are 
associated with pneumococcal colonization and otitis media in young children; 
Ȍ Ǧϐ      
epithelial cells; and iii) passive transfer of anti-Ply and anti-PhtD, but not 
anti-PcpA, reduces pneumococcal colonization in mice63,64.

ϐ
impact on pneumococcal carriage61. Notably, both vaccines are parenterally 
administered and adjuvanted with aluminum thus generating an antibody-
ȋͳȌǤ   ϐ  
the protein antigens are not expressed or accessible during pneumococcal 
ǤǦ 
 ϐ
levels on the mucosa to prevent acquisition, since high concentrations are
essential for agglutination to occur37. We propose that these vaccine formulations 
are not optimal in regard with their antigen and adjuvant choice, nor administered
via the proper route to have an impact on carriage.
Another vaccine that has been studied in humans is the GEN-004 vaccine 
developed by Genocea (Table 1)65. This vaccine was designed to have an impact 
on pneumococcal carriage, based on T-cell stimulation of three universal 
lipoproteins: SP2108, SP0148, and SP1912. This vaccine was administered to 
subjects followed by an intranasal challenge infection with S. pneumoniae. The 
primary end point of this study was a reduction in or prevention of colonization66,67.
The results show that GEN-004 prevented pneumococcal colonization in healthy 
volunteers65. However, GEN-004 did not affect carriage density measured at 
different time points in the carriage-positive individuals. This latter observation
is particular interesting and intriguing, as GEN-004 was proposed to be a
vaccine that induces Th17-mediated immunity. Such a vaccine should therefore 
reduce pneumococcal carriage density as shown by us (Chapter 2, 4 and 6) and
by others53,68. 
Intranasally administered GEN-004 adjuvanted with CT reduced pneumo-
coccal colonization in an IL17A-dependent manner in pre-clinical animal studies 
(Table 1)68. In the same study, the investigators showed that parenteral 
administration of GEN-004, adjuvanted with aluminum hydroxide, decreases
pneumococcal carriage. This was associated with an increased level of IL17A in
blood. However, they did not study whether this reduction was IL17A dependent. 
The underlying mechanism for the reduction in carriage by GEN-004 remains
therefore unclear68. It would have been interesting if mucosal Th17 responses 
had been measured during different time points in the carriage positive
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some individuals receiving GEN-004, suggests an antibody-based vaccine
mechanism of action that prevents pneumococcal acquisition. This is in 
agreement with the fact that the vaccine contained aluminum hydroxide and 
was administered via the parenteral route.
A common theme in the studies described above is that all three protein-based 
vaccines are supplemented with aluminum salts and parenterally administered
thus promoting strong antibody responses (Table 1). The choice of adjuvant and
route of administration for the human studies is not supported by the 
experimental set-up of the pre-clinical studies in animal studies, in which these 
vaccine formulations were often tested intranasally using CT as adjuvant (Table 1). 
The selection is probably determined by the regulatory authorities, whose 
authorization is needed for approval of novel vaccines. However, this approach 
Table 1  Overview of experimental vaccine formulations in the pre-clinical
and clinical testing phase





























CT Intranasal Alum Parenteral
In pre-clinical testing in animals, experimental vaccines are often formulated with a mucosal
vaccines and applied mucosally (intranasal) to impact on pneumococcal carriage. For clinical trials, 
experimental vaccines are switched to a formulation with aluminum as adjuvant following 






strongly impacts the development of novel vaccines against pneumococcal 
colonization, because of their different mode of actions (antibody- vs. Th17-
mediated). Similarly, in pre-clinical animal studies WCV was intranasally 
applied and adjuvanted with CT, but for human application WCV is supplemented 
with aluminum hydroxide and administered parenterally (Table 1)15,28,30,49,69.
We therefore suggest that future clinical studies should evaluate the effects of 
intranasal application of protein-based vaccines with a mucosal adjuvant for 
their impact on pneumococcal colonization.
Mucosal immunity restricting pneumococcal density in
the nasopharynx
Vaccine-induced reduction in pneumococcal colonization critically requires a 
Th17 memory response. Depletion of Th17 responses eliminates these protective
effects28,30. Therefore vaccines that aim to reduce pneumococcal carriage are
generally designed to generate Th17 immunity15,53,72. Chapters 2, 4 and 6
support the important role of Th17 memory responses to protect against 
S. pneumoniae Ǥ ǡ   ͳ͹ ϐ 
prone to develop diseases caused by Staphylococcus aureus and Candida albicans,
but not by S. pneumoniae73. This suggests that other immune responses than
Th17 can maintain the pneumococcus in the nasopharynx and prevent disease 
progression. Bacterial carriage has not been studied in these individuals.
A recent study indicates that individuals with a IL17 G-152A polymorphism, 
associated with reduced serum IL17 levels, showed increased rates of 
pneumococcal colonization74,75. Importantly, our observations and those of 
others suggest that mucosal immune responses, other than Th17, may contribute 
to a reduction in pneumococcal carriage (Chapters 4 and 5).
For example, agglutination is proposed to be an important mechanism
underlying PCV-mediated reduction of S. pneumoniae carriage (Figure 1)37,38.
To optimize the process of agglutination, in order to prevent acquisition, high 
antibody levels are required. The critical threshold for these levels is not 
achieved during natural carriage events37,76. Thus far it is unknown how long 
vaccine-induced protection by agglutination is maintained, e.g. how long the 
high antibody levels and resident plasma cells are retained in the nasal mucosa 
(Figure 1). A recent report demonstrated that PCV7-mediated IgG responses do 
not persist above natural serotype antibody levels in time, suggesting that 
agglutination is waning and requires serotype re-exposure to maintain 
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In Chapter 5 	ɀ
with a reduction in pneumococcal colonization following vaccination. The
 	ɀ    ϐ ϐ
that were critical for the reduction in pneumococcal colonization (Chapter 5).
ǡ	ɀ
recruitment and/or by promoting macrophage activation78-80. That macrophages 
are critical for clearance of pneumococcal colonization has been shown by 
others and is supported by our studies in Chapters 5 and 729. The studies 
described in Chapter 7 demonstrate that susceptibility to pneumococcal 
carriage is caused by defective macrophage responses in both infant and old
mice22,23. Both age groups are characterized by reduced Th1 responses24,81.
 	ɀ       
further and more detailed investigation.
There is also increasing evidence from our and other studies that IL10 
ϐǡ
or negative manner1,19,25,26,82-85. In Chapter 5 we describe a reduction in 
pneumococcal colonization following vaccination, which was associated with 
elevated levels of IL10 in the nasopharynx. To our knowledge direct effects of 
IL10 on reduction in pneumococcal colonization have not yet been described.
ǡ ͳͲ     ϐ    
 ϐ
bacterial outgrowth. This is based on reports which show that increased
ϐ
Ǧϐ82,83. Alternatively, Treg responses are associated
with overall higher pneumococcal densities and prolonged carriage in mice and
men as by other studies1,19,25,26,84ǤȋȌϐǤ
explanation for this contradiction is that vaccine-induced IL10, may prevent 
pneumococcal outgrowth in the nasopharynx. Simultaneously, increased IL10 
levels may hamper Th17- and/or Th1-mediated responses causing prolonged 
colonization85.
All together, we speculate that the combination of nasal T helper cell 
responses (Treg, Th17 and Th1) and their kinetics determine pneumococcal 
carriage density and duration (Chapters 4, 5 and 6)1,19,24,27,81,85. A plausible
hypothesis is that IL17A and IFNy activate cellular responses (macrophages and 
neutrophils) that reduce pneumococcal carriage, whereas IL10 simultaneously 
     ϐ ȋ
ϐ  ϐ ǦȌǤ     
Ǥǡͳ͹	ɀ
IL10 may act synergistically leading to reduction of pneumococcal colonization





demonstrating that IL17A and IFNy collaboratively drive neutrophil and 
macrophage responses for protection against mucosal infection by Staphylococcus 
aureus86. 
Evidence that combined T helper responses have an impact on pneumococcal
carriage is limited to association studies. Therefore, future studies should focus
on unraveling the role of mucosal T helper responses in restriction of 
pneumococcal carriage. Importantly, these type of immune responses are not 
limited to recruited CD4+ T cells, but are produced by resident innate and 
adaptive cells present in the nasal mucosa in response to bacterial infection87-89.
ϐ
effector cells, including macrophages and neutrophils. Experimental endpoints, 
such as pneumococcal densities, duration of carriage and transmission, should 
be monitored over time to understand causal relations between the cytokine 
dynamics and the stage of carriage.
Effects of pneumococcal vaccination on the nasopharyngeal ecology
Immediately after birth, the human respiratory tract becomes populated by a 
variety of microorganisms90,91. This composition is thought to change throughout 
life. In the mucosa, viral and bacterial co-infections may alter host responses
ϐǤ90 Important bacterial pathogens 
in the nasopharyngeal mucosa are: S. pneumoniae, ϔ, and
Staphylococcus aureus90. High carriage rates of S. pneumoniae andǤϔ in
healthy children suggest that co-carriage of these species is common90,92,93.
In an animal model, co-infection with Ǥ ϔ accelerated clearance
of pneumococcal colonization by recruiting neutrophils that subsequently 
opsonized pneumococci94. The accelerated clearance of S. pneumoniae involved
synergistic innate immune co-stimulation by pneumococcal and Haemophilus 
components90,95. Therefore, co-carriage with Ǥϔ is only occurring with
serotypes that are resistant towards opsonophagocytosis by neutrophils90,96. On
the other hand, an inverse relation exists between S. pneumoniae and S. aureus
carriage. Children carrying the pneumococcus will likely not be colonized by S. 
aureus90. It was shown in an animal model that cross-reactive pneumococcal 
antibodies against a conserved dehydrogenase prevented S. aureus acquisition,
probably via agglutination90,97.
ǡϐ
ǡ    ϐ  1,98. Animal studies have 
  Ǧ  ϐ   
carriage density and duration, and thereby promotes progression to disease and
transmission82,83Ǥ  ǡ       ϐ 
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ϐ        Ǥ 
        ϐ  
protective against pneumococcal disease99Ǥ  ϐ   
indirectly impact on pneumococcal carriage, a non-classical approach that 
requires further consideration.
Given these microbial interactions, a future vaccine that impacts on pneumo-
coccal carriage may alter the microbiome composition in the nasopharynx100. It is
important to note that the PCVs also strongly affect pneumococcal carriage in a 
ϐǤϐ
carriage and circulation of vaccine types (VTs)8-10,33,101. Therefore the major 
concern is replacement of VTs by non-vaccine types (NVTs) that more frequently 
cause disease8,9,101-104. The effects of the introduction of PCV on bacterial carriage
of other bacterial species colonizing the nasopharyngeal cavity, such as H.
ϔ and S. aureus, were also studied. These epidemiological studies were 
done in distinct human populations show opposing results10,93,101,105-107. Studies in
The Netherlands and the US demonstrate that PCV led to increased carriage of 
both Ǥϔ and S. aureus101,105,107. In contrast, in African and Israeli study 
populations carriage of Ǥϔ and S. aureus remained unaltered following 
PCV vaccination10,93,106. Whether a future vaccine that targets pneumococcal 
carriage will affect prevalence of Ǥϔ and S. aureus carriage seems to be 
dependent on the genetic background as well as on environmental factors.
Targeting a ‘certain carriage state’ (acquisition, density or duration) via 
vaccination likely results in distinct effects on the nasopharyngeal microbiome 
composition within the human population19. PCVs with antibody-immunity and 
mucosal vaccines with Th17 immunity employ distinct mechanisms for a 
reduction in pneumococcal carriage (Figure 1). PCVs prevent pneumococcal
acquisition by agglutination, and thus completely prevent pneumococcal 
carriage thereby creating an open niche in the nasopharyngeal microbiome37. In
contrast, a vaccine with Th17 immunity is unlikely to prevent pneumococcal
acquisition, because the neutrophils that clear the pneumococcus do not reside 
in the nasopharynx but are recruited following pneumococcal colonization28,29.
For that reason Th17-mediated immunity is proposed to prevent pneumococcal 
outgrowth and progression to disease and  simultaneously reduce transmission19,72,108.
How and to what extent a mucosal vaccine with Th17 immunity will disturb the
ecological niche remains currently unclear, but the effect will not be directly 
comparable to the PCV-mediated effects on the nasopharyngeal microbiome. 
Concluding remarks
It is evident that alternative vaccination strategies are required to stop the 





replacement due to PCV vaccination emphasizes the need for development of 
novel protein-based vaccines to target pneumococcal carriage. Such a vaccine is 
attractive as it prevents disease progression and simultaneously reduces 
transmission, providing herd immunity within the human population. The latter
may be particularly important for the protection of the elderly. Major changes in 
nasopharyngeal carriage rates of pneumococci may be undesired since they may 
result in unwanted alterations in the nasopharyngeal microbiome. However, an 
altered microbiome and herd immunity offered by reduced transmission likely 
represent two sides of the same coin. Also, a vaccine that targets pneumococcal
carriage will reduce further selection of antimicrobial resistance, as prolonged 
carriage promotes horizontal gene transfer109-111.
In our opinion, the best strategy to impact on pneumococcal colonization is
a protein-based vaccine that induces cell-mediated protection, including Th17 
memory responses. Mucosal application and the use of a strong mucosal adjuvant 
are essential for strong reduction of colonization. Also a novel vaccine should 
meet the criteria of low manufacturing costs and increased vaccine coverage. 
Approaches that indirectly impact on pneumococcal colonization should also be 
Ǥϐ
pneumococcal carriage and transmission. Improved understanding of the 
ϐǡS. pneumoniae, and host immunity on pneumo-
coccal carriage (density and duration) and transmission will facilitate novel 
vaccine strategies to decrease the residual disease burden.
A major challenge for a vaccine that impacts on pneumococcal carriage, is 
the lack of a correlate of protection (Figure 1). How can we measure vaccine 
ϐ      ǫ  
cannot be answered since it is currently unclear what level of reduction of 
pneumococcal carriage is required to prevent disease progression and reduce 
transmission. Therefore, future studies should address the impact of a vaccine
that reduces density and duration of colonization rather than only blocking
acquisition. These studies should also include vaccine-induced effects on 
protection against pneumococcal disease and reduction in transmission. Finally,
critical for pneumococcal vaccine development is the need for increased insight 
into the mechanisms that drive pneumococcal carriage densities and duration in
relation to pneumococcal disease and transmission within the human
population. This can be accomplished by improvements in the understanding of 
the (vaccine-induced) host, bacterial and viral factors that affect pneumococcal 
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De pneumokok (of Streptococcus pneumoniae) is een bacterie die aanwezig kan
zijn in bovenste luchtwegen van kinderen en volwassen zonder dat deze hiervan
ziek worden. Dit fenomeen wordt ook wel dragerschap of kolonisatie genoemd. 
Dragers van de pneumokok kunnen deze bacterie via direct contact met andere 
personen en inademing van kleine druppeltjes die ontstaan bij het uitademen, 
niezen of hoesten, overdragen naar anderen in hun omgeving. In een beperkt 
aantal gevallen kan kolonisatie gevolgd worden door ernstige, levensbedreigen-
de ziekten, zoals sepsis, hersenvliesontsteking en longontsteking. Infecties door 
pneumokokken vormen wereldwijd een belangrijke oorzaak van ziekte en 
overlijden. Vooral jonge kinderen en ouderen zijn extra vatbaar voor deze infecties.
De huidige vaccins beschermen zeer effectief tegen ziekte door pneumokokken.
In landen waar deze vaccins (nog) niet beschikbaar zijn overlijden echter nog 
steeds veel mensen aan de gevolgen van infectie. 
Pneumokokken vaccins worden met een naald toegediend en beschermen 
uitstekend tegen ziekte, maar in mindere mate tegen kolonisatie. Dit betekent 
dat pneumokokken, ook bij een goede vaccinatiegraad, nog steeds kunnen 
worden verspreid binnen de populatie. In dit proefschrift wordt onderzoek 
gedaan om te bestuderen of vaccinatie via de neus leidt tot vermindering van
kolonisatie door pneumokokken. Vermindering van kolonisatie wordt bewerk-
stelligd door activatie van het afweersysteem (immuunsysteem) dat het lichaam
beschermt tegen ziekmakende organismen, zoals bacteriën en virussen. Met 
ϐ
tot bescherming. In onze studies hebben wij voornamelijk de immuunreacties in 
de neus nader bestudeerd en het effect hiervan op vermindering van kolonisatie 
door pneumokokken. Omdat kolonisatie van de pneumokok een essentiële stap
is voor ontstaan van ziekte en voor verdere verspreiding van de bacterie 
(transmissie), zal een vaccin dat kolonisatie vermindert een reductie geven in
het aantal infecties veroorzaakt door pneumokokken. 
Pneumokokken kolonisatie, verspreiding en ziekte
Ieder kind en volwassene wordt tijdens het leven meerdere malen gekoloniseerd 
door pneumokokken. Dragerschap van de pneumokok vindt voornamelijk plaats
in onze neus-keelholte (nasopharynx). De duur van het dragerschap varieert van 
ϐȋȌ
de meeste pneumokokken maken om zich te beschermen tegen afweerreacties. 
Deze kapsels worden ook wel serotypes genoemd omdat de verschillen tussen 





suikergroepen herkennen (serologie). Er zijn inmiddels 90 verschillende
ÃϐǤ
neus-keelholte. In de westerse wereld zijn 20 tot 50% van de kinderen, jonger
dan 3 jaar, gekoloniseerd. Dit percentage ligt vele malen hoger in ontwikkelings-
landen. Jonge kinderen vormen dus een belangrijk reservoir voor pneumokokken en
bepalen voor een groot deel de verspreiding van de bacterie in de bevolking.
Kolonisatie met pneumokokken in de nasopharynx gaat ongemerkt voorbij, 
maar in sommige gevallen kan kolonisatie leiden tot ziekte. Hierbij kan een 
onderscheid gemaakt worden tussen relatief minder ernstige aandoeningen,
zoals keelontsteking (pharyngitis) of middenoorontsteking (otitis media) en 
ernstige, soms levensbedreigende ziekten zoals longontsteking (pneumonie), 
hersenvliesonsteking (meningitis) of bloedvergiftiging (sepsis). Jaarlijks 
overlijden wereldwijd meer dan 800.000 kinderen jonger dan 5 jaar ten gevolge 
van infecties door pneumokokken.
Pneumokokken vaccins en verbetering van bescherming
De pneumokokken vaccins die momenteel opgenomen zijn in rijksvaccinatie
programma’s (RVP) in verschillende landen zijn tot nu toe zeer effectief. Een
ȋȌǦϐ
opwekken. Dit betekent dat het vaccin alleen werkzaam is tegen een beperkt 
ȋȌǡǤϐ
in Nederland en Finland opgenomen is in het RVP, bestaat uit 10 verschillende
ϐͳͲ
tegen deze 10 varianten. Invoering van dit vaccin in het RVP heeft geleid tot een 
enorme vermindering van pneumokokken infecties in kinderen en ouderen. In
de laatste 10 jaar wordt echter steeds duidelijker dat andere serotypes, dan
degenen die opgenomen zijn in de huidige vaccins, kolonisatie veroorzaken en in 
toenemende mate ook milde en ernstige infecties. Dit benadrukt de noodzaak 
voor de ontwikkeling van vaccins die een bredere bescherming opwekken.
Om deze bredere bescherming op te wekken moeten nieuwe vaccins
ontwikkeld worden waarin andere onderdelen van pneumokokken, zoals 
eiwitten, opgenomen zijn. Deze andere antigenen (onderdelen van de bacterie 
die een beschermende immuunreactie opwekken) moeten een alternatief bieden
voor vaccinatie waar alleen gebruik gemaakt wordt van kapsel suikers. Een op
eiwit-antigeen-gebaseerd vaccin heeft als voordeel dat het potentieel bredere 
bescherming opwekt terwijl het ook goedkoper is om te produceren. Dit is een
groot voordeel in vergelijking met de huidige pneumokokken vaccins, die voor
ontwikkelingslanden veel te duur zijn. De belangrijkste vereiste van een nieuw, 
 Ǧǡ      Ǧϐ 






pneumokokken varianten. Dit kan worden bereikt door een pneumokokken
eiwit te selecteren dat voorkomt in alle pneumokokken, of door gebruik te maken 
van een combinatie van eiwitten.
Het op eiwit-gebaseerde vaccin zal intranasaal toegediend moeten worden 
om een maximale vermindering van kolonisatie te bewerkstelligen. Intranasale 
toediening ligt voor de hand om bescherming tegen kolonisatie op te wekken 
maar toediening via deze route leidt ook tot een sterke systemische reactie van 
het afweersysteem dat in het bloed gemeten kan worden. Een bijkomend 
voordeel van deze manier van vaccineren is het gemak (neusspray) en de hogere 
kans op acceptatie (geen naalden). Aangezien de neusholte continu blootgesteld
wordt aan lichaamsvreemde stoffen die worden ingeademd, is er een zekere
mate van tolerantie ontwikkeld, waardoor het moeilijker is om met een vaccin
een immuunreactie op te wekken. Aan bijna alle vaccins wordt een helperstof of 
adjuvant toegevoegd om de immuunrespons te versterken. Een belangrijke
uitdaging voor de ontwikkeling van een intranasaal vaccin is de noodzaak om 
een krachtig werkend adjuvant toe te voegen om een sterke en beschermende 
immuunreactie in de neus op te wekken. Op dit moment zijn er nog geen
adjuvantia in gebruik voor intranasale vaccins voor mensen. 
In dit proefschrift
De samenstelling of formulering van een vaccin, bestaande uit antigenen en, in 
veel gevallen ook van een adjuvant, zijn bepalend voor de effectiviteit. In
hoofdstuk 2 van dit proefschrift hebben wij de toepasbaarheid van een nieuw 
vaccin getest voor bescherming tegen kolonisatie door pneumokokken. Dit 
vaccin bestaat uit kleine vetblaasjes, ook wel outer membrane vesicles (OMVs) 
ǡϐȋȌǤ
worden gevormd tijdens de groei van Salmonella, maar zijn zelf niet infectieus. 
In samenwerking met andere onderzoekers zijn we er in geslaagd om 
pneumokokken eiwitten (antigenen) op het oppervlak van de OMVs te zetten. 
Omdat de OMVs het immuunsysteem stimuleren (adjuvant werking) hebben we 
op deze manier een eenvoudig vaccin geproduceerd waarbij zowel antigeen als 
adjuvant aanwezig zijn in eenzelfde deeltje. In deze studie hebben we gebruik 
gemaakt van een bekend pneumokokken eiwit, namelijk PspA.
In hoofdstuk 2 laten we zien dat intranasale vaccinatie met OMVs en PspA 
in muizen leidt tot vermindering van kolonisatie door pneumokokken. Verder
hebben we aangetoond dat de bescherming tegen kolonisatie sterk geassocieerd 
   ϐ  ǡ      
aanwezigheid van een bepaald type witte bloedcel, ook wel de T helper 17 (Th17) 






waar deze cellen betrokken worden bij het opruimen van de pneumokok. Het is 
bekend dat de Th17 respons een kritische rol speelt in vermindering van
kolonisatie door pneumokokken. De resultaten van deze studies tonen aan dat 
OMVs geschikt zijn om gebruikt te worden voor toepassing in een intranasaal
vaccin dat kolonisatie door pneumokokken beoogt te verminderen.
De bescherming tegen infecties door pneumokokken kan verbreed worden
door in nieuwe vaccins gebruik te maken van eiwit antigenen die in alle varianten 
van de pneumokok voorkomen en identiek (geconserveerd) zijn. In hoofdstuk 3
hebben we de functie bestudeerd van een sterk geconserveerd pneumokokken
eiwit, PapP genoemd. We hebben aangetoond dat PapP essentieel is voor de
structuur en het metabolisme van de pneumokok. Deze essentiële functie en het 
feit dat PapP geconserveerd is maken het een interessant antigeen voor
introductie in vaccins tegen kolonisatie door pneumokokken. Wij zullen hier in 
de toekomst nader onderzoek naar doen.
In hoofdstuk 2 hebben we aangetoond dat intranasale vaccinatie met 
OMVs, welke PspA bevatten, leidt tot bescherming, i.e. vermindering van
kolonisatie door pneumokokken. In hoofdstuk 4 wordt onderzocht of dit vaccin 
ook brede bescherming opwekt tegen verschillende pneumokokken varianten.
We hebben onderzoek gedaan met levende milt cellen uit gevaccineerde muizen
welke we buiten het lichaam (ex vivo) hebben blootgesteld aan verschillende 
pneumokokken stammen om te bepalen of er een Th17 respons te meten was. Uit 
deze ex vivo gemeten respons konden we opmaken dat er sprake was van kruis 
bescherming. Ook hebben we kunnen bepalen dat de Th17 respons die we ex vivo
gemeten hadden overeenkwam met de in vivo Th17 respons in de neus van de 
muis. De Th17 respons in de miltcellen en in de neus bleek ook goed te correleren
met bescherming tegen kolonisatie door pneumokokken. Samenvattend hebben 
we een goed werkende laboratorium test ontwikkeld die op een relatief 
eenvoudige manier de vaccin gestimuleerde beschermende responsen en het 
effect op de vermindering van kolonisatie na pneumokokken infecties kan 
voorspellen.  
In hoofdstuk 5 belichten we een ander aspect van vaccins dat tot nu toe 
weinig aandacht heeft gekregen. Het principe van vaccinatie is dat bescherming 
wordt verkregen door het immuunsysteem in contact te brengen met onderdelen
van een ziekmakend micro-organisme (vaccin antigenen). Deze antigenen
betreffen in ons geval pneumokokken eiwitten. Antigenen worden in veel
vaccins gecombineerd met een adjuvant om het immuunsysteem te activeren. 
Gebruik van een vaccin met alleen een adjuvant zou normaliter geen bescherming
moeten bieden. Interessant genoeg laten wij in hoofdstuk 5 op basis van een
aantal studies zien dat intranasale vaccinatie met alleen een adjuvant (CTB 






beschermt tegen kolonisatie door pneumokokken. We hebben in deze studie 
       ϐ 
immuuncel (de macrofaag), en niet door een Th17 geïnduceerde immuunreactie. 
Dit suggereert dat toekomstige studies naar mechanismen van bescherming 
tegen kolonisatie door pneumokokken niet alleen de Th17 immuunrespons
moeten bestuderen, maar ook andere celtype gemedieerde immuunreacties. 
De genetische achtergrond van de gevaccineerde individuen beïnvloedt 
eveneens de door het vaccin gestimuleerde immuunrespons en daarmee de 
mate van bescherming. Mensen zijn genetisch immers erg verschillend, ook in de 
manier waarop het immuunsysteem op ziekmakende organismen, zoals 
bacteriën en virussen, reageert. Het doel van vaccinatie is om de hele bevolking 
te beschermen. De vaccins die geproduceerd worden moeten dus ondanks deze 
individuele verschillen in alle individuele gevallen werken. In hoofdstuk 6
hebben wij onderzocht of de genetische achtergrond invloed heeft op de
bescherming tegen kolonisatie door pneumokokken door gebruik te maken van 
een experimenteel vaccin. Dit vaccin bestaat uit PspA en CTB en wordt veelvuldig 
gebruikt in dierstudies. We hebben door experimenten in verschillende muis 
stammen aangetoond dat dit type vaccin bescherming biedt tegen kolonisatie 
door pneumokokken ondanks de evidente verschillen in genetische achtergrond 
bij deze muizen. 
Met name jonge kinderen en ouderen zijn kwetsbaar voor infecties door 
pneumokokken. Waarom deze leeftijdsgroepen extra gevoelig zijn is niet 
duidelijk. Hoofdstuk 7 beschrijft ons perspectief over de gevoeligheid van jonge 
kinderen en ouderen voor kolonisatie door pneumokokken, gebaseerd op twee 
ϐǤ
beide studies dat zowel jonge als oude muizen een vergelijkbare gevoeligheid
laten zien tegen kolonisatie door pneumokokken, hetgeen zich in beide gevallen
uit door een langere duur van dragerschap. In hoofdstuk 7 bediscussiëren we 
dat de gevoeligheid van jonge en oude muizen voor kolonisatie door pneumo- 
    Ǥ ϐ
uitgevoerde studies door verschillende onderzoeksgroepen laten zien, dat een 
defect in de macrofaag ten grondslag ligt aan de verhoogde kolonisatie in zowel 
jonge als oude muizen. De aanwezigheid van een vergelijkbaar defect in de 
macrofaag in zowel jonge als oude muizen is een interessante bevinding gezien 
de enorme verschillen die bestaan in het afweersysteem tussen deze leeftijds-
groepen.
In hoofdstuk 8 worden de resultaten van dit proefschrift bediscussieerd in 
de bredere context van toekomstige ontwikkelingen op het gebied van vaccinatie 
tegen pneumokokken. Ons inziens is intranasale vaccinatie, om pneumokokken 





veroorzaakt door pneumokokken te verminderen, met name in de leeftijds-
groepen die een verhoogd risico hebben voor infectie door pneumokken. Verder
laat ons werk zien dat een Th17 immuunrespons belangrijk is om kolonisatie te 
verminderen, maar dat de immuunmechanismen van bescherming complexer
zijn en er ook andere type immuunreacties en immuuncellen bij betrokken zijn. 
Daarom zouden toekomstige studies zich niet alleen moeten focussen op een
analyse van de Th17 immuunrespons, maar eveneens op onderzoek gericht op
andere typen afweer reacties. Er zijn op het moment drie pneumokokken vaccins
die worden getest in klinische studies voor evaluatie van bescherming tegen
kolonisatie. Deze vaccins worden allen via een naald (in de spier) en niet 
intranasaal toegediend. Dit is in tegenstelling tot de pre-klinische dierstudies
waar deze geadjuveerde vaccins intranasaal werden toegediend.  Vaccineren via
een naald leidt tot een ander type immuunrespons en zal minder tot mogelijk 
zelfs geen effect hebben op kolonisatie. Wij achten het van groot belang, dat in de
toekomst klinische studies met een geadjuveerd intranasaal vaccin uitgevoerd
gaan worden en te bestuderen of hierbij inderdaad een sterkere reductie van 
kolonisatie en ziekte bewerkstelligd kan worden, dan door intramusculair
toegediende conjugaat vaccins.  Er zijn nog veel vragen die in dit proefschrift 
onbeantwoord zijn gebleven. Voorbeelden hiervan zijn: welke mate van
bescherming tegen kolonisatie is noodzakelijk om ziekte te voorkomen? en hoe 
kunnen we de effectiviteit van een intranasaal vaccin meten in toekomstige 
klinische trials? Om antwoorden op deze vragen te krijgen zullen we een beter 
inzicht moeten krijgen in welke factoren, zowel bacteriële als immunologische, 
de overgang van kolonisatie naar ziekte bepalen. Dit is essentieel voor de 
ontwikkeling van een intranasaal vaccin dat niet alleen beschermt tegen 












Daar zit ik dan in New York. Begonnen als postdoc afgelopen januari, terwijl ik 
me absoluut nog geen postdoc voel. De afgelopen maanden, het einde van mijn 
PhD en de start hier, zijn in een vogelvlucht voorbijgegaan en hebben veel impact 
op mij gemaakt. Dit in combinatie met de herinneringen aan mijn PhD maken 
me wat gevoelig. Natuurlijk het beste moment om het dankwoord voor mijn PhD 
te schrijven! Wat heb ik een geweldige tijd gehad. Wetenschappelijk heb ik 
ontzettend veel geleerd en ben ik gegroeid, maar zeker ook als persoon. Ik ben 
      ϐǡ    
geleerd, ontzettend veel mee heb gelachen (heel erg veel!), maar zeker ook 
frustraties bij heb geuit en gevoeligheden mee heb gedeeld. Ik denk al een tijdje
na over het schrijven van mijn dankwoord, waarin ik in mijn gedachten elke keer
tegen hetzelfde probleem aanloop. Hoe kan ik iedereen die belangrijk voor mij is 
geweest tijdens mijn promotietraject voldoende bedanken en erkennen in een 
paar pagina’s dankwoord? Ik ben tot de conclusie gekomen dat dat onmogelijk is,
dus zal ik het kort maar hopelijk toch persoonlijk houden. Degenen die mij goed 
kennen weten dat dat laatste, iets kort houden wanneer het persoonlijk voelt,
voor mij een behoorlijke uitdaging is. Daar ga ik dan…
Als ik naar andere dankwoorden kijk, zie ik dat deze meestal beginnen met het 
bedanken van de promotor. Toch doe ik dat niet. Waarom niet? Omdat jij Marien, 
mijn co-promotor, de reden was dat ik dit PhD traject binnen Laboratorium
Kindergeneeskunde Infectieziekten aan wilde gaan. Ik herinner me nog mijn 
sollicitatiegesprek met jou (en Fred) dat door ons beider enthousiasme, als ik 
het me goed herinner, bijna 2 uur heeft geduurd! Door onze goede klik verdwenen
de paar initiële twijfels als sneeuw voor de zon. Dat we een team zijn is wel gebleken
tijdens deze 4 jaar. Mijn PhD was een gezamelijke missie en dit proefschrift voelt 
daarom als ons werk (en natuurlijk dat van vele anderen) waar ik erg trots op
ben. Verder heb ik veel van je geleerd, vooral van jouw politieke management 
skills, iets wat erg handig was gezien mijn eigen (Overijsselse?) directheid. 
Marien, ik ken werkelijk niemand die zo betrokken is bij zijn mensen als jij. 
Je deur stond altijd voor mij open en je was (en bent dat nog steeds) bereid om
mij met alles te helpen en te ondersteunen. Ik heb er bewondering voor dat 
ondanks alles wat je op je bordje hebt, je het belangrijk vindt dat jouw mensen 
zich goed voelen en vooral ook goed terecht komen. Bedankt voor alles en ik 
hoop dat we dit in de toekomst voorzetten!  
Ronald, jij behoort tot het type promotoren dat erg betrokken is bij zijn 







gemotiveerd. Je was altijd benaderbaar en ik vond het erg verfrissend wanneer
je ondanks je eigen drukte af en toe een zoete inval deed in de PhD kamer, of in 
ϐǤ

hoe het met de promovendi was of voor een leuk verhaal, waardoor je ons
    ϐǤ   
vond ik jouw directheid verfrissend. Jouw duidelijke tips voor het schrijven,
maar zeker ook jouw advies voor de toekomst waardeer ik zeer en hebben me
al heel wat gebracht. Bedankt hiervoor! 
Dear members of the manuscript committee, Prof. dr. André van der Ven, Prof.
dr. Heiman Wertheim, and Prof. dr. Jeffrey Weiser, thank you for your time to
read and evaluate my thesis. Jeff and Daniela, I really appreciate the effort you
are taking to come all the way from New York and Liverpool to attend my defense. 
Nina, ik wil jou toch zeker ook bedanken, maar niet alleen omdat je zitting neemt 
in mijn corona. Ons contact begon tijdens mijn masterstage bij Victor in San 
Diego, waarvoor jij mijn Nederlandse supervisor was. Tijdens deze periode ben 
ik door jou in contact gekomen met het LKI, dank hiervoor, en sindsdien, zijn we 
altijd betrokken bij elkaar geweest. Door onze bijzondere klik heb ik jouw advies 
erg hoog staan. Ik hoop dan ook dat we dit zullen voortzetten in de toekomst. 
To all of the corona members, I am looking forward to our discussions on the 
29th of May!
Tijdens mijn PhD heb ik met veel mensen buiten het LKI mogen samenwerken. 
Joen, Wouter, en Diane, onze samenwerking begon bij de start van mijn PhD
door het Pneumovac consortium. In het begin was het misschien samen even 
zoeken, maar ik heb echt genoten van onze samenwerking. Qua werk stonden
onze neuzen dezelfde kant op en voor mijn gevoel hebben we samen het maximaal 
haalbare uit ons project gehaald in deze jaren. Wat ik geweldig vond was jullie 
humor. God wat heb ik gelachen met Marien om de grappige en droge
opmerkingen tijdens de teleconferenties of de consortium meetings! Wanneer
de andere consortium leden veel te serieus verder gingen en wij blijkbaar de
enigen waren die elkaars humor begrepen, kwam ik soms niet meer bij van het 
ǤǨϐǤ
het einde van mijn PhD niet het einde voor ons contact betekent. Wouter en
Diane, ook bedankt voor jullie tips m.b.t. mijn postdoc. Joen, ik hoop jou nog een 
keer te zien hier in New York. Je begrijpt natuurlijk wel dat ik je aan het beloofde 
etentje zal houden!
Mihai, ook onze samenwerking begon met de aanvang van mijn PhD. Je 





de meetings en bovenal voor je waardevolle input. Ik denk dat we ons werk mooi
hebben weggezet in The Journal of Infectious Diseases. Leo, jouw additionele
input en connecties hebben zeker een bijdrage geleverd aan dit werk. Ook dank 
voor de acceptatie als mijn mentor binnen het RIMLS. Jouw advies voor de
toekomst, qua baan en funding aanvragen, hebben me doen nadenken en invloed 
gehad op de keuzes die ik heb gemaakt en op dit moment nog maak. Eelke, 
hartelijk dank voor de hulp met de proeven die uitgevoerd zijn in Groningen. 
MarijeandTaj, thank you for all your efforts. I enjoyed our fruitfull collaboration.
Jan-Willem and Clement, and Markéta and Vaclàv, thanks for your major
contributions to our PapP project. Your input and perseverance led to the 
acceptance of this beautiful work for publication in Molecular Microbiology.
Pieter, Roel en Miriam, onze proefdierdeskundigen binnen het Radboud. 
Ik durf grif toe te geven dat jullie een aandeel hebben gehad in het grootste deel
van mijn proefschrift. Wat heb ik jullie vaak gebeld voor advies (echt vaak) over
hoe wij het beste onze aanvragen konden indienen. Wat de meest optimale weg 
was. Maar vaak toch ook wel wat de snelste route was. Jullie waren altijd 
vriendelijk, toegankelijk en deden jullie best om mij verder te helpen. Het was
prettig te voelen dat we in ‘hetzelfde team’ zaten. Hartelijk dank!
Stefanie en Mike, ook jullie heb ik vaak benaderd voor hulp. Het was zo 
prettig voor ons wanneer er onverwachte dingen gebeurden waarvoor actie
nodig was, dat jullie er waren om ons te ondersteunen. Hartelijk dank! Daarbij
ϐ
vond. Mike, ik moest zo hard lachen toen je zei, mede door het gezicht van Fred:
‘He Dushi, je hebt blote benen, dat mag helemaal niet!’ Stefanie, ik kijk er naaruit 
om je hier in New York te zien, dan gaan we gezellig een hapje eten en drinken en
rondwandelen in de stad.
Lieve Christa, Marc, Elles, en Fred, jullie vormen toch echt wel de ruggengraat 
Ǥϐ
gezellig met jullie. Wat heb ik veel tijd in jullie kamer door gebracht. We wisten 
ook allemaal dat als ik over de drempel van jullie deur stapte, ik minstens een 
kwartier bleef, waardoor de drempel een toch wat symbolische waarde kreeg. 
Meestal kwam ik gewoon even om te kletsen om te horen hoe het was, maar toch
ook wel eens om mijn frustratie te uiten als een proef geheel andere uitkomsten 
gaf (ik kan me nog herinneren dat we met dingen gegooid hebben...). Chrisje,
ϐ
waardevol was. Door deze intensievere samenwerking hebben we elkaar erg 
goed leren kennen. Wat hebben we ook veel gelachen, onze grappen en dansjes in
het lab (hilarisch!), die misschien niet door iedereen werden begrepen maar 






aandeel had. Ik ben blij dat je mijn paranimf wilt zijn op mijn belangrijke dag,
dank! Elles en Fred, met jullie heb ik veel lange dagen gemaakt in het CDL, 
bedankt voor jullie geduld, hulp en goede humeur! Meestal waren deze dagen
toch ook wel een klein feestje. Wat was het leuk om elkaar te plagen! Lieve Elles,
wij hebben elkaar ook op een andere manier leren kennen tijdens mijn PhD. 
Ik kan mijn gevoel niet goed op papier zetten zonder te veel in details te treden. 
Ik wil je heel erg bedanken voor onze gesprekken, je openheid en steun. Dat is van
grote waarde voor mijn 2e leven. Fred, Fredje, Fredretteketet, Fred ….(4 letters!)
plet. Haha ik moet al meteen lachen. Waar te beginnen? Wat hebben wij veel 
momenten beleefd in het CDL! Het was duidelijk dat er meteen synergie was 
tussen ons en we elkaars grappen (heel!) erg konden waarderen. Wat hebben wij 
gelachen zeg! Onze step momenten naar en van het CDL, door de kelder, of soms 
Ǥϐ
niet meer bij kwam van het lachen en de gedachte alleen al tranen in mijn ogen
doet komen! Dit zal ik maar niet op papier zetten, maar je weet heel goed wat ik 
bedoel. Behalve humor zochten we zeker ook de diepte op in onze gesprekken. 
ȋȌϐ
wanneer ik iets goed deed wanneer ik dat nodig had. Labpapa, zo noem ik je niet 
voor niets, bedankt voor werkelijk alles.
Ik wil ook zeker mijn kamergenoten bedanken. Ria, jij bent de enige met wie ik 
Ǥϐǡ
we hadden immers altijd interesse in elkaar en dingen die speelden in ons leven. 
De nieuwe PhD’ers, die nu eigenlijk niet meer zo nieuw zijn, Inge en Esther. 
We zochten elkaar vaak op, ook zeker buiten werk om, voor gezellige, grappige 
en diepgaandere gesprekken, die voor mij erg waardevol waren. Ik heb het 
ϐǡ
een drankje in ging gevolgd door een dansje! Ik hoop dan ook dat we in contact 
zullen blijven. To the really new PhD’ers Liz, Josh, Lucille, and Evi, I wish you
  ϐǤ
students, Michelle, Mariska, and Gosia, it was great to supervise you and thank 
you for all your work!
Ook de andere kamergenoten Erika, Hanneke, Corné, Fredrick, en de
onco’s Dorette, Liesbeth, Kirsten, Laurens, René, Frank, Miriam en andere
oud LKI’ers en onco’s bedankt voor de leuke klets en dansmomentjes en alle
andere gezelligheid. Dorette, het was hartstikke leuk om met je samen te werken 
en LKI en LKO wat dichter bij elkaar te brengen. Ik herinner me nog goed onze 






Gerben, Dimitri, Saskia, Jeroen, de ervaren science mensen in het lab, bedankt 
voor jullie ondersteuning tijdens mijn traject. Gerben, jouw enthousiaste 
creatieve geest en het stellen van de juiste vragen heeft ons onderzoek zeker
voortgeholpen. Je liet me met een andere blik naar ons onderzoek kijken. Ook 
dank voor de brainstormsessie over mijn toekomst. Dimitri, ik heb veel geleerd 
van jouw kennnis m.b.t. immunologie en jouw kritische blik op vraagstellingen, 
de daarbij horende proeven, maar zeker ook het schrijven. Saskia, jouw expertise
en ervaring omtrent dierproeven waren erg waardevol, vooral wanneer het 
anders liep dan gedacht. Jeroen, onze samenwerking kwam iets later op gang
toen je aan pneumokokken ging werken, jaja wie had dat gedacht! Onze discussies
over ons project en jouw gedrevenheid motiveerde me enorm en werkte 
aanstekelijk. Daarbij was je ook zeker niet vies van een biertje en een feestje
(KNVM), waarop ook jij de dansvloer onveilig hebt gemaakt!
Aldert en Hesterǡ ϐ  
publicatie heeft geleid en hopelijk binnenkort nog een. Ook al werkten jullie al
een tijdje elders, toch zochten we elkaar veel op tijdens congressen voor een
aantal drankjes en wanneer er de mogelijkheid was, toch ook zeker op de 
dansvloer voor een aantal dansjes. Tijdens de KNVM, behoorden we dan ook 
vaak tot de laatsten op de dansvloer en gingen we swingend door tot de D.J.
stopte!  
Sandra, bedankt voor al je hulp mbt organisatorische dingen. Je was altijd 
benaderbaar en zeker ook in voor een grapje op zijn tijd! Lieve Ada, ook al ben je 
niet meer onder ons, jouw ondersteuning tijdens mijn PhD waardeer ik zeer. Je
zult gemist worden.
Pittige dames Lilly, Amelieke, en Marloes, we klikken erg goed en konden 
werkelijk over van alles met elkaar praten. Volgens mij zit er geen limiet aan
hoeveel wij met elkaar kunnen kletsen, waarin we zelfs af en toe uitspraken 
   Ǥ 
 ϐǡ   ǡ
zelfs toen jullie al elders werkten. Wat ben ik blij dat ik jullie heb leren kennen en 
ik weet zeker dat we in contact zullen blijven. 
Dear Jeff, how grateful I am that you gave me the opportunity to work as a 
postdoc in your group. I know I will learn a great deal from the way you perform
science and know you will be a great mentor to me. You are genuinely involved in 
ϐǡ
look at pneumococci under the microscope (lab member quote: ‘he likes to do 
that every day’). The rest of the lab members, Jen, Pam, Alex, Shigeto, Mila, 
Kristen, and Ammar, thank you for being so welcoming! Jen, it is so nice to hang 






ginger tea and the painkillers for Toni and me after our wine outing the night 
before. Toni, how could anyone be more welcoming than you were! I cannot 
express my gratitude enough. You helped me with literally everything. It is so 
comforting to have you, I have not felt alone since the minute I came to NY. How 
I loved shopping with you at Ikea to choose ‘our’ furniture. How I love to hang out 
with you. I cannot wait to experience our list of plans with all the cool things we
have in mind!
Evelien en Michiel, jullie hebben me erg geholpen tijdens deze toch wel 
 Ǥ   ϐ      Ǯ  ǯ  
begrijpen waar je in zit. Bedankt voor jullie hulp, de gezelligheid, de uitjes en 
alvast voor alle uitjes en gezelligheid die nog gaan volgen!
En dan mijn vriendinnen voor het leven! De BMW chickies, bedankt voor alle
gezellige etentjes drankjes en dansjes tijdens deze periode! Eline, Anne, Janneke
en Judith, we zagen elkaar niet zo frequent als we zouden willen maar als we 
elkaar zagen was het altijd als vanouds. Zulke vriendinnen zijn goud waard! 
We praatten dan honderduit over werkelijk alles en qua PhD konden we elkaar 
met veel (nerden!) humor goed laten relativeren. Heerlijk met lekker eten en 
wijn&cocktails op de bank en zelfs een sleepover (blijkbaar kun je daar toch echt 
nooit te oud voor zijn). Lieve Juud, jij in het bijzonder bedankt voor de chille en 
ϐǤ´
goed een spiegel voor hield. 
Lieve Leonie, Eva en Majorie, we kennen elkaar al sinds de middelbare
school en hebben al heel wat belangrijke momenten in onze levens samen mogen
ervaren (wat zijn we al oud geworden!). Ik geniet van onze afspraakjes waarin 
we altijd te weinig tijd hebben om elkaar volledig op de hoogte te brengen. Onze
vriendschap is belangrijk voor mij en ik ben blij dat ik ook dit belangrijke moment 
met jullie mag delen.  
Vrienden uit Rijssen, bedankt voor alle borrels, feestjes en gezelligheid! 
Annelies, bedankt voor de gezellig borrels en de goede verhalen. Lieve Linda, 
ϐǡǤ
Lieve Tamara en Melanie, jullie hebben mij het meest ervaren van iedereen en
daarom ook al mijn ‘colors’ mogen zien, de leuke en zeker ook de minder leuke. 
Bedankt dat jullie mij wegtrokken uit mijn sleur en serieusheid wanneer dat het 
meest nodig was. Onze borrels, spelletjesmiddagen en feesten waren memorabel 
en ik hoop dat we dat in de toekomst nog heel veel gaan doen (want ja ik kom nu
immers terug naar NL). Mel, met je geweldige Queen of Darkness grappen, en 
Tammie, jij lief pittigheidje, kan niet wachten totdat we hier in New York gaan 





Lieve Inge, eerst was je mijn collega, daarna mijn oudcollega en nog later mijn 
roomie van de laatste maanden voordat ik naar New York ging. Hoe geweldig ben
je als je iemand zo spontaan opneemt in je huis als jij deed voor mij. Onder 
veelvuldig genot van wijntjes, lekkere hapjes, Indisch eten, en (heel erg veel) 
Ǥϐ
     ϐ  
of waar we mee bezig waren, om elkaar tot inzicht te brengen of juist dat extra
duwtje te geven wanneer nodig. Heel erg bedankt voor ALLE duwtjes die jij mij
hebt gegeven, je weet precies welke duwtjes in het bijzonder voor mij het verschil 
hebben gemaakt.
Voor iedereen is het duidelijk dat jij, Jop, mijn PhD hubby bent. Vanaf het begin
zijn we twee handen op één buik en we begrijpen elkaar met een enkele blik.
We hebben elkaar direct door wanneer een van ons een bepaalde benadering
hanteert, zowel op werk als daarbuiten, wat hilarische momenten oplevert. 
Onze etentjes, sleepovers at ‘Bed & Breakfast Jop Jans’ en stapavonden zijn 
onbeschrijfelijk. Altijd als ons nummer (Casanova, hoe is dat eigelijk ontstaan?) 
voorbij komt gaan we vol overgave in elkaar op. Werkelijk, mensen moeten eens 
weten wat voor hilarische momenten dat heeft opgeleverd! Jopje, jij pittige,
slimme, talentvolle, lieve, maar zeker ook professionele man (ik houd van die 
attitude), bedankt voor werkelijk alles! Alle momenten die je er voor mij was en 
bent en die we samen beleefd hebben en nog gaan beleven. Onze vriendschap
kent geen limiet. 
Pap, Mam, Wouter en Mieke, mijn lieve familie met wie ik het zo getroffen heb.
Wat geniet ik er altijd van als we samen zijn. Ook al woon ik allang niet meer bij 
jullie, het voelt nog altijd als thuis en dat zal het ook altijd blijven voelen. Wouter, 
grote broer, en Miekǡȋϐǡ
maar je bent wel ontzettend warm geworden hoor!), het is altijd lachen met jullie 
en ik weet dat we voor elkaar klaarstaan als we elkaar nodig hebben.
Pap en Mam, ik weet dat het is voor jullie de normaalste zaak van de wereld 
is, maar jullie stonden altijd voor mij klaar en werkelijk niets was jullie te veel. 
Ik ken weinig mensen die zo’n ontzettend goede band met hun ouders hebben 
als wij hebben. Jullie liefde en capaciteit voor ons de kinderen kent geen limiet.
Ik hoop jullie hierin later te mogen evenaren. De perioden, bij start van mijn PhD
als de periode wat meer naar het eind toe waren zwaar voor mij, waarin jullie
mij ontzettend veel gesteund hebben en mij belangrijke dingen hebben laten
inzien. Lieve Pap en Mam, jullie hadden geen wetenschappelijke, maar misschien
wel de belangrijkste rol tijdens mijn PhD periode en daarom draag ik mijn 






Om eerlijk te zijn had ik niet verwacht dat ik deze laatste alinea uberhaupt zou 
schrijven. Ik had grootste plannen voor New York - daar zou immers mijn hele
dating experience starten – maar belangrijker, omdat ik het absoluut niet wilde, 
was ik ervan overtuigd dat het mij daarom ook niet zou overkomen. Velen waren 
getuige van deze (nu toch wel naïeve) uitspraak. Maar blijkbaar werkt het zo 
echt niet, want jij, lieve Harvey, bent mij overkomen en linea recta mijn hart 
binnen gedrongen. Initieel heb ik me hier behoorlijk tegen verzet (wie doet zoiets
in de laatste periode van haar PhD, laat staan nog geen 3 maand voor haar 
emigreren?!). Jij was degene die nergens voor terug deinsde en vooral uitdagingen 
zag, geen problemen. Het is onbeschrijfelijk hoe jij mij de ruimte gaf tijdens de 
laatste periode van mijn PhD en mijn laatste periode in Nederland. Deze ruimte 
geef je me nog steeds, omdat je begrijpt dat ik dit moet doen en ergens naar op
zoek ben. Ons gevoel kent letterlijk geen grenzen. Geweldige man, ik ben blij dat 
je onderdeel uitmaakt van deze belangrijke dag. Daarbij, kan ik niet wachten tot 
mijn New York avontuur voorbij is en we echt samen kunnen zijn om samen het 
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